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Abstract 
 
PDIp is a close homolog of the well known protein folding catalyst PDI. Unlike PDI 
however, PDIp exhibits restricted protein expression and is found predominantly in 
the exocrine pancreas. Currently, the physiological function of PDIp is unknown but 
previous work has shown a clear specificity for substrates containing a hydroxyaryl 
group. Again this is in contrast to PDI which exhibits more general specificity. This 
work to investigate the in vitro activities of PDIp, was stimulated by the hypothesis 
that PDIp has an essential role in folding a specific subset of secretory proteins. The 
identity of these proteins is currently unknown.  
In this work, the redox-mediated conformational changes of PDIp have been studied 
and compared using far UV CD, dynamic light scattering and limited proteolysis. 
Compared to PDI, these changes are conservative in PDIp.  Also, unlike PDI for 
which b’xa’c is the minimal redox-active cassette, the PDIp a and b domains seem to 
be involved in modulating these conformational changes. This may indicate that 
PDIp has a unique substrate binding mechanism that may work synergistically with 
its restricted substrate specificity. 
Using the insulin reduction assay, PDIp was shown to have ~50% of the oxido-
reductase activity of PDI and this was not due to the aberrant threonine residue in the 
a’ domain active site motif (CTHC). Further investigation by stopped flow kinetic 
studies showed that the low activity could be due to the abnormally high pKa for the 
PDIp a domain N-terminal catalytic cysteine. This result was unexpected because 
PDI and PDIp a share the same catalytic active site motif (CGHC) indicating that 
nearby residues may act as mediators of activity. Future work to clarify this will be 
essential. 
This is the first study of the structure of PDIp and its molecular basis for activity. 
Through investigation of these two areas, it is hoped that the general understanding 
of the role of PDIp and its contribution to oxidative folding in secretory tissues will 
be improved.  
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Chapter 1. Introduction 
  
This chapter introduces the area of protein folding with particular emphasis on the 
roles taken by members of the protein disulphide isomerase (PDI) family. These 
proteins are catalysts of protein folding and typically exhibit oxido-reductase and 
isomerase activity. PDI, the archetypal family member, is very well characterised 
and a high resolution X-ray crystal structure of the human protein has recently been 
published (Wang et al. 2012). This chapter describes in detail the catalytic activities 
and redox-mediated conformational changes associated with the physiological role of 
PDI.  
In addition to PDI, the pancreas-specific PDI family member, PDIp is also discussed. 
Unlike PDI, there is very little data for PDIp in terms of structure and activity but it 
is known to have restricted substrate binding specificity. In this chapter, the current 
understanding of PDIp is reviewed. This includes its cellular and physiological 
location, potential activity and also probable role in disease pathogenesis.  
Finally the aims of this study will be specified, indicating any possible implications 
for the structure, activity or physiological role of PDIp.  
 
  
Chapter 1. Introduction 
2 
 
1.1. Protein Folding and the role of molecular chaperones in the cell 
 
1.1.1. Protein folding in the Endoplasmic reticulum 
 
1.1.1.1. Oxidative protein folding 
Oxidative protein folding occurs in the endoplasmic reticulum (ER) of eukaryotic 
cells and is a fundamental cellular process essential for the function of approximately 
one third of all eukaryotic proteins (Chen et al. 2005). Although occurring 
predominantly in the ER, some folding can take place co-translationally and begins 
when the nascent chain emerges from the ribosome and starts to translocate across 
the ER membrane (for review see Kolb, 2001). It is not until translocation and entry 
into the oxidising environment of the ER that the newly synthesised protein can 
become post-translationally modified; examples of which are N and O glycosylation 
and disulphide bond formation. Furthermore, before proteins leave the ER, it is 
crucial that they are correctly folded. It is the role of molecular chaperones and also 
the unfolded protein response (UPR) to regulate this (see figure 1.1). 
Protein folding is highly complex and can be illustrated by Levinthal’s paradox 
which states that there is a huge number of possible conformations for any given 
polypeptide chain (Levinthal, 1968). For example, a 100 amino acid polypeptide can 
have up to 3
198
 different conformations. The ‘paradox’ is that most proteins reach 
their native state much quicker than would be expected if each possible conformation 
was sampled. Therefore protein folding must be guided by rapid formation of local 
interactions which subsequently allow further folding of the polypeptide to occur. 
This mechanism of protein folding (by way of partially folded intermediates) has 
been clearly defined for bovine pancreatic trypsin inhibitor (BPTI) (Creighton et al. 
1995). 
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1.1.1.2. The fully characterised folding pathway of BPTI 
BPTI is a small protein containing only 58 residues and 3 disulphide bonds in its’ 
native structure (30-51, 5-55 and 14-38).  Although only small, the formation of 
BPTI involves 5 major intermediate stages (characterised by a disulphide bond) 
between the unfolded and the fully folded state of the protein (see figure 1.2). These 
intermediates ‘funnel’ BPTI via oxidation (S-S formation), reduction (S-S breaking) 
Figure 1.1: Protein folding and degradation pathways in the ER 
(figure from Ma and Hendershot, 2004). a) The nascent chain enters the 
ER via protein channels called translocons. b) Protein folding occurs in 
the presence of molecular chaperones e.g. BiP and PDI. Post-
translational modifications also take place including the formation of 
disulphide bonds. c) If correctly folded, the protein leaves the ER via 
transport vesicles. d) Misfolded proteins are targeted back to the cell 
cytosol where they will be degraded by the proteasome. e) As unfolded 
proteins accumulate, stress sensors IRE1, PERK and ATF6 are activated 
and initiate the unfolded protein response (UPR). 
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and isomerisation (S-S rearrangement) reactions towards the correct fully folded 
state (Arolas et al. 2006). 
 
 
 
 
 
 
The final, native state of BPTI is obtained following isomerisation of the 14-38 
disulphide bond. This is the rate limiting step of the folding process and can be 
catalysed by PDI. In the absence of a protein folding catalyst such as PDI, disulphide 
bond isomerisation can occur spontaneously but the time scale is not biologically 
feasible. Kinetically trapped species such as BPTI Des 30-51, are common in the 
folding pathways of many proteins and consequently protein folding catalysts and 
molecular chaperones are often indispensable.  
  
Figure 1.2: BPTI folding pathway (adapted from Wallis and Freedman, 2011). Shown 
is the kinetically favourable folding pathway of BPTI including 3 intermediate stages 
between the unfolded (U) and folded (F) state. 1) The first disulphide forms quickly and 
efficiently giving rise to 1S 30-51 (major product) and 1S 5-55. 2) These species are 
constrained by the newly formed disulphide bond and the second disulphide bond 14-38, 
is made (missing disulphides between steps are indicated by the prefix ‘Des’). 3) 
Progression from Des 5-55 and Des 30-51 requires both unfolding and isomerisation of 
the 14-38 bond as all free thiols are buried and unreactive. This is the rate limiting step. 
Once Des 14-38 is made the full-folded state can be reached easily. 
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1.1.2. Protein misfolding in the endoplasmic reticulum (ER) 
 
1.1.2.1. Implications of protein misfolding for the cell 
Protein misfolding can be quite common, and unfolded or partially folded proteins in 
the overcrowded ER can very quickly begin to aggregate. The role of molecular 
chaperones is to identify proteins that are susceptible to aggregation and prevent it 
from occurring.  However, if a protein does become misfolded and is not noticed by 
various cellular ‘check points’ (such as the UPR) or corrected by molecular 
chaperones it can become cytotoxic (Elgaard and Helenius, 2003). 
There are many well known protein misfolding diseases such as cystic fibrosis 
(misfolded CFTR protein), Gaucher’s disease (misfolded β-glucocerebrodisase) and 
Fabry disease (misfolded α-galactosidase). Additionally, there are diseases caused by 
the accumulation of misfolded proteins: Alzheimer’s disease (deposits of amyloid, 
beta and tau), Type II diabetes (deposits of amylin) and Creutzfeldt-Jakob disease 
(deposits of prion protein).  The latter class of disease can often be caused later in life 
if a reduction in molecular chaperone number/ efficacy is seen (Dobson, 2003). 
 
1.1.2.2. The Unfolded Protein Response (UPR) 
Under periods of ER stress the unfolded protein response (UPR) is activated (for 
schematic see figure 1.3. The UPR attempts to regulate cellular stress by: 1) targeting 
misfolded proteins to the proteasome for degradation, 2) increasing expression of 
foldases and molecular chaperones and 3) reducing translation (Yoshida, 2007). As 
misfolded protein accumulates, three ER stress sensors located in the ER membrane 
become activated: 1) IRE-1 (inositol-requiring enzyme 1), 2) PERK (pancreatic ER 
kinase (PKR)-like ER kinase) and 3) ATF6 (activated transcription factor 6). If stress 
is prolonged, these molecules are also able to enable apoptotic pathways (Lin et al. 
2008). 
In response to ER stress, IRE-1 becomes oligomerised. This activates both its kinase 
and endoribonuclease functions allowing it to perform specific splicing of XBP-1 
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mRNA. Once sliced, this encodes a potent transcription factor of the basic leucine 
zipper (B-ZIP) family which can enter the nucleus of the cell and enhance the 
transcription of a select group of genes, so increasing the protein-folding capacity of 
the ER and degradation of misfolded proteins (Lin et al. 2008).  
 
 
 
 
 
In higher eukaryotes, IRE-1 binds to adaptor protein TRAF2 via its kinase domain. 
This activates the apoptosis signal regulating kinase 1 (ASK1). The activation of 
ASK1 causes phosphorylation and activation of c-Jun N-terminal kinase (JNK) 
Figure 1.3: The mammalian UPR (taken from Lin et al. 2008).  PERK, 
ATF-6 and IRE-1 proteins found transversing the ER membrane are 
essential for sensing ER stress. Upon activation each invokes signalling 
cascades which reduce stress and/or promote apoptosis. 
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which induces apoptosis. Incidentally, binding of TRAF2 by IRE-1 can also lead to 
displacement of pro-caspase 12 and its conversion into the active enzyme (Lin et al. 
2008).  
The ER lumenal domain of PERK is homologous to that of IRE-1 and becomes 
oligomerised in response to ER stress (Lin et al. 2008). Once activated, PERK 
phosphorylates eukaryotic initiation factor 2α (eIF2α), a molecule involved in the 
assembly of 80S ribosomes at the intiation codon. Phosphorylation of eIF2α by 
PERK leads to inhibition of this function and therefore attenuates protein synthesis. 
As some protein synthesis is essential, GADD34 mediates the phosphorylation of 
eIF2α by PERK to ensure that protein synthesis is able to sustain vital functions 
(Novoa et al. 2001). Interestingly however, when ribosomal assembly is impaired by 
the interaction of PERK and eIF2α there is increased enhancement of ATF-4 
translation (Lin et al. 2008). ATF-4 is another B-ZIP transcription factor and reduces 
stress by targeting molecular chaperones. It also increases transcription/translation of 
CHOP a B-ZIP transcription factor involved in regulating cell death by increasing 
GADD34 expression. 
ATF-6α consists of an ER-stress sensing lumenal anchor coupled to a 
transmembrane domain and a cytosolic B-ZIP transcription factor domain (Haze et 
al. 1999). In periods of ER stress, ATF-6α travels from the ER to the Golgi where 
the transmembrane domain is cleaved allowing the liberated transcription factor 
domain to travel to the nucleus. Following entry to the nucleus, ATF-6α upregulates 
various genes some of which overlap with those activated by XBP-1 and ATF-4 e.g. 
BiP and CHOP and also others that are known to be connected to ER-associated 
degradation (ERAD) (Lin et al. 2008).   
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1.1.2.3. ERAD 
Incorrectly folded proteins are targeted to ERAD to prevent their accumulation in the 
cell. This process is split into 3 main stages: 1) recognition, 2) retrotranslocation and 
3) degradation which are shown in figure 1.4 (Vembar and Brodsky, 2008). 
 
 
 
 
 
 
 
 
In stage one, unfolded proteins are recognised by the ERAD machinery. This can 
occur via interaction with molecular chaperones or via the calnexin-calreticulin 
cycle. The latter relies on the fact that during co-translational translocation into the 
ER, many proteins are glycosylated. The presence of an N-glycan itself increases the 
hydrophilicity of the protein and encourages it to fold correctly (Daniels et al. 2003). 
If the protein is folded correctly, 3 glucose molecules are removed by ER-resident 
glucosidases, it is released from calnexin/calreticulin and then it can exit the ER 
Figure 1.4: ERAD (adapted from Vembar and Brodsky, 2008).  a) Misfolded proteins are 
recognised by various chaperones including: Hsp70 family members, calnexin, calreticulin and the 
protein disulphide isomerases. b) ERAD substrates are targeted to the retrotranslocation machinery 
and/or E3 ligases. c) Substrate retrotranslocation may be initiated by the cell-division cycle-48 
(Cdc48). The molecular chaperones or the proteasome may also be required for this step. d) As 
proteins exit the retrotranslocon they are polyubiquitinated by the E3 ubiquitin ligases. This 
promotes further retrotranslocation and is aided by cytoplasmic ubiquitin binding protein 
complexes. e) Having entered the cytoplasm, polyubiquitinated ERAD substrates are recognised 
by receptors in the 19S subunit of the proteasome. Once the polyubiquitin tag has been removed, 
the substrate can enter the 26S core of the proteasome where it is degraded. Ubiquitin generated in 
this process is then recycled for further rounds of modification. 
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(Wang and Hebert, 2003). If the protein is unfolded however (has exposed 
hydrophobic surfaces etc) it is recognised by UDP-glucose: glycoprotein 
glucosyltransferase (UGGT) which re-adds a single glucose molecule. The misfolded 
monoglycosylated protein then re-enters the calnexin-calreticulin cycle where 
aggregation is prevented and hopefully the correct protein conformation is achieved. 
Incidentally it is at this stage that ERp57 is able to interact with calnexin thereby 
promoting oxidative protein folding (Ellgaard and Frickel, 2003). 
After recognition, unfolded proteins are extracted from the calreticulin/calnexin 
cycle and targeted for retrotranslocation by the ER degradation-enhancing α-
mannosidase-like lectins (EDEMS) (Wang and Hebert, 2003). During exit from the 
retrotranslocon, the ERAD substrates are polyubiquitinated by E3 ubiquitin ligases 
which are embedded in the ER membrane (Mehnert et al. 2010). These ligases work 
alongside accessory proteins involved in substrate recognition (described previously) 
and their activities are specific to the substrate class in question (Hirsch et al. 2009).  
Once polyubiquitinated, misfolded protein binds to ubiquitin receptors on the 19S 
proteasome and in doing so drives the unfolded protein into the proteasome core for 
degradation.   
 
1.1.2.4. Molecular chaperones as protection against protein misfolding 
Somewhat unsurprisingly, molecular chaperones rank among the most highly 
abundant proteins in cells and are found in most cellular compartments (cytosol, ER, 
mitochondria and chloroplasts) (Saibil, 2008). The major role of molecular 
chaperones in the cell is to assist protein folding i.e. correct any mistakes that are 
made along the way and reduce external pressure opposing the folding reaction. In 
doing this, molecular chaperones improve the efficiency and thus increase the speed 
of protein folding allowing the folding event to occur on a biologically feasible 
timescale. Additionally, many chaperones (including the Heat shock family of 
proteins; Hsps) also function to target misfolded protein out of the cell to the 
proteasome (see figure 1.1) or by directing the cell to apoptosis (Saibil, 2008).  
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There are a huge number of different molecular chaperones in both eukaryotic and 
prokaryotic cells which all have 3 common properties: 1) they recognise structural 
elements that are in the unfolded protein such as hydrophobic surfaces, 2) they do not 
bind to proteins that are correctly folded and 3) they exhibit very little substrate 
specificity (Hartl et al. 1994).  
 
1.1.2.5. BiP 
BiP is an abundant and ubiquitous ER-resident molecular chaperone and a member 
of the Hsp70 family. It exhibits broad substrate specificity for newly synthesised, 
unfolded proteins, but does not bind to native proteins (Gething, 1999). Once nascent 
protein is bound, BiP promotes folding and prevents the formation of insoluble 
aggregates. Examples of well characterised, natural substrates of BiP are antibodies 
(Hendershot et al. 1996). 
Like other members of the Hsp70 family, BiP has 2 domains: an N-terminal domain 
and a C-terminal domain. The N-terminal domain has ATPase activity and the C-
terminal domain contains the substrate binding site (Gething, 1992). Thus the 
interaction between BiP and its protein substrates is coupled to ATP-dependent 
conformational change (Mayer et al. 2003). 
 
1.1.3. PDI and the oxidative protein folding pathway 
 
1.1.3.1. Oxidative protein folding in the ER and the role of Ero1 
PDI is a molecular chaperone and protein folding catalyst essential for the in vivo 
formation of disulphide bonds. This process (i.e the oxidation of dithiols) requires 
that oxidising equivalents are passed from molecular oxygen to PDI and then to the 
reduced protein substrate. Contributors to this include oxidised/reduced glutathione 
(GSSG/GSH), hydrogen peroxide (H2O2), ER oxidoreductins and various 
peroxiredoxins and peroxidases (Ruddock, 2012).  
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Unlike many of the molecules mentioned previously, the role of glutathione in 
disulphide bond formation is probably more indirect. Although initially thought to be 
pivotal to the process, it is now known that a major source of oxidising equivalents 
comes from ER oxidoreductin 1 (Ero1) (Appenzellor et al. 2010). The role of 
glutathione therefore seems to be maintaining the redox potential of a variety of 
intracellular compartments including the ER, where a high GSSG: GSH ratio gives 
rise to its characteristic, oxidising environment and consequently promotes oxidative 
protein folding. Currently the exact role of glutathione in disulphide bond formation 
is poorly understood although it is possible that GSH is responsible for maintaining 
the oxido-reductases in a reduced state and therefore allowing catalysis of reduction 
and isomerisation reactions (Chakravarthi and Bulleid, 2004). For a comprehensive 
review of glutathione see Appenzellor, (2011). 
 
 
 
 
 
Figure 1.5: Oxidative protein folding (taken from Flohé and Maiorino, 
2013). Disulphide bond formation in newly synthesised protein is catalysed by 
PDI. Reduced PDI is re-oxidised by Ero1 in a reaction that generates H2O2.  
Peroxide made in this way can then be used by peroxiredoxin 4 (Prx4) or the 
glutathione peroxidases, GPx7 and Gpx8 as an additional mechanism for the 
re-oxidation of PDI. 
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Although often regarded as a potentially dangerous by-product of disulphide bond 
formation, peroxide itself may be important for oxidative folding. H2O2 is made by 
sulphydryl peroxidases such as Ero1 in vitro (see later) and work by Karala et al. 
(2009) shows that it is more efficient than a glutathione redox buffer in refolding 
non-native proteins in vitro. Additionally, hydrogen peroxide can be metabolised by 
peroxiredoxin 4 (Prx4) and glutathione peroxidases, Gpx7 and Gpx8 (also discussed 
later). In this way the ER is able to regulate the accumulation of potentially 
dangerous hydrogen peroxide while also promoting the efficient oxidative folding of 
non-native proteins (Tavender et al. 2010, Nguyen et al. 2011).  
As mentioned previously, a major source of oxidising equivalents comes from the 
ER oxidoreductins (Ero’s). In mammalian cells there are two Ero proteins: Ero1α 
and Ero1β (Dias-Gunasekara et al. 2005). Ero1α is a flavin dependent oxidase 
located on the ER membrane that is able to transfer oxidising equivalents from 
molecular oxygen to the a’ domain of PDI. This activity is not specific to the a’ 
domain but is position dependent and in PDI a’bb’a mutants, a rather than a’ is 
oxidised (Wang et al. 2009). Preferential oxidation at the C-terminus of PDI is likely 
to be due to specific binding of Ero1α at the b’ domain and similarly, the minimal 
requirement for oxidation by Ero1α is PDI b’xa’ (Wang et al. 2010) (see figure 1.6).  
 
 
 
 
Figure 1.6: Mechanism for Ero1α mediated oxidation of the PDI a’ 
domain (adapted from Wang et al. 2009). Ero1 binds to the b’ domain of 
PDI positioning itself in such a way that its active site is in proximity of the 
catalytic site of the a’ domain.   
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The implication of this for PDI is that substrate binding at b’ cannot occur while 
Ero1α is still bound, and therefore substrate cannot bind until the reaction cycle has 
been completed and PDI is in the oxidised state (Wang et. al 2008). Incidentally, 
despite having identical domain architecture, Ero1α is unable to oxidise ERp57 
(Inaba et al. 2010). This indicates that the reaction between Ero1α and PDI is 
specific (Wang et al. 2011). 
Unlike Ero1α, Ero1β is constitutively expressed in the chief cells of the stomach and 
the islet cells of the pancreas (Dias-Gunasekara et al. 2005). Interestingly, its 
expression does not correlate with expression of PDI or PDIp and therefore its 
physiological role is unknown.  It does however form homo and heterodimers with 
other Ero1 proteins and it is the complex form that predominates in the stomach and 
pancreas (Dias-Gunasekara et al. 2005). Authors suggest that this work indicates a 
possible role for Ero1β in passing oxidising equivalents to Ero1α within these highly 
secretory tissues.  
 
 1.1.3.2. Alternative mechanisms for re-oxidation of PDI 
The role of Ero1 as an oxidant of PDI is not unique and in its absence, mammalian 
cells retain some degree of thiol oxidation activity (Appenzellor-Herzog et al. 2010). 
Alternative oxidants of PDI include: quiescin sulphydryl oxidases, glutathione 
peroxidases, and also certain peroxiredoxins (Tavender et al. 2010).  
One of the attractive features of peroxiredoxin 4 (Prx4) mediated PDI oxidation is 
that it can metabolise H2O2 created by Ero1 mediated oxidation (see figure 1.6). This 
is important because although H2O2 is able to oxidise PDI itself, it can also be 
harmful to the cell (Tavender et al. 2010, Karala et al. 2011). The activity of Prx4 
relies on the reduction of an active site disulphide bond. Some PDI family members 
are able to directly reduce Prx4 themselves becoming oxidised in the process and 
leaving Prx4 in a position to oxidise other family members (Tavender et al. 2010). 
Therefore it is probable that oxidation of PDI by Prx4 increases the efficiency of 
EroI mediated disulphide formation and subsequently allows disulphide formation 
via alternative sources of H2O2. 
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An additional mechanism to reduce the concentration of H2O2 is via two ER-resident 
glutathione peroxidases, Gpx7 and Gpx8. Similar to Prx4, these proteins can use 
H2O2 to transfer oxidising equivalents to PDI family members while at the same time 
reducing intracellular peroxide levels (Nguyen et al. 2011). Perhaps more interesting 
is that both Gpx7 and Gpx8 have also been shown to interact with Ero1 in vivo and 
that in vitro, Gpx7 can increase oxygen consumption by Ero1α. The net consequence 
of the presence of the glutathione peroxidases and the peroxiredoxins in the ER is 
that high intracellular H2O2 concentrations are avoided despite its constant 
production via Ero1 mediated oxidation of PDI (Nguyen et al. 2011). In this way, the 
ER has evolved to protect itself from the side effects of oxidative folding. 
 
1.2. The protein disulphide isomerases  
 
1.2.1. The PDI family 
 
1.2.1.1. The domain architecture of hPDI family members 
One very large molecular chaperone family found in eukaryotic cells is the protein 
disulphide isomerase (PDI) family.  
       
Figure 1.7: The domain 
structure of the human 
protein disulphide 
isomerase (PDI) family 
(adapted from Hatahet and 
Ruddock, 2007). PDI, 
ERp57 and PDIp share 
identical domain architecture 
although the a’ active site 
motif of PDIp is slightly 
different.  
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The human PDI family has been extensively studied and ~17 members have now 
been identified (Hatahet and Ruddock, 2007). Although the domain architecture of 
the PDI family members varies considerably (see figure 1.7) each has at least one 
domain with the thioredoxin fold, αβ-fold and mixed β sheet core (Ferrari and Söling 
1999).  
In addition to domain architecture, figure 1.7 also shows the catalytic active sites of 
various PDI family members. Of the 17 shown, figure 1.7 indicates that 5 of the PDI 
family members (PDILT, ERp27, ERp29, ERp44 and TMX2) lack a CXXC catalytic 
active site and therefore may not be able to perform thiol: disulphide exchange 
(Hatahet and Ruddock, 2007). For these proteins, their place in the PDI family is 
defined by their ER residency and structural homology to thioredoxin rather than 
their catalytic activity (Hatahet and Ruddock, 2007).  
 
1.2.1.2. The Thioredoxin fold 
As mentioned previously, human PDI family members have at least one thioredoxin-
like domain (Hatahet and Ruddock, 2007). The thioredoxin (TRX) fold was first 
identified in the small (12kDa) E.coli protein thioredoxin (for review see Holmgren 
and Bjornstedt, 1981) but has since been observed in both eukaryotes and 
prokaryotes. Furthermore, the thioredoxin super-family incorporates protein families 
such as the protein disulphide isomerases, DsbAs and glutaredoxins all of which are 
known to be involved in thiol-disulphide exchange.  
In the 1.6 Å X-ray crystal structure of oxidised E.coli TRX, there is a central 
(hydrophobic) core of five β-strands surrounded by four α-helices (see figure 1.8). 
Typically however, the TRX fold consists of four β-strands and three α-helices (Katti 
et al. 1990). The structure can be separated further into an N-terminal βαβ motif 
(parallel β- strands) containing the CGPC active site and a C-terminal ββα motif 
(anti-parallel β- strands). The two are connected by a loop incorporating the third 
helix (see figure 1.8) and of the two, the N-terminal motif is the least conserved 
within PDI family members whereas the C-terminal motif indicates the most highly 
conserved region (Ferrari and Söling, 1999).  
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In the catalytic domains, the active site motif (CGPC) is located at the N-terminus of 
α2 and allows catalysis of the thiol: disulphide exchange (Hatahet and Ruddock, 
2007). When reduced, (two reactive thiols in active site) TRX binds target proteins 
via its hydrophobic surface before subjecting their disulphide bonds (now in close 
proximity of the reactive thiols) to nucleophilic attack. Ultimately this leads to a 
disulphide bond being formed between active site cysteines and the reduction of a 
disulphide bond in the target protein. Subsequently the activity of TRX is restored by 
reduction with thioredoxin reductase. 
 
1.2.1.3. PDI 
PDI is probably the best characterised member of the PDI family and also the most 
abundant being found ubiquitously in all eukaryotes. It is both a molecular chaperone 
and a general folding catalyst aiding the formation (oxidation), breakage (reduction) 
and rearrangement (isomerisation) of disulphide bonds in a wide range of protein 
substrates.  
 
Figure 1.8: Schematic of 
the thioredoxin fold. 
Arrows indicate β-sheet 
structures and rectangles α-
helices. 
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Figure 1.9: Superimposition of the yPDI and hPDI X-ray crystal structures 
(adapted from Wang et al. 2012). The two structures are superimposed based on 
alignment of the b and b’ domains.  hPDI is shown in multi-colour and yPDI in 
light blue. The rotations associated with the a domain (yPDI) and a’ domain 
(hPDI) are shown). 
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High resolution X-ray crystal structures for both yeast PDI (yPDI) and human PDI 
(hPDI) are now available (Tian et al. 2005, Tian et al. 2008, Wang et al. 2012). 
These proteins share ~30% sequence identity and significant structural homology 
(see figure 1.9).  
Despite structural similarities, yPDI and hPDI clearly undergo different mechanisms 
of conformational change. For yPDI, the two published full-length structures 
(obtained at 4ºC and 22ºC) show that conformational change is centred on the a and 
b domains (Tian et al. 2005 and Tian et al. 2008 respectively). However molecular 
dynamic simulations of yPDI, performed by Emilio Jiminez-Roldan (data currently 
unpublished) show that it has flexibility at both the N and C-terminus i.e. ab and 
b’xa’c. 
Published data for hPDI which includes: fluorescence experiments, limited 
proteolysis, a solution structure of bb’ and full length X-ray crystal structures 
indicates that its flexibility is centred on the x-linker region (Wang et al. 2010, 
Denisov et al. 2008, Wang et al. 2012). Furthermore the major redox-active cassette 
is defined as b’xa’c (Wang et al 2011, Wang et al. 2012). Differences between hPDI 
and yPDI in terms of conformational change are probably indicative of the two 
proteins having different protein substrates and catalytic activity. 
In yeast, the PDI1 gene is essential for viability (Farquhar et al. 1991). This is not the 
case for human PDI however which can be compensated for by other PDI family 
members including ERp57, ERp72 and P5 (Rutkevich et al. 2010). 
 
1.2.1.4. PDIp 
PDIp is a pancreas-specific homolog of PDI (Desilva et al. 1996, Desilva et al. 
1997). It is also a glycoprotein and has 3 glycan chains (Desilva et al. 1996, Walker 
et al. 2012). Like PDI, PDIp has the abb’a’ domain architecture and they share 
~45% sequence identity. Unlike PDI however, PDIp is very poorly characterised and 
currently little is known about its domains: isolated or domain constructs/full length 
protein. Furthermore there are a considerable number of papers on PDIp that use an 
incorrect construct. This construct incorporates part of the signal peptide into the 
Chapter 1. Introduction 
19 
 
mature protein (Desilva et al. 1996). The correct construct has now been published 
(Walker et al. 2012). Consequently studies of the activities of PDIp now need to be 
reviewed.  
 
1.2.1.5. ERp57 
ERp57 is another close homolog of PDI sharing ~33% sequence identity (Frickel et 
al. (2004). Unlike many of the PDI family members however, a specific 
physiological role has been determined. ERp57 interacts with calreticulin and 
calnexin and therefore is important for the oxidative folding of glycoproteins (Oliver 
et al. 1999). ERp57 has also been implicated as an important component of the major 
histocompatability complex (MHC) class I peptide loading complex and in the 
folding of influenza hemagglutinin (Bouvier 2003, Daniels et al. 2003).  
 
 
 
Figure 1.10: PyMOL alignment of PDI and ERp57.  PDB structures 4EKZ (reduced PDI) 
and 3F8U (ERp57) were aligned in PyMOL and shown in blue and red respectively. Tapasin, 
which was co-crystallised with ERp57, has been deleted from the alignment for clarity. 
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The crystal structure of ERp57 complexed with tapasin, has been determined to 2.6Å 
(Dong et al. 2009). It shows remarkable similarity to the recently determined 
structure of hPDI (see figure 1.10) (Wang et al. 2012). The greatest region of 
difference between the two proteins is seen at the C-terminus but this may be due to 
the presence of tapasin, because in PDI the C-terminus is the greatest region of 
flexibility (Wang et al. 2011, Wang et al. 2012). The structure of ERp57 with tapasin 
bound is useful because it provides information about substrate binding in the PDI 
family.  
 
1.2.1.6. ERp72 
Unlike PDI, ERp72 has 3 catalytic domains and the domain architecture a
0abb’a’ 
(Hatahet and Ruddock, 2007). Also unlike PDI but similar to ERp57, ERp72 does 
not have a hydrophobic surface in bb’ that is associated with substrate binding 
(Kozlov et al. 2010). This is particularly interesting because this region is 
structurally homologous to the bb’ domains of ERp57 in terms of the isolated 
domain and domain orientation (Kozlov et al. 2009).  
The catalytic domains of ERp72 are unequal in their contribution to activity in the 
insulin reduction assay (Satoh et al. 2005). ERp72 a
0
 seems to act predominantly as a 
catalyst of oxido-reductase activity, a has an intermediate role in both catalysis and 
substrate binding and the a’ domain is involved in substrate binding (Satoh et al. 
2005). Molecular modelling of ERp72 using crystal structures of a
0
a and bb’ 
domains and aligning to the structure of ERp57, indicate that in correlation with the 
activity data described above and in total contrast to other PDI family members, the 
a
0
, a and a’ domains make up the substrate binding site (Kozlov et al. 2010).  
 
1.2.1.7. P5 
P5 is another poorly characterised member of the PDI family. It is unlike PDI in that 
it has just two domains, both of which are catalytic and contain a PDI-like active site 
motif (Hatahet and Ruddock 2007). Unsurprisingly therefore, PDI and P5 share only 
11% sequence identity (Kikuchi et al. 2002). 
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Currently the function of P5 is unknown but it has been shown to have ~45% 
isomerase activity and ~50-60% chaperone activity relative to PDI (Kikuchi et al. 
2002). These relative percentages are high considering that P5 has no obvious 
substrate binding domain like PDI. It is thus likely that P5 exhibits more restricted 
substrate specificity than PDI and that this is also limited by size. Like PDI however, 
P5 shows asymmetry of activity and the first catalytic domain of P5 seems to be 
more important for isomerase activity than the second domain (Kikuchi et al. 2002, 
Wang et al. 2008). 
 
1.2.1.8. PDILT 
PDILT, like PDIp is also tissue specific and is found in the testes (van Lith et al. 
2005). Also like PDIp, PDILT is an ER-resident glycoprotein. This is an unusual trait 
for PDI family members and is probably linked to its unique physiological role in the 
quality control of sperm membrane protein ADAM3 and male infertility (Tokuhiro et 
al. 2012). Unlike both PDI and PDIp however, PDILT has only one catalytic 
cysteine: in its a’ domain SXXC motif (see figure 1.7). This is sufficient for 
interaction with Ero1α indicating that binding of PDI family members is not 
dependent of the N-terminal cysteine of the CXXC motif (van Lith et al. 2005). 
 
1.2.1.9. Functional redundancy of PDI family members 
PDI1 is essential for viability in yeast indicating that it is unique in its role as a 
protein folding catalyst in these cells (Farquhar et al. 1991). This does not appear to 
be the case in human cells however, and PDI depletion from human hepatoma cells 
has only a minimal effect on the secretion of selected proteins; giving rise to a delay 
in oxidative folding rather than causing arrest (Rutkevich et al. 2010). The 
combination of PDI and ERp57 depletion causes a more significant phenotype: 
slower export of secretory proteins from the ER, slower rate of oxidative folding and 
accumulation of misfolded protein (Rutkevich et al. 2010).  This therefore suggests 
that in vivo, ERp57 may well be able to compensate for loss of PDI (and vice versa) 
Chapter 1. Introduction 
22 
 
and is in agreement with previous work that showed that an ERp57 knockout had 
minimalistic implications (Solda et al. 2006).  
The effect of depletion of either P5 or ERp72 on the secretory properties of the 
hepatoma cells was negligible and no significant difference was seen for 
combinations including P5 and PDI, P5 and ERp57 etc, relative to PDI and ERp57 
depletion alone (Rutkevich et al. 2010). Again this is indicative of PDI and ERp57 
being able to compensate for one another in the cell. This is interesting because if the 
roles of the PDI family members are able to interconvert, it is difficult to explain 
why so many (~17) have been conserved.  
 
1.3. PDI- structure and activity 
 
1.3.1. Structural elucidation of full length hPDI and implications for 
activity 
 
1.3.1.1. The domain architecture of PDI 
Despite having been studied for many years previous, PDI cDNA was first isolated 
from rat liver and characterised just 30 years ago (Edman et al. 1985). It encoded a 
508 amino acid protein that had both a signal peptide and a C-terminal ER-retrieval 
signal. In addition, this protein was shown to have two distinct regions of homology 
(a and a’) with ~ 47% sequence identity and homology to thioredoxin, and two 
further regions (b and b’) that shared ~28% sequence identity (Edman et al. 1985).   
In total, PDI genomic DNA has 11 exons and 10 introns (Tasanen et al. 1998).  On 
account of this, it was suggested that the domain boundaries of PDI could be defined 
using the exon patterns. The a and a’ domains were found to be encoded by exon 1-2 
and 8-9 respectively and exon 3 was thought to encode the e domain as it shared 
sequence homology to oestrogen receptors (Tsibris et al. 1989). This was not the 
case and the e domain was later found to be an artefact when structural studies 
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showed that this region constituted part of the thioredoxin fold of the a domain 
(Kemmink et al. 1997). Additionally, further studies showed that the isolated e 
domain had no independent secondary structure and therefore was more susceptible 
to proteolysis than other regions of the molecule (Darby et al. 1996, Freedman et al. 
1998). 
After many years of collective effort, the current domain boundaries for abb’a’ were 
defined in 2003 (Alanen et al. 2003, Pirneskoski et al. 2003). Figure 1.11 (below) 
shows a schematic representation of the domain architecture of PDI. 
 
 
 
 
 
Determination of the correct domain boundaries for PDI was a collaboration of 
limited proteolysis, studies of recombinant protein expression and NMR (Kemmink 
et al. 1995, Darby et al. 1996, Kemmink et al. 1997, Freedman et al. 1998, Kemmink 
et al. 1999, Darby et al. 1999, Alanen et al. 2003 and Pirneskoski et al. 2003). The 
domain boundaries of PDI were defined as a (V26-T133), b (A137-N232), b’ (Q233-
E348) and a’ (V369-S472). The 19 amino acid linker between b’ and a’ and an 
acidic C-terminal tail of 36 amino acids were also identified (x and C respectively).  
 
1.3.1.2. The catalytic domains of PDI 
As described previously, the catalytically active domains of PDI are a and a’. These 
share 41% and 32% sequence identity with thioredoxin and exhibit a typical TRX 
Figure 1.11: The domain architecture of PDI. The a and a’ domains of PDI are 
catalytically active and share 41% and 32% sequence identity with thioredoxin 
(respectively). The b and b’ domains do not contain an active site and share low 
sequence identity with thioredoxin. Nonetheless both b and b’, display a typical 
thioredoxin-like fold. 
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fold (Kemmink et al. 1995, Dijkstra et al. 1999, Tochio et al. 2005). The a and a’ 
domains each present a CGHC active site motif and therefore are responsible for 
both the oxido-reductase and isomerase activities of PDI. The unique active site 
properties and functional activities of PDI will be discussed later. 
 
 
 
 
 
1.3.1.3. The non-catalytic domains of PDI 
The b and b’ domains of PDI do not contain an active site and therefore are not 
catalytically active. Interestingly, despite sharing very little sequence homology to 
thioredoxin family members, it was shown by NMR that PDI b, like the catalytic 
domains, displayed a thioredoxin-like fold (Kemmink et al. 1997, Kemmink et al. 
1999). Traditionally PDI b’ has been more difficult to study but the solution NMR 
structure of PDI bb’ shows that it too has a thioredoxin-like fold (Denisov et al. 
2008).  
The intransigent nature of b’ has been blamed for the delay in obtaining a high 
resolution 3D structure for full length PDI. It is now understood that the b’ domain is 
highly dynamic and that this is essential for redox-mediated conformational change 
(Wang et al. 2010, Wang et al. 2011, Wang et al. 2012). Furthermore b’ contains the 
Figure 1.12: Comparison of the structures of E. coli thioredoxin and human PDI a (taken 
from Ferrari and Söling (1999)). A) The structure of thioredoxin as determined by Katti et al. 
(1990). B) The structure for PDI a as determined by Kemmink et al. (1997). The active site is 
shown in green, α-helix in red and β-sheet in yellow.  
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major ligand binding site and is therefore essential for substrate binding (Klappa et 
al. 1998a, Darby et al. 1998, Byrne et al. 2009). It is expected that the 
conformational changes (described previously) enable this (Klappa et al. 1998a, 
Byrne et al. 2009, Wang et al. 2011). 
 
1.3.1.4. The x-linker region 
The x-linker is a region of intrinsic flexibility separating the b’ and a’ domains. 
Although poorly understood, it has been identified as a possible modulator of 
substrate binding and as a contributor to changes in redox conformation (Nguyen et 
al. 2008, Byrne et al. 2009, Wang et al. 2011, Wang et al. 2012).  
 
1.3.1.5. The C-terminal Tail 
The C-terminal tail is a 29 amino acid extension comprising predominantly acidic 
residues and containing an ER-retention signal (Pihlajaniemi et al. 1987). Its 
functional importance remains largely unknown but it has been implicated in 
sequestration of calcium in the ER (Macer and Koch, 1988). Unlike yeast PDI 
(yPDI), the C-terminal tail of human PDI (hPDI) does not seem to have any 
appreciable secondary structure (Tian et al. 2006). Furthermore in order to facilitate 
crystallisation, C-terminal truncates (abb’xa’) were used (Wang et al. 2012).  
 
1.3.1.6. Full length structures of PDI 
The first low resolution full length structure of hPDI was the product of small angle 
X-ray scattering (SAXs) studies and atomic force microscopy (AFM) (Li et al. 
2005). Using available NMR structures of the a and b domains it was possible to 
determine a structure for PDI (in solution) which showed the abb’a’ domains aligned 
in an annular arrangement about a central cavity (Li et al. 2005). However, the 
central cavity was found to be not sufficiently large for binding of all possible 
substrates so it was postulated that PDI must undergo some degree of conformational 
flexibility in order to carry out its full range of activities. 
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The first X-ray structure of yPDI showed that at 4ºC, its 4 domains were ordered in a 
twisted ‘u’ conformation. In this structure, the a and a’ domains face each other at 
either side of the ‘u’ and the b and b’ domains form the base (Tian et al. 2006). 
Furthermore the inner surface of the ‘u’ is made up of hydrophobic residues that 
likely facilitate substrate binding but again the central cavity was found to be too 
small to accommodate the majority of PDI target proteins. 
In hPDI, extensive flexibility has been seen around the x-linker region indicating that 
this is a very dynamic region (Wang et al. 2010). Unexpectedly despite similarities 
with hPDI in this area, the major site of flexibility in yPDI is between a and b (Tian 
et al. 2008).  Consequently, conformational changes that increase cleft size in yeast 
PDI are probably not mirrored by human PDI as previously postulated (Tian et al. 
2008). It is likely therefore that many PDI family members use inter-domain 
flexibility in order to regulate their activity.  
The second crystal structure for yPDI at 22ºC indicates the full extent of this motion 
(see figure 1.13). The a domain turns away from a’ via a 123º rotation of the loop 
between a and b. Contact with the b’ domain is lost and this gives rise to a ‘boat-
shaped’ structure with an increased cleft diameter (Tian et al. 2008). When the 
flexibility of a was stabilised with inter-domain disulphide bonds, a reduction in both 
isomerisation and oxidoreductase activity of ~60-70% was seen. This is in stark 
contrast to an a’ stabilised mutant which saw just a 24% reduction in both activities 
indicating that the domain motion of a is essential for the physiological function of 
yPDI (Tian et al. 2008).  
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Figure 1.13: Alternate conformations of yPDI associated with changing 
crystallisation temperature (taken from Tian et al. 2008). The structure of 
yPDI at 4ºC is shown in magenta and 22ºC in cyan.  A) change in the 
position of the  a domain relative to b. B) relative conformation of the b 
and b’ domains.  C) Comparison of the orientation of b’ and a’. Clearly the 
biggest conformational change is at the a domain. 
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1.3.1.7. X-ray crystal structures of hPDI 
Structural elucidation of full length hPDI has revealed that it is an enzyme with 
alternative conformations. Currently two well resolved conformations have been 
identified but it is expected that there are still many dynamic structures yet to be 
observed (see figure 1.14). One such structure shows that in the presence of DTT: a 
well characterised reductant, PDI exhibits a tight, ‘closed’ conformation but in 
another (in the absence of DTT), PDI is ‘open’ (Wang et al. 2012).  
The minimal domain requirement for these structural changes is b’xa’ with position 
of the x-linker region in relation to these domains being particularly important 
(Wang et al. 2011, Wang et al. 2012). In the recent X-ray crystal structure for 
example, DTT-treated PDI displays tight packing of the a’ domain upon b’ with 
clear interaction between the two domains. In untreated PDI however, b’ and a’ are 
more distinct (Wang et al. 2012). It is likely that the plasticity of the x-linker region 
facilitates these movements. 
 
 
 
 
 
The ‘opening’ of PDI gives rise to an increase in cleft diameter from 15Å to 30Å and 
increases the distance between the catalytic active sites from 27.6Å to 40.3Å (Wang 
Figure 1.14: X-ray crystal structures of PDI. Domains shown a-b-b’-a’ (left to right) a) PDI 
crystallised in the presence of 50mM DTT. Diffraction to 2.5Å. b) PDI crystallised as a) but in 
the absence of DTT. Diffraction to 2.9Å. (Wang et al. 2012). 
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et al. 2012). Clearly this suggests an attractive mechanism for substrate binding with 
the ‘open’ form being far more likely to be able to bind large protein substrates than 
the ‘closed’ form. Furthermore, oxidised bb’xa’ has greater chaperone activity than 
the reduced form (Wang et al. 2011) Examples of substrates that could use these 
structural changes for association/dissociation with/from PDI have not yet been 
identified and currently a molecular explanation for these conformational exchanges 
remains controversial.  
One such explanation is that in the presence of DTT, PDI is reduced and therefore 
tethering interactions between the b’ and a’ domains are intact. In the absence of 
DTT or in the presence of an oxidant however, PDI becomes oxidised and this leads 
to these linkages being broken. In particular, a cation-π interaction between the a’ 
active site adjacent tryptophan (W396) and an arginine (R300) in the b’ domain is 
broken in the ‘open’ structure (Wang et al. 2011, Wang et al. 2012). As would be 
expected, an R300A mutant presents a permanently ‘open’ conformation (Wang et 
al. 2011). 
The notion that the activities of PDI may be redox-regulated was highlighted when it 
was found that the cholera toxin A1 chain (CTA1) would only bind to reduced PDI 
and not oxidised PDI (Tsai et al. 2001, Taylor et al. 2011). Consequently it was 
suggested, that oxidation of PDI would lead to dissociation of the CTA1: PDI 
complex giving rise to a very pleasing mechanism for redox-regulated substrate 
binding (Tsai et al. 2001, Tsai et al. 2002). Recent work however has shown that 
disassembly of the CTA1: PDI complex occurs spontaneously at physiological 
temperature (Taylor et al. 2011) and therefore examples of substrates that utilise 
these redox-dependent conformational changes remain to be identified. 
An alternative, contrasting explanation is that organic oxidants/reductants (such as 
DTT, GSH, GSSG etc) are able to bind to PDI and therefore substrate/ligand binding 
gives rise to changes in conformation rather than redox state. This is not unheard of 
and GSSG: a common oxidant used in PDI structural studies, has been shown to 
compete with the α subunit of prolyl-4-hydroxylase for binding to PDI (Lumb and 
Bulleid, 2002). Furthermore, a recent X-ray structure of human PDI bb’xa’ shows a 
molecule of oxidised DTT bound at the b’ domain (Wang et al. 2011) (see figure 
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1.15). It is thus clear that subsequent work to further understand these 
conformational changes is required. Investigators must also be aware of the possible 
implications of using organic molecules to modulate the redox state of PDI and 
should look for alternatives. 
 
 
 
 
 
1.3.1.8. Structural conformations associated with capping of the b’ domain 
Alternative examples of dynamic movements within the PDI structure have also been 
identified. The x-linker region, shown to be pivotal in the above conformational 
changes is found in at least two different conformations (Nguyen et al. 2008, Byrne 
et al. 2009). In the first species the b’ substrate binding site is capped by the x-linker 
but in the second this interaction does not occur, giving rise to the uncapped species 
(see figure 1.16).  
Figure 1.15: PyMOL figure of hPDI bb’xa’. The recent crystal structure of 
bb’xa’ (PDB ID: 3UEM. Wang et al. 2011), shows that a molecule of oxidised 
DTT is bound at the b’ domain (shown in yellow). 
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Interestingly, in the presence of ligand (e.g. somatostatin) equilibrium is shifted 
towards the uncapped species suggesting a possible mechanism for substrate 
modulation (Byrne et al. 2009). Similar capping events have also been seen for other 
PDI family members including ERp44 which is capped by its C-terminal tail in a 
comparable manner (Wang et al. 2008).  
Unlike the previous structural change there is no evidence to suggest that these 
capping/uncapping events are redox-regulated (Nguyen et al. 2008). In addition 
when looking at the X-ray structure of DTT-treated PDI it is clear that the majority 
of the b’ binding site (defined by Byrne et al. 2009) is not in contact with the x-
linker region. The same is true for the un-treated PDI structure. This could indicate 
that the two types of conformational changes described here are unconnected. It 
might also imply that again molecules like DTT have competed successfully with the 
x-linker for binding at b’ supporting a substrate binding induced model for 
conformational change in PDI.  
 
  
Figure 1.16: Alternative conformations of the x-linker region (taken from Byrne et al. 
2009). When uncapped, the b’x molecule has a natural propensity to dimerise. In the capped 
form, the x-linker binds to the substrate binding site and this prevents dimerisation from 
occurring. In the presence of ligand, neither dimerisation nor x-linker binding occurs because 
the substrate binding site is already occupied. 
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1.3.2. The functional activities of hPDI 
 
1.3.2.1. Disulphide bond chemistry in vivo 
Disulphide bond formation is essential for protein folding and occurs in the 
periplasm of bacteria and the ER of eukaryotic cells. Spontaneous disulphide bond 
formation however, is very slow and therefore it is the role of oxido-reductases such 
as PDI and other PDI family members to catalyse this reaction in vivo (Anfinsen, 
1973). The catalytic activities of PDI that enable this are: oxidation, reduction and 
isomerisation, i.e. the formation, breakage and rearrangement of disulphide bonds.  
 
1.3.2.2. The catalytic active sites of PDI 
Common to all oxido-reductases of the TRX family, the catalytic domains of PDI (a 
and a’) contain CXXC active site sequences. For PDI this is CGHC for both, but the 
exact active site sequence can vary between family members with some not having 
an active site at all (see figure 1.7). For PDI a, the N-terminal cysteine (C53) is 
essential for activity. Not only is it accessible (unlike the C-terminal cysteine), it also 
has a pKa of 4.8 +/- 0.1 (Karala et al. 2010). This is particularly low (a typical 
cysteine residue has a pKa of ~8.3) and means that at physiological pH (pH~7.3) the 
reactive thiolate form is stabilised. On account of this, PDI is able to act as an oxido-
reductase and isomerase (see figure 1.17).  
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The requirement for the C-terminal cysteine however, is much more complex. While 
a low pKa at this position favours reduction and the last step in oxidation, it has an 
Figure 1.17: Oxidation, reduction and isomerisation reactions of PDI (taken from 
Hatahet and Ruddock, 2007). When PDI is oxidised: 1) A substrate thiol nucleophilically 
attacks the active site disulphide bond of PDI forming a mixed disulphide. From here there 
are 3 possible reactions 2, 3 & 4. 2) The substrate thiol can nucleophilically attack the 
disulphide bond of the mixed disulphide leading to formation of a disulphide bond in the 
substrate and reduction of the PDI active site. 3) The C-terminal cysteine could also 
nucleophillically attack the mixed disulphide leading to re-formation of the PDI active site 
disulphide bond and leaving the substrate cysteine in the reduced state. 4) Finally a 
substrate thiol could nucleophilically attack the substrate disulphide i.e. isomerisation. 
When PDI is reduced: 5) The N-terminal thiol group of PDI nucleophilically attacks the 
substrate disulphide. This gives rise to formation of a mixed disulphide. Again there are 3 
possible reactions 6, 7 & 8. 6) Nucleophilic attack of a different substrate thiol on the 
mixed disulphide leading to isomerisation in the substrate. 7) Nucleophilic attack by the 
substrate thiol on the mixed disulphide to give rise to reduced PDI and a disulphide bond 
in the substrate protein.  8) Or finally, nucleophilic attack by the C-terminal cysteine of 
PDI on the mixed disulphide leasing to reduction of the substrate thiol and disulphide 
formation in PDI. 
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inhibitory effect on earlier steps in the oxidation pathway and also isomerisation (see 
figure 1.17).  The actual pKa of the C-terminal cysteine of PDI a (C56) is ~8.6 +/-0.0 
and so in order to meet the requirements described previously, it must be modulated 
by nearby residues (Karala et al. 2010). Molecular dynamic simulations indicated 
that the residue most likely to display this activity was R120 and this was supported 
in later work by the same group (Lappi et al. 2004, Karala et al. 2010). 
R120 is highly conserved in the catalytic domains of PDI family members (PDI, 
PDIp, ERp57, ERp72, P5 and PDIr) and is located on a loop between β5 and α4 
(Lappi et al. 2004). In silico studies have suggested that in PDI in vivo, this loop can 
have alternative conformations leading to its movement in and out of the active site 
locale. Consequently, when R120 is in proximity of the active site, it may stabilise 
the thiolate state of the C-terminal cysteine via electrostatic interactions with its 
positively charged side chain (Lappi et al. 2004). In support of this hypothesis, 
mutations in R120 lead to a significant increase in pKa and thus these mutants are 
also less active in the peptide oxidation assay (Karala et al. 2010, Lappi et al. 2004). 
The two catalytic domains of PDI share high sequence identity, especially around the 
active site. Therefore, despite the fact that the pKa’s of the a’ active site cysteines 
have not been determined, it is likely that they are comparable to the pKa of C53 and 
C56. In addition there is no evidence to suggest that the a’ domain of PDI is any less 
active as an oxido-reductase than PDI a, although clearly there is some positional 
benefits of being at the C-terminus of the molecule adjacent to the ligand binding b’ 
domain (Wang et al. 2008). 
 
1.3.2.3. Influences on redox activity 
The activity of all thioredoxin family oxido-reductases (including PDI), is 
determined by the standard redox potential of the disulphide/dithiol pair formed by 
the two active site cysteines. This is highly variable within the PDI family, and the 
stability of the active site disulphide can vary by up to 7 kcal/mol, equivalent to a 10
5
 
fold difference in the equilibrium constant (Kortemme et al. 1996). For the a and a’ 
domains of PDI, the redox potentials are -163mV and -169mV respectively 
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(Chambers et al. 2010). Contributing to these redox potentials and subsequently the –
SH/S- equilibria, are the two residues between the active site cysteines i.e. Gly54 and 
His55.  
As the pKa of the N-terminal cysteine of PDI a is very low, its thiolate state must be 
stabilised by nearby positive charges. As discussed previously, interaction with R120 
on the loop between β5 and α4 is probably very important for this but it is likely that 
the imidazole group of H55, immediately adjacent to the C-terminal cysteine also 
plays a stabilising role (Lappi et al. 2004, Karala et al. 2010, Kortemme et al. 1996). 
In support of this, the pKa of the imidazole group of H55 is altered in the presence 
and absence of a C53 thiolate ion indicating that when exerting a stabilising effect on 
the thiolate ion, it too is stabilised (Kortemme et al. 1996). Furthermore this histidine 
residue is conserved in DsbA, confirming that it may be important for stabilising the 
N-terminal thiolate ion and promoting oxidase activity. 
The importance of the residues at positions 2 and 3 in the Cys1-Xaa2-Xaa3-Cys4 motif 
can be seen by studying the activities of thioredoxin and DsbA, which have the 
active site sequences CGPC and CPHC respectively. In both cases, the active site 
differs from that of PDI by just one amino acid but contributes to pKa’s for the N-
terminal cysteines of 6.3+/-0.1 and 3.4+/-0.2 for thioredoxin and DsbA respectively 
(Forman-Kay et al. 1992, Bardwell et al. 1991, Grauschopf et al. 1995). The net 
effect of this is that thioredoxin predominantly acts as a reductase and DsbA as an 
oxidase.  
Interestingly, mutation of the thioredoxin active site to that of PDI (CGPC to CGHC) 
increases the redox potential (from -270mV to -235mV), lowers the pKa of the N-
terminal cysteine, decreases reductase activity and improves isomerase activity 
(Krause et al. 1991, Lundstrom et al. 1992). Similarly, mutation of the PDI active 
site (CGHC to CGPC), increases the pKa of the N-terminal cysteine and has a 
negative effect on its oxidase and isomerase activities (Chambers et al. 2010). For 
DsbA however, mutation of its active site (CPHC to CGHC) reduces the reduction 
potential and increases the pKa of the N-terminal cysteine, making it less active as an 
oxidase (Huber-Wunderlich and Glockshuber, 1998). Hence it is clear that the 
residues between the catalytic cysteines of the active sites of PDI, thioredoxin and 
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DsbA contribute to maintaining the redox potential and also the catalytic activity of 
the enzymes. Furthermore a high pKa value for the N-terminal cysteine promotes 
reductase activity and a low pKa value, oxidase activity. 
 
1.3.2.4. Roles of additional regions of PDI in activity 
The isolated a and a’ domains have limited catalytic activity of protein substrates; 
the sum of which does not equal the total activity of PDI. For example, in their 
studies of the disulphide bond rearrangement of BPTI, Darby et al. (1998) saw 
no/negligible activity for the isolated a and a’ domains despite them being wholly 
responsible for the isomerase activity in the full-length protein. In the presence of b’ 
however, activity is markedly improved suggesting that substrate binding is essential 
for complicated disulphide isomerisations of larger protein substrates (Darby et al. 
1998, Klappa et al. 1998a). Subsequently the minimal requirement for disulphide 
bond rearrangement is b’xa’ and maximal isomerisation efficiency is seen in 
constructs containing all 4 domains (Darby et al. 1998). This work is indicative of 
synergy between the thioredoxin-like catalytic and ligand binding domains of PDI 
(Freedman et al. 2002). 
 
1.3.2.5. The chaperone activity of PDI 
Alongside its activity as a protein folding catalyst, PDI also exhibits molecular 
chaperone activity. Although this activity complements the catalytic activity of PDI, 
it is actually independent of it and consequently, PDI is able to prevent the 
aggregation of proteins that do not have disulphide bonds e.g. D-glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (Cai et al. 1994).  
Unlike the oxido-reductase and isomerase activities of PDI for which the catalytic 
sites are fundamental, the b’ domain has been shown to be essential for chaperone 
activity. Furthermore the addition of a small peptide substrate that binds to PDI b’ is 
able to completely abolish chaperone activity (Quan et al. 1995). This is perhaps an 
over simplification however, and chaperone activity is probably linked to the 
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interaction of non-native protein with the hydrophobic surface that spans the inside 
of the ‘u’ shaped structure of PDI (Wang et al. 2012). Certainly it has recently been 
shown that the oxidised ‘open’ form of PDI exhibits greater chaperone activity than 
the reduced form (Wang et al. 2011). 
 
1.4. Pancreas-specific PDI (PDIp) 
 
1.4.1. Identification of PDIp and observation of its domain architecture 
 
1.4.1.1. Initial identification of PDIp 
PDIp is a relatively newly identified PDI family member having been identified for 
the first time in 1996 (Desilva et al. 1996). Located on chromosome 16p13.3, initial 
studies of the PDIp gene (Pa-1) suggested that it encoded an ORF of 511 amino 
acids. As no in-frame stop codon was identified and a typical ER signal sequence 
was lacking, authors agreed that the assigned ATG start was tentative (Desilva et al. 
1996). This has now been resolved and it seems that Pa-1 is the product of an 
aberrant recombination event that led to introduction of an incorrect start codon 
(Walker et al. 2012). Figure 1.18 explains how this may have occurred.  
 
 
 
 
Figure 1.18: Comparison of Pa-1 cDNA with correct PDIp cDNA (taken from Walker et al. 
2012). The region of reverse homology is shown in red. Direct homology is shown in blue. 
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Unfortunately, the incorrect Pa-1 construct has been used in a number of published 
studies of the activities and binding properties of PDIp. It is known that this incorrect 
form of PDIp has increased propensity to dimerise on account of a cysteine residue 
in its uncleaved signal peptide (Fu and Zhu, 2009a). Thus, recently published studies 
on the activity and binding properties of PDIp (that use the Pa-1 construct) must be 
considered with caution.  
 
1.4.1.2. The domain architecture and unusual a’ active site sequence of PDIp  
Like PDI and ERp57, PDIp has 4 thioredoxin-like domains and abb’a’ domain 
architecture (Hatahet and Ruddock 2007). It shares 45% sequence identity with PDI 
and despite a distinct lack of structural information available, is anticipated to have a 
similar 3-dimensional structure (Ferrari and Söling, 1999). In addition, PDIp has an 
extended N-terminus which is very negative charged. The implications of this are 
unknown.  
Perhaps one of the most significant differences between PDI and PDIp, is the Gly to 
Thr substitution seen in the a’ active site of PDIp (CTHC instead of CGHC). 
Although seemingly unimportant, changing the dipeptide between active cysteines 
residues (from CGHC) can have major side effects for the reactivity of the protein 
(as described previously for DsbA and thioredoxin). Furthermore, the presence of a 
Thr residue at position 2 in the a’ active site of PDIp may prevent stabilising 
interactions between the N-terminal  Cys and active site His due to steric hindrance. 
The net result of this would be that the pKa of the a’ domain N-terminal cysteine is 
increased leading to a reduction in reactivity (relative to the a domain that has a 
CGHC active site).  
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1.4.2. Localisation of PDIp: cellular and physiological 
 
1.4.2.1. The cellular location of PDIp 
Full length PDIp is a 525 amino acid protein with both a 21 amino-acid signal 
peptide and a KEEL ER-retention signal. Unlike PDI and ERp57, PDIp is found 
exclusively in the ER (Walker et al. 2012). Captivatingly, when expressed in 
transfected HeLa cells, both wild-type and glycosylation-null PDIp co-localise with 
calreticulin, an ER marker but not ERGIC53 a marker for the ER-Golgi intermediate 
compartment. This indicates that none of the 3 N-linked glycans of PDIp (located in 
a, b’ and c) are modified by Golgi-resident enzymes. This was further confirmed by 
sensitivity of wild-type PDIp to PNGase F and Endo H (Walker et al. 2012). 
 
1.4.2.2. The physiological location of PDIp 
The exact location(s) of PDIp expression is disputed in the literature. Early Northern 
blot studies observed PDIp mRNA in (human) pancreatic acinar cells but not brain, 
pituitary gland, lymph node, thyroid, thymus, lung, liver, kidney, spleen, testes or 
stomach (Desilva et al. 1996). Furthermore, this restricted expression pattern was 
later confirmed via Western analysis and also a radio-labelled somatostatin binding 
assay (Klappa et al. 1998b). In contrast to these results, RT-PCR has since been used 
to identify low levels of PDIp expression in the human brain (Conn et al. 2004).  It is 
likely that the increased sensitivity of RT-PCR over blotting techniques (used 
previously) has made this possible and it would be interesting to determine other 
tissues exhibiting low level PDIp expression that may have been formerly 
overlooked. 
More recently PDIp expression has also been observed in (mouse): liver, kidney, 
lung, uterus, stomach, caecum and ileum by Western blot (shown in figure 1.19) (Fu 
et al. 2009). This is opposed to previous data that saw no expression of PDIp in (rat): 
liver, kidney, lung, reproductive organs or intestinal tract also by Western blot 
(Klappa et al. 1998b). At this time it is not possible to explain these conflicting 
results but it is interesting that PDIp expression seems to be specific to secretory 
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cells e.g. pancreatic acinar cells, chief cells in the stomach and paneth cells in the 
ileum (Fu et al. 2009b). 
 
 
 
Interestingly, Western and Northern blots show that PDIp is expressed (protein and 
mRNA respectively) in the stomachs of auto-immune regulator (AIRE) deficient 
NOD mice (Niki et al. 2006). NOD mice are typically used as an animal model for 
Type-1 diabetes and classically exhibit islet cell destruction, but in AIRE-deficient 
NOD mice, acinar cells are targeted instead. Furthermore PDIp (both from mouse 
serum and also the recombinant protein) acts as an auto-antigen in these mice (Niki 
et al. 2006).  These results may indicate that non-acinar cell expression of PDIp 
occurs in diseased tissues following induction of the UPR. 
Therefore the physiological role of PDIp may be to ensure correct folding of 
secretory molecules such as zymogens thereby preventing cellular stress and 
induction of the UPR caused by the heavy work load of the secretory cell (discussed 
later). Furthermore, this function is likely to be independent of PDI which is 
Figure 1.19: 
Comparison of 
PDI and PDIp 
expression in 
various mouse 
tissues by Western 
blot (taken from Fu 
et al. 2009b). 
Shaded arrow 
probably indicates 
unglycosylated 
PDIp.  
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ubiquitously and abundantly expressed in all tissues including the exocrine pancreas 
as it is improbable that PDIp would have been evolutionarily conserved otherwise. 
 
1.4.2.3. PDIp expression during Xenopus development 
Pancreatic development is highly conserved in vertebrates and is regulated by signals 
from adjacent tissues such as the mesenchyme (Sogame et al. 2003, Golosow and 
Grobstein, 1962).  
 
 
 
 
 
Figure 1.20: Development of the pancreas and expression patterns for PE2 and 
PDIp (adapted from Sogame et al. 2003). A-C: Schematic diagrams of gut tubes taken 
from tadpoles. All associated endodermal organs except the pancreas have been removed 
for clarity. The developing pancreas is shown in blue. A) Stage 40 embryo, B) stage 42 
embryo and C) stage 44 embryo. 1-6: Expression patterns of PE2 and PDIp in the gut 
tubes of tadpoles; examined by in situ hybridisation. 1) PE2 expression, stage 40, 2) PE2 
expression, stage 42, 3) PE2 expression, stage 44, 4) PDIp expression, stage 40, 5) PDIp  
expression, stage 42 and  6) PDIp expression, stage 44. 
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During pancreatic development, PDIp cDNA is first detected at embryonic stage 40 
and is much stronger by stage 42 (see figure 1.20). This coincides with the 
development and finally the fusing of the ventral buds and overlaps significantly 
with the expression of pancreatic elastase 2 (PE2) cDNA (Sogame et al. 2003). 
This work indicates that expression of both PDIp and PE2 occurs during the late 
stages of pancreatic development. This is consistent with studies showing that 
transcription of exocrine enzymes occurs later than that of endocrine hormones 
(Debas, 1997). The co-expression of PDIp and PE2 may indicate that as 
hypothesised, the physiological role of PDIp is to ensure the correct folding of 
pancreatic zymogens (Klappa et al. 1998b).  
 
1.4.3. PDIp, cellular stress and disease 
 
1.4.3.1. PDIp and the Unfolded Protein Response (UPR) 
Despite the preferential expression of PDIp in the pancreatic acinar cells, there is 
increasing evidence for its role in the UPR in other tissues. For example, expression 
of PDIp mRNA is up-regulated following MPP
+ 
treatment of retinoic acid 
differentiated SH-SY5Y neuroblastoma cells whereas that of other PDI family 
members (PDI, PDIR, P5, ERp29, ERp44, ERp57 or ERp72) was not (Conn et al. 
2004). Similar results were seen for two known proteasome inhibitors lactacystin and 
MG115, but not H2O2 or canavanine which cause oxidative stress and the 
accumulation of misfolded proteins respectively (Conn et al. 2004). Furthermore 
MPP
+ 
and lactacystin treatment of cell lysates also results in up-regulation of PDIp 
protein expression although to a lesser extent (shown by Western blot). This is 
probably due to a reduction in translation caused by ER stress. This work suggests a 
role for PDIp in proteasomal impairment although currently there is no evidence of 
PDIp being present in the cytosol (Walker et. al 2012).  
Immunohistochemistry of diseased human brains (Parkinson’s disease, Dementia 
with Lewy bodies and Altzheimer’s Disease) shows the presence of PDIp within 
Chapter 1. Introduction 
43 
 
some Lewy bodies (LBs) but not in senile placques or neurofibrillary tangles (Conn 
et al. 2004). Approximately 57% of α-synuclein immunostained LBs also stained 
positive for PDIp and the two have been shown to co-localise (see figure 1.21). 
Unpublished data from C.C. Wang (personal communication) shows that PDIp 
cannot inhibit formation of the α-synuclein fibril. Consequently it is likely that the 
presence of PDIp within LBs is circumstantial and a result of sequestration after up-
regulation and the initial stress response.  
 
 
 
 
  
Figure 1.21: Co-localisation of α-
synuclein and PDIp expression in 
human DLB substantia nigra 
(taken from Conn et al. 2004). SN 
tissue immunostained with PDIp 
(green) and α-synuclein (red). 
Overlaying immunoreactivity 
(yellow). 
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1.4.3.2. The role of XBP-1 activation in induction of PDIp expression 
As described previously, the transcription factor XBP-1 is activated in times of 
cellular stress. XBP-1
-/- 
Liv
XBP-1 
mice survive the embryonic lethality of XBP-1 
deficient mice but exhibit severe abnormalities in secretory organs, particularly 
pancreatic acinar cells. While islet cells develop normally, acinii are poorly 
distributed and numbers of zymogen granules are reduced (Lee et al. 2005). In 
addition the ER is also poorly developed. This leads to reduced zymogen production 
and consequently mice with this phenotype die shortly after birth due to an inability 
to digest milk (Lee et al. 2005). On this basis it is likely that XBP-1 is essential for 
the development of highly secreting cells. 
XBP-1 has previously been shown to induce ER-resident chaperone genes involved 
in the UPR (Lee et al. 2003). RT-PCR studies used to identify genes regulated by 
XBP-1 in the pancreas identified significantly reduced expression of Sec61α, EDEM, 
PDI and PDIp mRNAs in XBP-1
-/- 
Liv
XBP-1 
mice (Lee et al. 2005). Expression of 
ERdj5, P5 and Grp58 mRNAs were unaffected and this is probably due to 
compensation by alternative pathways such as the ATF6 pathway.  
Overall this work suggests that PDIp expression may be up-regulated by activation 
of XBP-1 and the UPR. It could also be evidence of a role for PDIp in zymogen 
production as postulated previously (Ruddock et al. 1998).  
 
1.4.3.3. PDIp and Cancer 
Although PDIp is abundantly expressed in pancreatic tissue, its expression is absent 
from pancreatic tumour cell lines (Fu et al. 2009). Furthermore, PDIp expression was 
not detected in 17 out of 18 human pancreatic duct adenocarcinoma samples and this 
indicates that the disappearance of PDIp may be associated with the development of 
disease (Fu et al. 2009). Figure 1.22 shows the results of immunohistochemical 
staining of PDIp in various different human pancreatic tissue samples. 
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From figure 1.22 it is clear that expression of PDIp was absent from all cancerous 
tissues tested. Interestingly, PDIp was still expressed in cancer adjacent tissue and 
authors have suggested therefore that loss of PDIp expression could be used as a 
biological marker for pancreatic cancer (Fu et al. 2009). Currently the relationship 
between PDIp expression and cancer is poorly understood. Based on the medical 
implications of this work, it probably warrants further investigation.  
 
  
Figure 1.22: Immunohistochemical staining of human pancreatic tissue (taken from Fu 
et al. 2009). Staining of normal tissue indicates high expression of PDI (1). In duct 
adenocarcinoma, islet cell carcinoma and acinic cell carcinoma there is no staining, 
indicating that PDIp is not expressed (2, 3, 4, 6 & 7). However PDIp staining is seen in 
cancer adjacent tissue (5) indicating that loss of PDIp may be indicative of disease onset.  
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1.4.4. The unique substrate binding specificity of PDIp  
 
1.4.4.1. Binding studies of PDIp 
Early studies showed that like PDI, PDIp only interacts with non-native proteins. 
Moreover these reactions are independent of cysteine residues within the ligand or 
presence of glycans. When ERp57 is inhibited in canine pancreatic microsomes, 
cross-linking to PDI and PDIp is increased (Elliott et al. 1998) indicating that PDI 
family members exhibit some degree of functional redundancy. Consequently it is 
difficult to understand the cellular requirement for a pancreas specific-PDI, but 
determining a natural substrate may aid elucidation of a physiological role.  
The substrate binding properties of PDIp have been determined by measuring the 
ability of various ligands to inhibit Δ-somatostatin binding to PDIp. From these 
studies it has been possible to define the minimal requirement for ligand binding to 
PDIp as a hydroxyl-aryl group (Klappa et al. 1998b, Ruddock et al. 2000, Klappa et 
al. 2001). This is in stark contrast to PDI which exhibits broader substrate specificity 
linked to its role as a general folding catalyst and could be indicative of an exact role 
for PDIp that is also related to its unusual expression pattern.  It is also clear that the 
presence of an N-glycan protruding from the putative substrate binding domain (b’) 
has no effect on ligand binding specificity with similar results being reported for both 
microsomal (rat, sheep and dog) and also recombinant PDIp (Klappa et al. 2001). 
The significance of this is not yet known.  
As expected, only pentapeptides containing a tryptophan or tyrosine residue inhibited 
cross-linking of labelled peptides to PDIp although this was impeded if either residue 
was adjacent to an acidic amino acid. Similarly, single tryptophan or tyrosine 
residues could compete for binding but only if the C-terminus was modified 
(Ruddock et al. 2000). In addition compounds lacking a hydroxyl-aryl group and 
those with a modified hydroxyl-aryl group showed little or no competition for 
binding to PDIp at any concentration tested (Klappa et al. 2001). It is thus clear that 
PDIp requires only single amino acid recognition for ligand binding but that there is 
some additional specificity in regards to chemical environment.   
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In some cases, modification of the aromatic ring (particularly substitutions at the para 
position to –OH) can lead to reduced inhibition (Klappa et al. 2001). It is likely that 
these modifications decrease ligand binding by destabilising π-π interactions between 
the aromatic ring of the ligand and an aromatic ring structure in the substrate binding 
site of PDIp. Conversely, a 2-4C substituent at the para position to –OH improves 
substrate binding and this becomes further enhanced as alkyl chain length increases 
(Klappa et al. 2001). Clearly hydrophobic interactions are important for binding of 
substrate to PDIp but currently this is not well understood. 
Various compounds containing a hydroxy-aryl group have been tested for their 
ability to inhibit cross-linker binding including synthetic peptides derived from 
digestive enzymes and also various oestrogens (Klappa et al. 1998b, Klappa et al. 
2001). All enzyme derived peptides tested (synthetic peptides derived from 
pancreatic lipase, pancreatic α-amylase, cholesterol esterase etc) interacted with 
PDIp as did 17β-oestradiol, oestriol and oestrione (see figure 1.23) (Klappa et al. 
1998b). Binding of 17β-oestradiol to PDIp was particularly tight (approximately 
stochiometric) and could inhibit the binding of synthetic digestive enzyme derived 
peptides (Klappa et al. 1998b). In this way high oestrogen concentration (i.e. during 
oestrogen replacement therapy or pregnancy) might modulate the activity of PDIp in 
vivo. 
 
 
 
Figure 1.23: Oestrogens 
inhibit cross-linking of 
PDIp.  Oestrogens were 
tested for their ability to 
prevent radiolabeled 
somatostatin from binding 
to PDIp (adapted from 
Klappa et al. 1998). 
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Interestingly, despite the high affinity for 17β-oestradiol, no significant interaction is 
seen for 17α-oestradiol and PDIp (Klappa et al. 1998b). This finding clearly 
indicates a complexity to substrate binding that is linked to structural and steric 
requirements rather than specific chemical groups.  
 
1.4.4.2. PDIp as a modulator of intracellular oestrogen 
It has been suggested that the physiological role of PDIp may be to act as an 
intracellular oestrogen modulator (Fu et al. 2012). This coincides with previous work 
that shows that PDIp is able to bind to 17-β-oestradiol in vitro (Klappa et al. 1998b, 
Fu and Zhu, 2009b and Fu et al. 2011). Further characterisation of this interaction 
shows that when PDIp and 17-β-oestradiol are separated from a crude pancreatic cell 
lysate, the apparent Kd for their interaction is ~150nM (Fu et al. 2012). There are a 
number of issues with the hypothesis that PDIp and 17-β-oestradiol would interact in 
vivo: 1) recent data shows that PDIp is exclusively expressed in the ER of the cell 
(Walker et al. 2012). There is currently no data for 17-β-oestradiol in the rough ER, 
indicating that its concentration may be negligible or insufficient for interaction with 
PDIp. 2) The normal concentration of 17-β-oestradiol in the blood serum of a fertile 
woman is <1.5nM. Consequently very little/no interaction would be seen in vivo 
according to the specified Kd (Akerlund et al. 1981). 3) No difference in PDIp 
expression was seen between male and female rats, whereas oestrogen concentration 
is significantly higher in females (Fu et al. 2009). 
Although 17-β-oestradiol is probably not the physiological substrate of PDIp itself, it 
may help to mediate the interactions of PDIp with proteins that are. One suggestion 
is that PDIp is involved in the folding of acinar cell-specific proteins such as the 
pancreatic zymogens. This may explain conditions such as hyperemesis (morning 
sickness) which are associated with an increase in blood serum oestradiol 
concentration (Baron et al. 1993). Presently, the role of molecular chaperones in 
folding pancreatic zymogens has not been studied but it is clear that for prochymosin 
(zymogen found in the stomach), refolding efficiency is increased from 2% to 28% 
in the presence of PDI (Wei et al. 2000). Furthermore with the high secretory output 
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of the acinar cells, chaperones would be essential to ensure correct folding and 
reduce the toxicity caused by misfolded proteins.  
 
1.4.4.3. The oestradiol binding site of PDIp 
Similar to the interaction of PDI and its substrates, binding of oestradiol occurs 
predominantly at the b’ domain of PDIp. Unlike for PDI however, some binding also 
occurs in the b domain and it seems that both the b and b’ domains are important for 
efficient binding of 17-β-oestradiol (Fu et al. 2011).   
Computational modelling analysis, using the solution structure of PDI bb’ (Denisov 
et al. 2009), showed that the binding pocket of PDIp was similarly located to that 
shown for PDI in work by Byrne et al. (2009). Furthermore, using a combination of 
mutagenesis and molecular modelling, authors were able to identify PDIp His278 as 
a residue essential for the interaction between PDIp and 17-β-oestradiol (Fu et al. 
2011). Unpublished data by the RBF group however shows that the PDIp H278A 
mutation is destabilising and therefore suggests that further investigation is required.  
 
1.4.4.4. The functional activities of PDIp 
Although the functional activities of PDIp have been studied quite extensively, much 
of the work has been performed using the incorrect Pa-1 construct. This construct 
gives rise to protein with an un-cleaved signal peptide: MASCPWG.  The presence 
of an additional cysteine residue at the N-terminus leads to aberrant formation of an 
inter-subunit disulphide bond and therefore increased dimerisation (Fu and Zhu, 
2009a). As a consequence of this, studies of activity that use the incorrect Pa-1 
construct must be considered with caution and will not be discussed here.  
PDIp is able to bind to scrambled RNAse but not native protein indicating that like 
PDI, it too has chaperone activity (Klappa et al. 1998b, Ruddock et al. 1998). This 
activity was later assigned to the bb’ domains by Fu and Zhu (2010) having studied 
the PDIp bb’ domain construct for its ability to suppress aggregation of GAPDH.  
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There is very little published data for the oxido-reductase and isomerase activities of 
wild-type PDIp. In a peptide oxidase assay however, PDIp was ~50% as active as 
PDI and had unusual pH dependence compared to other PDI family members 
(Alanen et al. 2006). The low activity of PDIp in this assay could be due to the 
unusual CTHC active site sequence in the a’ active site. Certainly it is well known 
from studies of the active sites of thioredoxin and DsbA that the residues between 
catalytic cysteines are important for defining their reactivity (see previously). 
 
1.5. Aims of this study 
 
This chapter has introduced protein folding and the quality control systems that 
regulate protein folding in the ER. The role of protein disulphide isomerase (PDI), an 
abundant ER-resident molecular chaperone has also been discussed. This protein is 
the most characterised member of the PDI family; a family categorised by their 
intracellular location and structural homology to thioredoxin. PDIp, a PDI family 
member with identical domain architecture to PDI, is by comparison, very poorly 
characterised.  
Using comparisons to PDI, this work aims to investigate the redox-mediated 
conformational changes and oxido-reductase activity of PDIp (in vitro) in order to 
improve understanding of this otherwise poorly characterised PDI family member. 
This is important because the majority of available data for recombinant PDIp uses 
an aberrant DNA construct.  
 
The aims of this work can be broken down as follows: 
1. Identify suitable conditions for optimal expression, purification and storage 
of PDIp and PDIp constructs. 
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2. Characterise the redox-mediated conformational changes and oxido-reductase 
activity of wild-type PDIp relative to PDI using far UV CD, limited 
proteolysis, DLS and the insulin reduction assay. 
3. Identify regions within PDIp that contribute to its redox-mediated 
conformational changes and activity using both chimera proteins and active 
site mutants. 
4. Examine the role of the a domain in the oxido-reductase activity of PDIp 
using stopped flow pKa determination and oxidase/reductase assays. 
It is hoped that studying PDIp (as described above) will facilitate understanding of its 
role within the exocrine pancreas and perhaps enable identification of physiological 
substrates. 
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Chapter 2. Materials & Methods 
 
 
2.1. Molecular Biology 
 
2.1.1. Clone list and primer design 
 
2.1.1.1. The pET 23b vector 
All constructs were cloned into a pET 23b vector (Novagen) between the NdeI and 
SalI sites of the multiple cloning region (see figure 2.1). This vector also has 
ampicillin resistance, conferred by base pairs 2211-3068.  
The vectors used for this work have been modified slightly to add coding for an N-
terminal hexa-His tag and also a ribosome binding site between the NdeI and XbaI 
sites of the multiple coding region (courtesy of Lloyd Ruddock). The His-tag is not 
removed after protein purification because there is no evidence to suggest that it has 
a negative effect on the structure/function of any of the proteins tested. All plasmids 
were stored in DH5α cells and transformed into BL21(DE3)pLysS competent cells 
for expression. 
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Figure 2.1: Vector map showing pET- 23a (+) vector (Novagen).  pET- 23b is identical to 
pET- 23a except that it lacks a base pair just after the BamHI site (198) making it a 3665bp 
plasmid. Furthermore the region between NdeI and XbaI contains coding for an N-terminal 
hexa-Histidine tag and also a ribosome binding site. This alteration has been designed to 
improve protein expression levels. 
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2.1.1.2. PDI/PDIp clone list 
Table 2.1. lists the PDI/PDIp constructs used in this study. Constructs identified by 
pKLW were designed and created specifically for this work.  
 
Plasmid  Protein  Donor 
pLR188 PDIp b’xa’c Prof. Lloyd Ruddock 
pLR330 PDIp Prof. Lloyd Ruddock 
pRF631 PDI Prof. Lloyd Ruddock 
pLR1368 PDIp a Prof. Lloyd Ruddock 
pLR1370 PDIp a’ Prof. Lloyd Ruddock 
pKLW1 PDIp (K40-L525) N/A 
pKLW2 PDI H256A N/A 
pKLW3 PDIp H278A N/A 
pKLW4 PDIp R300H N/A 
pKLW5 PDIp a C71S N/A 
pKLW6 PDIp a C74A N/A 
pKLW7 PDIp C71S N/A 
pKLW8 PDIp C418S N/A 
pKLW9 PDIp C421A N/A 
pKLW10 PDIp C71S C74A N/A 
pKLW11 PDIp C71S C74A C364S N/A 
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pKLW12 PDIp C71S C74A C418S N/A 
pKLW13 PDIp C71S C74A C421A N/A 
pKLW14 PDIp a W146F N/A 
pKLW15 PDIp K40- L525 Q75K N/A 
pKLW16 PDIp a Q75K N/A 
pKLW17 PDIp a Q75K W146F N/A 
pKLW18 PDIp a C71S Q75K N/A 
pKLW19 PDIp a C74A Q75K N/A 
pAKW5 PDIp (ab) PDI (b’xa’c) Dr. Katrine Wallis 
pAKW6 PDIp T419G Dr. Katrine Wallis 
pAKW11 PDIp (ab) PDI (b’x) PDIp (a’c)  Dr. Katrine Wallis 
pAKW12 PDIp (ab) PDI (b’x) PDIp (a’c) 
T419G 
Dr. Katrine Wallis 
 
 
  
Table 2.1: Description and details of PDI.PDIp constructs used in this study. 
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2.1.1.3. Primer list 
 
 
 
A number of different clones were made for this work. Both the mutagenesis 
protocol and primers used are shown in table 2.2.  
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2.1.2. Truncation PCR 
 
2.1.2.1. PCR 
This protocol was used for construction of pKLW1 (for primers and construct 
description see table 2.2.). The forward primer was designed to anneal to the ORF of 
pLR330 (excluding 54 nucleotides at the 5’ end) and contains an NdeI site. The 
reverse primer was designed to anneal to the ORF at the 3’ end and contains a SalI 
site. 
 
 
 
  
 
PCR was performed using PWO DNA polymerase (Roche Diagnostics) to amplify 
the ORF situated between primers. 50μl reactions were set up and implemented as 
described by the manufacturer’s guidelines. The DNA template was pLR330 DNA: 
obtained using a Miniprep kit (QIAGEN).  
 
  
Figure 2.2: Primer annealing for truncation PCR. Primer annealing is shown in yellow. 
Restriction site sequences are shown in orange and green for NdeI and SalI respectively. Notice 
that the forward primer does not anneal at the extreme 5’ end of the ORF. 
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2.1.2.2. Obtaining insert DNA 
DNA gel electrophoresis was performed using a 1% agarose gel stained with SYBR 
Safe DNA stain (Invitrogen). The PCR product (~1500 bp) was cut from the gel and 
purified using a Gel Extraction kit (QIAGEN). Following purification, the PCR 
product was digested using NdeI and SalI (following manufacturer’s guidelines, 
(Fermentas)) and then re-purified by DNA gel electrophoresis and gel extraction (as 
described previously). 
 
2.1.2.3. Obtaining vector DNA 
NdeI and SalI restriction digests were set up (overnight) using the manufacturer’s 
guidelines (Fermentas) and containing 5μg template DNA (pLR330).  The vector 
DNA (~3600 bp) was then purified using DNA gel electrophoresis and gel extraction 
(as described previously in section 2.1.2.2.). 
 
2.1.2.4. Ligation 
Ligation reactions were set up following the manufacturer’s guidelines (Fermentas) 
ensuring an excess of insert to prevent self-ligation. Control reactions (- insert) were 
also set up. 
 
2.1.3. QuikChange 
 
The QuikChange protocol is a method of site-directed mutagenesis in which a pair of 
complementary primers are used to amplify an entire plasmid. It is essential that a 
high fidelity polymerase such as Pfu is used for this. The template DNA can then be 
removed from the mutant plasmid using DpnI, a restriction digest that is specific for 
methylated DNA.  The QuikChange kit is available commercially (Agilent). 
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Plasmids: pKLW2-6, pKLW11 and pKLW14-19 were made using the QuikChange 
protocol and using the primers detailed in table 2.2.  
 
2.1.3.1. Mutagenesis 
Primers were designed following the manufacturer’s guidelines and are shown in 
table 1.2. (QuikChange, Agilent). The reaction was set up as described in the 
QuikChange protocol and using Pfu Ultra (Agilent).  
 
2.1.3.2. Dpn1 digest and DNA purification 
Following mutagenesis, DNA was incubated with Dpn1 overnight at 37ºC (set-up as 
described by manufacturer (Fermentas)). Following incubation, the mutagenic DNA 
was purified by DNA gel electrophoresis and gel extraction (as described in section 
2.1.2.2.). 
 
  
Figure 2.3: Schematic for QuikChange mutagenesis (taken from 
http://www.stanford.edu/~loening/protocols/Site_Directed_Mutagenesis.pdf). Parental DNA 
is denatured and mutagenic primers anneal. The whole plasmid is amplified, and parental 
DNA is digested by Dpn1 which is specific for methylated DNA.  
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2.1.4. 3 step PCR 
 
The a and a’ domains of PDIp (and also PDI) are very similar to one another on both 
protein and DNA level. Consequently the QuikChange method of site-directed 
mutagenesis can be very difficult when trying to mutate either the a or a’ domain 
because the mutagenic primers can easily mis-align. The 3 step PCR protocol avoids 
this by focussing on just one domain at a time and is explained in figure 2.4.  
 
 
 
 
 
 
 
 
In this protocol, the intrinsic BamHI site of PDIp is used. This is approximately mid-
way in the ORF of PDIp and a ‘middle’ primer incorporating this restriction site was 
designed. In this way it is possible to split PDIp into two halves and this prevents the 
difficulties associated with primer mis-aligning.  
Figure 2.4: 3 step PCR protocol for mutation of the a and a’ domains. Flanking primers 
contain digest sites and are shown in red (start or end) and blue (middle).  a) in the first stage of a 
domain mutagenesis, the DNA between the start  primer (red) and the reverse mutagenic primer 
(green) is amplified giving rise to the first PCR product (purple). b) using the forward mutagenic 
primer (green) and the middle reverse primer (blue) the second PCR product is made (purple). c) 
using the two PCR products from a & b  and the start and middle primers, (red and blue 
respectively), the full insert is made (purple). d) in the first stage of a’ domain mutagenesis, the 
DNA between the middle forward  primer (blue) and the reverse mutagenic primer (green) is 
amplified giving rise to the first PCR product (purple). e) using the forward mutagenic primer 
(green) and the end reverse primer (red) the second PCR product is made (purple). c) using the two 
PCR products from d & e  and the middle forward and end reverse primers, (blue and red 
respectively), the full insert is made (purple). 
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Plasmids: pKLW7-10 were made using the 3 step PCR protocol and using the 
primers detailed in table 2.2.  
 
2.1.4.1. PCR 
3 step PCR requires 3 different reactions. These are different according to the 
domain being mutated (either a or a’) and are described in figure 2.4. 
For a mutation in the a domain, the first reaction amplifies a fragment of the ORF 
between the start and the mutation and the second reaction amplifies from the 
mutation to the middle of the ORF (utilising a mid-sequence BamHI site). In the 
third reaction, the two products of reactions one and two are used as template DNA 
(purified as described by section 2.1.2.2.), and the start and middle primers are used 
to amplify the entire insert (~700bp) which now incorporates the required mutation 
(see figure 2.4.).  
To mutate the a’ domain, the first reaction amplifies between the middle primer and 
the mutagenic primer and the second reaction amplifies from the mutation to the end 
of the ORF. In the third reaction, the two products of reaction one and two are used 
as template DNA (purified as described in section 2.1.2.2.) and the middle and end 
primers are used to amplify the entire insert (~700bp) which is now mutated.  
For this protocol Phusion high fidelity polymerase (New England Biolabs) was used. 
This enzyme is a fast, accurate and thermostable polymerase. It also comes with 
specially optimised buffers for amplification of GC rich DNA. As the a and a’ 
domains are particularly GC rich, mutagenesis can be particularly difficult. Using 
this system, the required mutations were successfully made.  
These PCRs, were set up according to optimal reaction conditions for Phusion high 
fidelity polymerase (NEB). In this study, the GC buffer (rather than the standard 
buffer) and 3% DMSO were used (for reasons described previously).  
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2.1.4.2. Obtaining insert DNA 
Following step 3, the full 700bp insert was digested with either NdeI and BamHI or 
SalI and BamHI (for a and a’ domain mutations respectively). This was done 
according to manufacturer’s guidelines (Fermentas) and creates sticky ends. Inserts 
were then purified by DNA gel electrophoresis and gel extraction (see section 
2.1.2.2.). 
 
2.1.4.3. Obtaining vector DNA 
To obtain vector DNA, the parental DNA (pLR330 for KLW7-9 and pKLW6 for 
pKLW10) was digested with either NdeI and BamHI or BamHI and SalI (for a and 
a’ domain mutations respectively). This was done overnight according to 
manufacturer’s guidelines (Fermentas). The vectors were then purified by DNA gel 
electrophoresis and gel extraction (as described previously). 
 
2.1.4.4. Ligation  
As described in 2.1.2.4.  
 
2.1.5. Digest and ligation 
 
To make pKLW12 and pKLW13 a restriction digest and ligation strategy was used. 
For both, the insert DNA was obtained by restriction digest of pKLW8/pKLW9 
using BamHI and SalI (according to manufacturer’s guidelines (Fermentas)). The 
inserts were then purified by DNA gel electrophoresis and gel extraction (as 
described previously).  
For the vector, pKLW10 was cut with BamHI and SalI overnight and purified (as 
before). Vector and insert were then ligated as described in section 2.1.2.4.  
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2.1.6. Transformation 
 
Super competent cells (DH5α, NEB) were incubated on ice with plasmid for 30 
minutes and then subjected to heat shock (42°C) for 30 seconds. After a further 2 
minutes on ice, 0.9ml Soc was added and cells were left to grow for 90 minutes at 
37°C and 180 rpm. Cells were then plated onto lysogeny broth (LB) + ampicillin 
(35ng/ml) agar plates and incubated overnight at 37°C. 
 
2.1.7. Screening/checking possible clones 
 
A single colony was used to inoculate 5ml LB (containing 35ng/ml ampicillin) 
before being incubated overnight at 37°C and 180rpm. The DNA was extracted and 
purified using a Miniprep kit (QIAGEN). 1hr restriction digests were set up 
(according to manufacturer’s guidelines (Fermentas)) each containing ~100ng of the 
purified plasmid DNA and the appropriate restriction enzyme. Having visualised the 
digest products by DNA gel electrophoresis (as before), accurate clones (those that 
showed the correct size on the gel) were sent for sequencing using a T7 primer pair 
(Sanger). 
 
2.2. Protein expression 
 
2.2.1. PDI expression protocol 
Frozen glycerol stocks of the appropriate plasmid in BL21(DE3)pLysS, were used to 
streak out cells onto an LB agar plate ( containing 100ng/ml chloramphenicol and 
35ng/ml ampicillin). Plates were then incubated overnight at 37°C. Following 
incubation, a single colony was used to inoculate 50ml LB (antibiotics as before) 
contained in a 250ml conical flask. Again this was incubated overnight at 37°C and 
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180rpm. Following measurement of the optical density (OD) at 600nM, 1L conical 
flasks were inoculated such that the final OD600 = 0.05 in 400ml LB. Cells were left 
to grow at 37°C until OD600 = 0.5, which takes ~2.5 hours. Expression of protein was 
induced with a final concentration of 1mM isopropyl-β-galactoside (IPTG) and cells 
were left to express for 4 hours at 37°C and 180 RPM. Cells were harvested by 
centrifugation at 5,000 RPM using a Beckman JLA-8.1000 rotor for 15 minutes at 
4°C. 
 
2.2.2. PDIp expression protocol 
As for PDI, except that when OD600 = 0.5, cells were induced with IPTG (final 
concentration 1mM) and left for 16 hours at 25°C and 180 RPM. Cells were then 
harvested by centrifugation at 5,000 RPM using a Beckman JLA-8.1000 rotor for 15 
minutes at 4°C. 
For the expression studies described in section 3.3., the above protocol was altered as 
indicated in the text. 
 
2.2.3. EnBase expression system 
Protein expression in EnBase media was performed exactly as described by the 
manufacturer (BioSilta). 
 
2.2.4. Cell Lysis 
The cell pellet was resuspended in 20mM sodium phosphate, pH 7.3. DNase (final 
concentration: 10μg/ml), PMSF, leupeptin and pepstatin (final concentration for 
each: 200μM) were also added at this stage (protease inhibitors only added during 
cell harvest of PDIp). Cells were lysed by a combination of freeze/thaw and 
sonification. The latter was perfomed on ice using a Bandelin Sonoplus HD 2070 
sonicator for 3 x 30 second bursts of 70% power with 90 second rest intervals. 
 
Chapter 2. Materials & Methods 
65 
 
2.3. Purification 
 
2.3.1. Immobilised metal ion affinity chromatography (IMAC) 
Lysed cells were centrifuged at 12,000 RPM for 15 minutes (4°C) to pellet insoluble 
cell debris. IMAC columns were produced by adding Chelating Sepharose Fast Flow 
Resin (GE healthcare) to a syringe to produce a column volume (CV) of ~5ml. The 
column was rinsed with 10 CVs water before adding 2ml 0.2M Nickel chloride. 
After rinsing with a further 5 CVs of water, 5 CVs 20mM sodium acetate, 0.5M 
sodium chloride, pH 3.0 was added to remove unbound nickel. The column was then 
equilibrated with 5 CVs 20mM sodium phosphate, pH 7.3. The supernatant (total 
soluble portion of cell lysate) was loaded onto the column and loosely bound 
impurities removed with 2 CVs 25mM Imidazole, 0.5M sodium chloride, 20mM 
sodium phosphate, pH 7.3. This was followed by 5 CVs of 20mM sodium phosphate, 
pH 7.3 and finally, protein was eluted using 5 CVs of 50mM EDTA, 20mM sodium 
phosphate, pH 7.3. 
 
2.3.2. Salt precipitation  
Reactions were set up containing 35% saturated ammonium sulphate solution and 
left for 1hr at 4°C for precipitation to occur. After 1hr, the reaction was centrifuged 
for 15 minutes at 20,000 rpm. The supernatant was dialysed overnight into 20mM 
sodium phosphate buffer (pH 7.3) (see 2.3.4.). 
 
2.3.3 Batch purification 
5ml High performance chelating sepharose (which already has Ni
2+
 bound (GE 
Healthcare)) was resuspended in 10 CVs water and centrifuged at 500g for 10 
minutes. The supernatant was discarded and the column material resuspended in 5 
CVs 20mM sodium acetate, 0.5M sodium chloride, pH3.0 before centrifugation (as 
before). The supernatant was once again discarded, and the material resuspended in 5 
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CVs 20mM sodium phosphate, pH 7.3 in order to neutralise the low pH. The column 
material was centrifuged at 500g for 10 minutes and the supernatant removed. 
Cells were lysed and centrifuged as described in 2.4.1 but with the addition of PMSF, 
pepstatin and leupeptin (final concentration for each = 200μM). 20ml of the cell 
supernatant (containing soluble proteins) was added to the column material and then 
left for 1hr at 4°C on rollers to ensure thorough mixing. After this time, the 
sepharose/supernatant solution was poured into an empty PD-10 column (GE 
Healthcare) and the flow through discarded. 
Unspecifically bound protein was washed from the column material by 2CVs 20mM 
sodium phosphate, 20mM imidazole, 0.5M sodium chloride (pH 7.3). Finally, 
protein was eluted with 5CVs 20mM sodium phosphate, 200mM imidazole, 0.5M 
sodium chloride (pH 7.3). After protein elution, the column material was washed 
with distilled water and stored in 20% ethanol. 
 
2.3.4. Buffer exchange by dialysis 
Unwanted salts were removed by overnight dialysis into sodium phosphate buffer, 
pH 7.3 (4ºC). The dialysis membrane that was used had a molecular weight cut off 
(MWCO) of 12 – 14 kDa (Medicell International). 
 
2.3.5. Ion Exchange Chromatography (IEC) 
Anion exchange chromatography was performed with a 10ml Source 30Q column 
(GE Healthcare) connected to an ÄKTA purifier 100 fast protein liquid 
chromatography (FPLC) system (GE Healthcare). The column was rinsed and 
equilibrated with 20mM sodium phosphate, pH 7.3. The protein sample was loaded 
onto the column via an injection loop. A gradient from 0-100% 20mM sodium 
phosphate, 0.5M sodium chloride, pH 7.3 was used to elute the protein over a total of 
10 CVs. 2ml fractions were collected and those corresponding to a peak in the 
chromatogram were analysed by SDS-PAGE.  
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2.3.6. Gel filtration 
Size exclusion chromatography was performed with a Superdex 200 10/300 GL 
column (GE Healthcare) connected to an ÄKTA purifier 100 fast protein liquid 
chromatography (FPLC) system (GE Healthcare). 20mM sodium phosphate, 150mM 
sodium chloride, pH 7.3 was used as the buffer. The protein sample was loaded onto 
the column via a 2ml injection loop (protein concentrated previously to volume (and 
desalted if necessary)). Protein elution was monitored at A280 and 5 ml fractions were 
collected until a drop in conductivity was seen corresponding to NaCl being eluted 
from the column. Fractions were analysed by SDS-PAGE. 
 
2.3.7. Protein concentration 
Vivaspin 20 protein concentrators (Sartorius Stedim) with a molecular weight cut off 
(MWCO) of 10,000 were used to concentrate fractions containing protein from IEC 
or SEC. During the concentration process, samples were also desalted. 
 
2.3.8. Estimating Protein Concentration 
The concentration of PDIp was determined by measuring the A280 of the sample 
using a Jenway 6305 spectrophotometer. The extinction coefficient (ε280) determined 
using ProtParam (http://www.expasy.ch/tools/protparam.html), can then be used to 
derive protein concentration using the Beer-lambert Law: 
 
Protein Concentration (M) = A280 / (ε280 (M
-1
) x path length of cuvette (cm)) 
 
The extinction coefficients for proteins used in this study are shown in table 2.3 (see 
over). Single point mutants have the same extinction coefficient as their background 
proteins.  
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Protein  Extinction Coefficient (M-1 cm-1) 
PDI 45380 
PDIp 43890 
PDIp 1/2 42400 
PDIp 3/4 42400 
PDIp a 16960 
PDIp a' 16960 
  
 
2.4. Analysis 
 
2.4.1. Polyacrylamide Gel Electrophoresis (PAGE) 
SDS-PAGE was used to analyse proteins under denaturing and reducing conditions 
and was carried out according to the Tris-Glycine buffer system (Laemmli, 1970). 
Typically, a 12% separation gel (pH 8.8) and 7% resolving gel (pH 6.8) were used 
and cast using the Mini Protean II gel kit (Bio-Rad). Samples for SDS-PAGE were 
reduced with loading buffer (1M Tris-HCl pH 6.8, 50% glycerol, 0.8% SDS, 0.1% 
w/v bromophenol blue and 10% β-mercaptoethanol). Gels were run at 60mV until 
protein had entered the separation gel and then 180mV for ~60 minutes in a 10% 
SDS buffer. A low molecular weight marker (GE Healthcare) was used to estimate 
the molecular weight of protein seen on the gel. Gels were stained with Instant Blue 
gel stain (Expedeon).  
Native-PAGE was performed as for SDS-PAGE but with the complete omission of 
SDS and β-mercaptoethanol.  
 
2.4.2. Mass Spectrometry 
Approximately 1mg of protein was dialysed into 10mM ammonium acetate 
overnight at 4°C. Samples were then freeze-dried (ScanVac) and sent to Kevin 
Howland (University of Kent) for high resolution electrospray ionisation (ESI) mass 
spectrometry.  
Table 2.3: Extinction 
coefficients for PDI, PDIp 
and PDI.PDIp constructs. 
The extinction coefficients 
were calculated using 
ProtParam. The values 
provided here are for the 
reduced proteins. 
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2.4.3. Circular Dichroism (CD) 
Far UV CD was performed on all constructs using a Jasco J-815 CD 
spectropolarimeter at various different temperatures (controlled by a Peltier 
thermostat controller). Samples containing 0.1mg/ml protein in 5mM sodium 
phosphate buffer (pH 7.3) were prepared. Data were recorded using 0.1mm cuvette, 
260nm-190nm, step resolution 0.2nm, response 0.25s, bandwidth 1nm, scan speed 
20nm/min, average of 16 scans.  All data was corrected against a buffer blank and 
analysed using DichroWeb (Whitmore and Wallace, 2008). 
 
Mean residue ellipticity was calculated using the following equation taken from 
Kelly et al. (2005): 
 
[θ]mrw, λ = (MRW x θλ) / (10 x d x c) 
 
Where MRW = M/ (N-1) and M is the molecular mass of the polypeptide (in Da) and 
N is the number of amino acids in the chain. θλ is the observed ellipticity (degrees), d 
is the pathlength (nm) and c is the concentration (g/ml). 
 
2.5. Structural studies  
 
2.5.1.  Intrinsic fluorescence 
The intrinsic fluorescence of samples containing 10μM protein in 20mM sodium 
phosphate buffer (pH 7.3.), was measured using a Perkin/Elmer LS50 fluorimeter. 
Excitation wavelength 280nm, emission 290-400nm, slit width 2nm, scan speed 
100nm/min, an average of 3 scans and temperature, 25ºC. 
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2.5.2. ANS fluorescence 
An ANS saturation curve for both PDI and PDIp was determined using 1μM PDI/ 
PDIp in 20mM sodium phosphate buffer (pH 7.3) and increasing concentrations (0-
200μM) of anilino naphthalene sulphonate (ANS) (Sigma). For these measurements 
a Perkin/Elmer LS50 fluorimeter was used, excitation wavelength 390nm, emission 
400-600nm, slit width 2nm, scan speed 100nm/min, an average of 3 scans and 
temperature 25ºC. The relative fluorescence unit (R.F.U.) at λmax was then plotted 
against [ANS] to produce a saturation curve.  
For ANS enhancement, 10μM protein (reduced or oxidised) was incubated with 
100μM ANS for 30 minutes at 37ºC before measurements were taken (as described 
above). The ANS enhancement factor was calculated as follows: 
 
ANS enhancement factor at λmax = (Fprotein + ANS) /FANS 
 
Where F = fluorescence. 
 
2.5.3. Thermal denaturation 
Thermal denaturation was monitored using far UV CD. The secondary structure of 
samples containing 0.1mg/ml protein in 20mM sodium phosphate buffer (pH 7.3) 
was measured at 222nm on a Jasco J-815 CD spectropolarimeter and in 0.1mm 
cuvettes. Temperature was increased in 4ºC steps from 20-80ºC, controlled by a 
Peltier thermostat controller. Samples were allowed to equilibrate for 10 minutes at 
each temperature before data collection (2 minutes). All data was corrected against a 
buffer blank (measured at the same temperature) and the mean residue ellipticity for 
each temperature was calculated as described previously (see section 2.4.3.)  
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2.5.4. Thermal re-naturation 
Thermal re-folding was measured described in section 2.5.3. but with temperature 
decreasing from 80-20ºC. 
 
2.5.5. Preparation of oxidised and reduced samples 
For studies of redox-state dependent structural change, samples were oxidised or 
reduced. Sample preparation is described below but otherwise the method is 
unchanged from the un-redox controlled protocol. 
Buffer stocks were prepared to contain 20mM sodium phosphate (5mM for far UV 
CD samples) and in addition 0.5M DTT/diamide stocks were also made (Sigma) (pH 
7.3). Protein samples were treated with a 10x molar excess of the DTT/diamide stock 
and incubated for 15 minutes at room temperature. Samples were desalted into 
20mM (or 5mM for CD samples) sodium phosphate buffer (pH 7.3) using a PD-10 
column (GE Healthcare) following the manufacturer’s standard gravity based 
protocol. If required, samples were then concentrated as described in section 2.3.7. 
 
2.5.6. Limited proteolysis  
For each protein, a 200µl sample containing 15µM protein and 50mM sodium 
phosphate buffer, 10mM DTT/diamide, 10mM CaCl2 (pH 7.6) was prepared (as 
described in Wang et al. 2010). Chymotrypsin (Worthington) was then added to a 
final concentration of 75nM and the stock solution incubated at 37°C. After 0, 5, 10, 
20, 40, 60, 90 and 120 minutes, an aliquot was removed from the stock and the 
reaction stopped with SDS-loading buffer and boiling at 95°C for 5 minutes. A 
sample of each aliquot was then run on a 12% SDS-gel (see section 2.4.1) and the 
results visualised. 
For further analysis, the required band was cut from the SDS-PAGE gel and 
subjected to tryptic digest using the manufacturers recommended protocol on the 
MassPrep robotic protein handling system. The resulting peptides from each sample 
were analysed by nanoliquid chromatography (LC) - electrospray ionisation – 
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MS/MS using a 45 minute LC gradient. All data collected was corrected for mass 
drift using reference data collected from human [Glu
1
]-fibrinopeptide B (Sigma). 
Finally the amino acid sequence of the protein was used to determine percentage 
sequence coverage of the peptides present. 
Alternatively, samples were prepared as described above but no aliquots were taken 
and the reaction was incubated for the full 120 minutes. After this time, the reaction 
was stopped with a 10x molar excess of PMSF and samples were dialysed into 
10mM ammonium acetate overnight (4°C). Samples were freeze-dried (ScanVac) 
and sent to Kevin Howland (University of Kent) for ESI mass spectrometry.  
 
2.5.7. Dynamic Light Scattering (DLS) 
DLS was performed using a Malvern Zetasizer Nano instrument. Samples contained 
10μM protein (oxidised or reduced as described in section 2.5.5.) and 20mM sodium 
phosphate (pH 7.3). A minimum of 5 measurements were taken, at 25ºC and using 
the dispersant/solvent properties of water for comparison.  
 
2.5.8. Nuclear Magnetic Resonance (NMR) sample preparation 
PDIp a was expressed using identical conditions to PDIp but in minimal media 
instead of LB (see section 2.2.). NMR measurements of PDIp a were taken at the 
University of Kent by Michelle Rowe using a 4-channel Varian Unity INOVA 600 
MHz NMR spectrometer. 
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2.6. Activity studies 
 
2.6.1. Insulin assay 
In the insulin assay, the reduction of insulin disulphides by GSH, catalysed by PDI, 
generates GSSG and this is coupled to the reduction of GSSG by NADPH, catalysed 
by glutathione reductase. The latter process is monitored by a decrease in A340 (see 
figure 2.5.) 
 
 
 
 
Samples containing 120μM NADPH, 8mM GSH, 1 unit of glutathione reductase and 
0.5-2μM protein were prepared and 200mM sodium phosphate, 5mM EDTA buffer 
(pH 7.5) was then added to give a total volume of 1ml. Measurements were taken 
using a Cary UV-Vis spectrophotometer (Agilent), absorbance: 340nm and 
temperature, 37ºC. The sample was equilibrated at 37ºC before starting sample 
measurement. After a background rate has been obtained, 15μM insulin was added 
and the consequent change in A340 recorded as a function of time. All reagents 
(except the protein) were obtained from Sigma.  
  
  
Figure 2.5: Reaction scheme for insulin oxido-reductase assay. 
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2.6.2. Oxidation/reduction stopped flow assay 
The rates of oxidation by GSSG and reduction by GSH of the a domain active site of 
PDI a W128F and PDIp a W146F mutants were determined by a change in 
fluorescence of the active site adjacent tryptophan using a method similar to that of 
Lappi and Ruddock (2011). This was measured using a KinTek SF-2004 stopped 
flow fluorimeter (KinTek), excitation 280nm and band-pass emission >320nm at 
25ºC. PDI/PDIp a concentration was 10μM, GSSG concentration 1-20mM and GSH 
concentration 1-50mM. Enzyme samples were reduced/oxidised and desalted as 
described in section 2.5.5 but using the assay buffer (100mM disodium hydrogen 
phosphate, 100mM boric acid buffer (pH 7)) instead of 20mM sodium phosphate. 
 
2.6.3. Stopped flow pKa calculations 
The pH dependence of the reactions of 25μM PDIp a C71S and PDIp a C74A with 
0.073 mg/ml 5,5-dithio-bis(2-nitrobenzoic acid) (DNTB) (Sigma) was measured 
using KinTek SF-2004 equipment, absorbance wavelength 412nm and temperature 
25ºC (as described by Karala et al. 2010). Sample buffers (pH 6.5 - 10.0) were 
100mM disodium hydrogen phosphate, 100mM boric acid buffer, pH corrected with 
5M NaOH.  
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Chapter 3. Optimisation of expression & 
purification 
 
 
3.1. Introduction 
 
Prior to this work, PDIp had not been studied by the RBF group and therefore 
protocols for the expression and purification of recombinant PDIp were not yet 
optimised. Standard expression and purification conventions for PDI were not 
compatible with PDIp and gave rise to low yields of relatively unstable protein.  
This aim of this work was to identify conditions suitable for obtaining a maximal 
yield of PDIp and PDIp constructs, in order to facilitate future studies of their 
structure and activity. 
 
3.2. Preliminary work 
 
3.2.1. Expression, Purification and Stability of PDIp 
When PDIp was expressed and purified using standard PDI protocols (see methods) 
the total yield obtained was ~2μg/ml culture: 10 fold less than the average yield for 
PDI. The problem was associated with both a low level of expression and a poor 
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protein recovery from expression (see below) In addition, purified PDIp was found to 
be very unstable under conventional storage conditions (see figure 3.1). 
 
 
 
 
 
Figure 3.1 shows the absence of full-length PDIp (Mw: 56919 Da) and the extent of 
degradation after 4 weeks at -20ºC. The most abundant species is a ~40kDa fragment 
probably corresponding to His-tagged PDIp abb’x (Mw: 42kDa, ProtParam). This 
indicates that like PDI, PDIp may also have intrinsic flexibility centred on the x-
linker region (Wang et al. (2010).  
 
3.3. Optimisation of Expression 
 
3.3.1. Varying host, temperature and expression period  
Initial studies to improve the expression of PDIp involved comparing total soluble 
protein produced by 5 different host cell-strains, 4 different expression times and 3 
Figure 3.1: High resolution electrospray ionisation (ESI) MS spectra for PDIp after 4 weeks 
storage at -20°C. There is no peak corresponding to hexa-His tagged full length PDIp (Mw: 
56919 Da) indicating that the sample is significantly degraded.  
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different temperatures.  The results of this were visualised by SDS-PAGE and are 
shown in figure 3.2.  
 
 
 
 
 
Figure 3.2 shows that in each instance tested, cells incubated at 37°C post-induction 
expressed less PDIp than their counterparts at lower temperatures. This is not 
Figure 3.2: Recombinant expression of PDIp. SDS-PAGE showing total soluble 
proteins produced during expression of PDIp. 5 different competent cell strains were 
studied: 1) B834(DE3), 2) BL21(DE3), 3) BL21(DE3)pLysS, 4)  C41(DE3) and 5) 
Rosetta Star (DE3) (marker depicted by M). Cells were grown at 37°C to A600 = 0.5 
and then induced with 1mM IPTG and incubated at 20, 25 or 37°C for 4, 8, 16 or 24 
hours. Arrow indicates expected position of PDIp on the gel (Mw = ~ 57kDa) and 
highest yields are circled. 
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uncommon in recombinant protein expression where high and non-physiological 
rates of protein production give rise to accumulation of misfolded/partially folded 
protein which leads to cellular stress, formation of insoluble aggregates and 
proteolysis. The benefits of reducing expression temperature as a solution to 
reducing cellular stress are widely discussed in the literature (For review see Gasser 
et. al 2008). 
Supporting the suggestion that cellular stress is affecting total yield, figure 3.2 shows 
that optimal induction time is temperature dependent i.e. that optimal expression time 
increases as temperature decreases. This means that while cells induced at 20ºC 
benefit from a 24 hour expression period, those induced at 25°C have optimal 
expression after 8-16 hours. Furthermore in the latter, expression times of >16 hours 
lead to a reduction in yield probably due to formation of insoluble aggregates and/or 
proteolysis (unconfirmed). It is thus clear that when expressing PDIp recombinantly, 
measures must be taken to balance both protein production and cellular stress. 
Perhaps surprisingly, C41(DE3) cells were consistently the least successful cell-type 
tested despite being designed to resist expression-derived toxicity. Rosetta Star 
(DE3) cells also showed poor expression yields for the majority of conditions tested. 
This was also unexpected because these cells have optimised translation efficiency 
conferred by an additional plasmid (pRARE). B834(DE3) cells did produce a fair 
yield in most conditions tested but not enough to outweigh the disadvantage of them 
being methionine auxotrophs. BL21(DE3) and BL21(DE3)pLysS were consistently 
the best cell-strains tested in terms of yield but also grew quickly prior to induction 
making them more user-friendly. Consequently further study was performed on 
BL21(DE3) and BL21(DE3)pLysS only (see figure 3.3). 
 
3.3.2. Varying IPTG concentration 
Sevastsyanovich et al. (2009) suggested that induction of recombinant protein 
expression using high concentrations of IPTG could lead to increased cellular stress 
and reduce total yield. Figure 3.3 shows that expression of PDIp by BL21(DE3) cells 
is  not dependent on IPTG concentration at either 25ºC or 37°C.  At 25ºC however 
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there is no appreciable yield of PDIp at any concentration of IPTG implying a fault 
of the experiment as previous work had shown that good yields of PDIp could be 
obtained in these conditions with induction by 1mM IPTG (see figure 3.2).  
 
 
 
 
 
Figure 3.3: Recombinant PDIp expression after induction by varying [IPTG].  
SDS-PAGE showing PDIp expression using BL21(DE3) and BL21(DE3)pLysS 
competent cells. 5 different concentrations of IPTG were studied for each cell line: 1) 
0mM, 2) 1mM, 3) 0.5mM, 4) 0.25mM, 5) 0.1mM and  6) 10µM. M indicates marker. 
Cells were grown at A) 25°C or B) 37°C and then left to express at 25°C for 8 hours. 
Arrow indicates expected position of PDIp on the gel (Mw= ~ 57kDa). 
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At 37°C total yield of PDIp was roughly equivalent for all cultures induced with 
1mM, 0.5mM, 0.25mM or 0.1mM IPTG. Surprisingly, a total IPTG concentration of 
10μM was sufficient to induce BL21(DE3) cells at 37°C although yield was far 
reduced compared to at higher IPTG concentrations.  
Expression of PDIp by BL21(DE3)pLysS is dependent on IPTG concentration and 
this seems to be linked also to expression temperature. At 25°C, yield decreases as 
IPTG concentration decreases but at 37ºC, yield increases as IPTG concentration 
decreases. This implies that the combination of high IPTG concentration and high 
temperature leads to an increase in cellular stress. Again it is clear that in order to 
achieve optimal yields of PDIp, cellular stress must be controlled. This correlates 
well to published work by Sevastsyanovich et al. (2009) which shows that optimal 
protein expression occurs when cellular stress is kept to a minimum.  
 
3.3.3. Conclusions of Expression Studies 
Expression of PDIp clearly promotes cellular stress to a greater extent than PDI. 
Therefore in order to improve total yield of PDIp, cellular stress must be controlled.  
The optimal conditions for the recombinant expression of PDIp are: 
1. BL21(DE3)pLysS host cell: although little difference was observed between 
yields of PDIp obtained from BL21(DE3)pLysS or BL21(DE3) cells, 
BL21(DE3)pLysS cells were chosen as expression vector because they have 
the advantage of having a pLysS plamid which prevents background 
expression.  
2. Temperature (growth and expression) 25ºC: an expression temperature of 
25ºC allows a shorter expression time than at 20°C and benefits from reduced 
cellular stress compared to expression at 37ºC. 
3. Expression time 8-16 hrs: at 25ºC, expression times of >16 hours led to an 
increase in cellular stress and a reduction in total protein.  
Chapter 3. Optimisation of expression & purification 
 
81 
 
4. IPTG concentration 1mM: at 25°C and using BL21(DE3)pLysS host cells, 
highest yields of PDIp were obtained following induction with 1mM IPTG. 
Decreasing IPTG concentration led to a reduction in yield.  
 
3.3.4. EnBase Expression Trials  
EnBase is an expression system that uses enzymatic digestion of a synthetic substrate 
to slowly feed bacterial cells glucose. This means that much higher cell densities can 
be achieved prior to induction and subsequently higher yields of protein can be 
obtained.  
 
   
 
Figure 3.4 shows that the total yield of PDIp obtained using the the EnBase system is 
very low. Although unconfirmed it is possible that the long expression time (~24 
hours) may be inducing cellular stress and giving rise to formation of inclusion 
bodies and proteolysis. Consequently a low yield would be obtained.  Clearly 
recombinant expression of PDIp is prone to induction of cellular stress in both LB 
and EnBase media.  
Figure 3.4: Recombinant 
PDIp expression using 
EnBase system. SDS-PAGE 
showing total soluble protein 
obtained using 
BL21(DE3)pLysS competent 
cells and EnBase media. 
Protocol as described by 
manufacturer. Gel shows 
products of two separate 
expression batches in 
duplicate (batch 1 (1-2) and 
batch 2(3-4) Arrows shows 
expected position of PDIp.  
 
Chapter 3. Optimisation of expression & purification 
 
82 
 
Although found to be unsuitable for expressing PDIp, the EnBase system was used to 
produce very high yields (~0.1mg/ml culture) of recombinant single domain 
constructs, specifically PDIp a, PDI a and also mutant forms of both proteins. Figure 
3.5 shows the quantity of PDIp a C71S found in 10μl samples of fractions 
corresponding to the elution peak after IEC (data not shown). Clearly the gel is very 
overloaded indicating that a large yield of protein was obtained and this explains why 
PDIp a C71S appears to have a Mw of ~16kDa instead of 14.5 kDa. Total yield was 
10x more than typically expected from standard expression in LB (described 
previously).  
 
 
 
3.4. Optimisation of Purification 
 
3.4.1. Standard IMAC 
Using a standard IMAC protocol (see methods) only ~1/3 of the available hexa-His 
tagged PDIp binds to the Ni
2+
 column (see figure 3.6). As a result of this a 
considerable amount of protein is lost via the flow through. Losses are not due to 
column overloading as regeneration was shown not to significantly improve total 
Figure 3.5: IEC of 
PDIp a C71S. 10μl 
samples were taken 
from fractions 
corresponding to major 
peak of IEC 
chromatogram (not 
shown) and analysed by 
12% SDS-PAGE. Mw 
of hexa-His tagged 
PDIp a: 14552 Da 
(ProtParam)  
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protein binding (figure 3.6). Clearly, the interaction between the His-tag of PDIp and 
the Ni
2+
 sepharose is weak and therefore protein is lost during washing with low 
concentrations of imidazole and even during a simple buffer wash to remove salt 
(figure 3.6). Loss of binding is not caused by choice of metal ion (i.e. Ni
2+
) as similar 
protein losses were seen when a Co
2+
 charged column was used instead (data not 
shown). 
 
 
 
 
 
It was suggested that PDIp may be losing the His-tag from the N-terminus as a result 
of instability issues discussed previously. To try and reduce the likelihood of 
degradation and subsequent loss of the His-tag, IMAC was repeated at 4°C. 
Unfortunately, this did not improve binding of PDIp to the Ni
2+
 column (data not 
shown). 
Figure 3.6: SDS-PAGE showing fractions collected by IMAC. M= marker, 1) total 
cellular protein, 2) supernatant, 3) flow through, 4) wash, 5) loss of salt, 6) elution, 7) 
flow through(2), 8) wash(2), 9) loss of salt(2) and 10) elution(2). Column was 
regenerated and the flow through collected during primary IMAC was loaded onto it. 
Arrows indicates PDIp.  
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3.4.2. His-tag Western blot of PDIp  
A Western blot using antibodies specific to the His-tag showed that it was present on 
both purified PDIp and also PDIp that had been lost in the flow through (see figure 
3.7A). In addition, His-tag staining was also seen for the sample of degraded PDIp 
(faint band at ~40kDa) implying that degradation occurs at the C-terminus of the 
molecule in a similar manner to that seen for PDI (Wang et al. 2010). These results 
suggest that reduced binding occurs as a result of the His-tag of PDIp not being 
solvent-exposed, rather than because it has been lost.  
Regrettably, figure 3.7A also shows a small degree of unspecific staining. His-tag 
staining is particularly susceptible to this as there are a number of E.coli proteins that 
contain multiple His sequences. However despite this, the results are clearly 
indisputable and demonstrate that the His-tag has not been lost. 
 
 
 
 
 
Figure 3.7: His-tag Westen Blot of PDIp. A) SDS-PAGE of his-tag Western 
blot B) Duplicate His-tag Western blot image. M= marker, 1) flow through, 2) 
pure PDIp and 3) degraded PDIp. (Arrows indicate position of PDIp) 
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3.4.3. Sequence alignment of the N-terminal region of PDI and PDIp 
Sequence alignment of His-tagged PDI and PDIp indicates that the N-terminal region 
of PDIp (before the ‘TRX-fold’ domain) is much longer and more negatively 
charged than the same region in PDI. It can be seen in figure 3.8 that PDIp has 6 
negatively charged amino acids at its N-terminus compared to only 3 for PDI. This 
region is also unstructured.  Consequently it is possible that the positively charged 
His-tag is folding back onto the N-terminus of PDIp.  This may explain why the hexa 
His-tagged PDIp is unavailable and therefore unable to bind to the Ni
2+
 column. 
 
 
 
3.4.4. Molecular biology to improve binding of PDIp to the Ni
2+ 
column 
To determine whether the N-terminus of PDIp interacts with the His-tag and 
therefore prevents binding, a new clone (pKLW1) with a truncated N-terminus was 
designed (see figure 3.9).  
 
 
 
 
Regrettably, pKLW1 did not express very well using optimal conditions for wild-
type PDIp (described previously) and as such it was difficult to determine its binding 
properties. Figure 3.10 shows total soluble proteins obtained from expression of 
Figure 3.8: CLUSTAL sequence alignment of the N-terminus of PDI and PDIp. 
Figure 3.9: CLUSTAL sequence alignment of the N-terminus of a wild-type PDIp and 
PDIp truncate (pKLW1). 
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pKLW1 and subsequent IMAC fractions. Total PDIp is minimal in all samples 
shown. 
Poor expression of pKLW1 may indicate that the N-terminal region of PDIp is 
structured and important for the overall structure of the a domain. It may also 
indicate that the domain boundary of PDIp a has been compromised by the 
truncation. In order to determine whether this is the case, alternate truncation mutants 
could be made to see if expression can be improved.  
 
 
 
 
 
 
3.4.5. Ammonium sulphate precipitation 
Due to difficulties purifying PDIp via IMAC, an alternative purification technique: 
ammonium sulphate precipitation was tested. Initial studies showed that PDIp 
dropped out of solution in 35% saturated ammonium sulphate meaning that it was 
Figure 3.10: N-terminal truncate purification by IMAC. In order 
as seen on the gel: M = marker, 1) supernatant, 2) flowthrough, 3) 
20mM imidazole wash, 4) 50mM imidazole wash and 5) 200mM 
imidazole elution step. Arrow indicates position of PDIp on the gel. 
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possible to significantly reduce the amount of contaminating protein. This method 
ultimately led to increased precipitation of PDIp in subsequent purification steps and 
reduced binding to the IEC column. Essentially this meant that a) PDIp losses were 
high and b) PDIp could not be purified to a high standard (see figure 3. 11).  
 
 
 
 
 
 
Figure 3.11 indicates that although the expression yield of PDIp was high, significant 
losses were observed as a result of an inability to bind to the Source 30Q column. 
Consequently, a high percentage of PDIp was lost during the purification steps that 
followed ammonium sulphate precipitation. The reason for this is unclear but it may 
be that this method reduces the overall stability of PDIp. Furthermore only one IEC 
fraction, (shown in lane 5, figure 3.11) was shown to contain a considerable amount 
of PDIp but unfortunately it was also significantly contaminated. Yield of PDIp in 
subsequent fractions was minimal. 
To try to improve binding of PDIp to the IEC column, the dialysed protein sample 
was centrifuged at high speed (20,000 rpm) and IEC was performed using a Hepes 
Figure 3.11: IEC of PDIp following salt precipitation. Gel showing 
fractions collected during IEC. M= marker, 1) supernatant 1, 2) pellet, 3) 
supernatant 2 (following ammonium suphate precipitation, resuspended 
protein had a tendency to drop out of solution), 4) wash, 5-11) IEC 
fractions (arrow shows position of PDIp on the gel) 
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buffer (10mM Hepes, 5mM DTT (pH 8)). In contrast to the standard phosphate 
buffer, this buffer has an overall positive charge and it was hoped that this might 
improve the binding affinity of PDIp to the IEC column. This was not the case and 
there seemed to be no noteworthy difference between elution profiles produced for 
either buffer (not shown). 
 
3.4.6. Purifying PDIp using a batch IMAC protocol 
A new protocol for purification of PDIp published after this work was initiated 
utilises a long binding step (incubating PDIp and column material for 1hr at 4ºC) and 
also a batch methodology. However a standard yield for this protocol was not 
published (Fu and Zhu, 2009a). Figure 3.12 clearly shows that this method of 
purifying PDIp markedly improves total yield and reduces total losses in the flow 
through.  
The conclusion that can be taken from this is that the N-terminal His-tag of PDIp is 
dynamic. This means that a long binding step is providing a longer period of time for 
the His-tag and the Ni
2+
 column to interact. If the N-terminus of PDIp is structured 
(as postulated previously) its ability to exist in alternate conformations may be 
indicative of a capping mechanism and may have implications for the catalytic 
activity of PDIp a.  
 
 
Figure 3.12: Batch 
purification of PDIp. SDS-
PAGE shows that a higher 
yield of PDIp was obtained 
when a long binding step 
was employed (see arrow). 
M= marker, 1) flow-
through, 2) wash 1, 3) wash 
2, and 4) elute. 
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The batch protocol for IMAC gives rise to significantly less contamination than was 
seen previously for ammonium sulphate precipitation (see figure 3.12) and there 
were no further problems encountered in subsequent IEC steps. Evidently binding to 
the Ni
2+ 
column remains temperamental even after a long binding step because 
protein is still lost in the flow through and during both wash steps prior to elution. 
The small band at ~40kDa (see figure 3.12) is probably caused by degradation of 
PDIp and is linked to the increase in processing time. Again the size of this fragment 
suggests loss at the C-terminus and is almost certainly the loss of the a’ domain 
(Wang et al. 2010). 
 
3.4.7. Ion exchange chromatography (IEC) 
Following purification of PDIp by IMAC, the protein is dialysed and purified again 
by IEC. A typical IEC chromatogram for PDIp is shown in figure 3.13. 
 
 
 
Figure 3.13: IEC chromatogram for PDIp and corresponding SDS-PAGE. 
Red line shows the region of the elution profile analysed by SDS-PAGE. 
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It is not dissimilar to that seen for PDI and shows a major elution peak with a clear 
shoulder. By SDS-PAGE no difference can be seen for samples taken from within 
the major peak or from the shoulder region but by native-PAGE it is clear that the 
shoulder peak is made up of dimer (not shown). Again this is similar to what is seen 
for PDI (Wallis et. al 2009). Fractions containing dimer are excluded when protein is 
pooled and concentrated although this does not prevent dimeric species from forming 
later. 
Figure 3.13 shows a number of minor peaks indicating that although IMAC 
significantly reduces the number of contaminating proteins in a sample, there are still 
a lot remaining. IEC is able to remove them and these can be seen at lower salt 
concentrations than the major peak. It is important to analyse main peak fractions by 
SDS-PAGE to confirm that contaminants had been removed. 
 
3.5. Stability 
 
3.5.1. Stability studies of PDIp 
Given that PDIp had previously been shown to be unstable (see figure 3.1, 3.7, 3.12), 
it was important to establish the extent of instability in order to arrange suitable 
storage conditions. Figure 3.14 indicates that after 3 days storage at 4ºC, untreated 
PDIp (lacking protease inhibitors) exhibits ~80% degradation and ~50% degradation 
when stored at -20°C or -80°C. At each storage temperature tested degradation could 
be reduced by the addition of PMSF at cell harvest and sonication (figure 3.14). 
Furthermore the addition of PMSF, leupeptin and pepstatin during cell harvest and 
sonication has since been shown to further improve the stability of PDIp and ensure 
that it can be stored for up to 2 months at -20°C (data not shown). 
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Athough clearly a requirement for this work, the use of PMSF must be controlled as 
it is possible that it could bind to PDIp. With the substrate binding specificity of 
PDIp being a hydroxy-aryl group it is likely that the phenolic ring structure of PMSF 
would fulfil this requirement. Studies of substrate binding in the presence and 
absence of PMSF would clarify this. 
Interestingly, the major degradation product seen at ~40kDa in figure 3.14 correlates 
with the majority peak seen in the original MS data (see figure 3.1) and also the 
Western blot figure 3.7. Again, this is likely to be due to the loss of the a’ domain as 
in hPDI, the intrinsic flexibility of the x-linker region has been shown to be most 
susceptible to proteases (Wang et al. 2010).  
As a final attempt to improve stability, IEC was performed using a water jacket set at 
4ºC. This had a negative effect on the binding of PDIp to the IEC column (data not 
shown) giving rise to a reduced yield. Moreover, the stability of PDIp did not appear 
to be altered relative to the standard procedure. 
 
  
Figure 3.14: Stability of PDIp. 
Gel shows effect of storage and 
presence/absence of PMSF on 
stability of PDIp over a 3 day 
period. M= marker, 1) 4°C – 
PMSF, 2) 4°C + PMSF, 3) -20°C 
– PMSF, 4) -20°C + PMSF, 5) -
80°C – PMSF and 6) -80°C + 
PMSF. 
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3.6. Mass spectrometry of full length PDIp 
 
ESI mass spectrometry was used to confirm that the expressed protein was full length 
PDIp and that it had not been modified during expression and purification. The Mw 
of hexa-His tagged PDIp is 56919 Da. The major peak shown in figure 3.15 (peak a) 
is indicative of un-modified PDIp and has a measured mass of 56915 Da. This 
difference between actual and measured masses (~4Da) is within the standard error 
of the machine. It may also be indicative of the oxidised form of the protein (as 
formation of a disulphide bond at each active site would result in loss of 4 protons). 
The difference between peak A and peak D is 178 Da and represents α-N-6-
phosphogluconylation of the His-tag (Geoghegan et al. 1999). This is a common 
adduct of N-terminally His-tagged proteins. The exact identity of the adducts 
corresponding to peaks C and G has not been determined.  
 
 
 
Figure 3.15: Deconvoluted high-resolution ESI MS of full length wild-type PDIp.  Mw of 
hexa-His tagged PDIp is 56919 Da. 
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3.7. Yield 
 
3.7.1. Improvement in yield due to optimisation of expression and purification  
Pre-optimisation, expected yields of PDIp were ~2μg/ml culture. Following 
optimisation of expression this was more than doubled to ~5μg/ml culture although it 
was clear that there were losses during IMAC due to limited binding (see 
previously). Introducing a batch purification method where protein is incubated with 
Ni
2+ 
sepharose for 1 hour has improved yields by 1000%. In addition, studies to 
improve stability have allowed us to store purified PDIp for up to 2 months if 
necessary which is also highly advantageous.  
 
3.8. Constructs of PDI and PDIp  
 
3.8.1. Expression and purification of PDI and PDIp constructs 
Using the expression, purification and storage protocols developed above, it was 
possible to express and purify large amounts of WT PDIp, PDIp mutants and also 
PDI/PDIp chimeras. These are summarised in table 3.1 which also includes standard 
PDI expression and purification protocols for reference.  
The expression of PDIp and PDIp constructs has markedly improved and typically a 
yield of 20μg/ml of culture can be expected for the full length protein in LB. 
Although there were issues expressing full length PDIp in EnBase, this system was 
very successful in improving yields of PDI a and PDIp a proteins.  
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Table 3.1: Expression/purification protocols for various PDI/PDIp constructs with expected yield 
 
Protein 
 
Expression/Purification Protocol 
 
Yield (µg/ml 
culture) 
PDI & full length 
PDI mutants 
Growth & expression at 37°C. Expression time: 4hrs. 
Standard IMAC protocol. IEC at pH 7.3 (phosphate 
buffers) 
24 
PDIp & full length 
PDIp Mutants 
Growth at 37ºC & expression at 25°C. Expression time: 
overnight. Batch IMAC protocol including 1hr binding 
step at 4°C  IEC at pH 7.3 (phosphate buffers) 
20 
PDIp (N-terminal 
truncation) 
As for PDIp but expression levels very low so purification 
studies have not been completed. 
N/A 
PDIp b’xa’c As for PDIp except IEC at pH 8 in 10mM Hepes, 5mM 
DTT buffer (protein did not bind to column under 
standard conditions) 
4 
PDIp (ab) PDI 
(b’xa’c) 
As for PDIp + size exclusion chromatography (SEC). 15 
PDIp (ab) PDI (b’x) 
PDIp (a’c) 
As for PDIp + SEC (if necessary) 29 
PDIp (ab) PDI (b’x) 
PDIp (a’c) T419G 
As for PDIp + SEC (if necessary) 17 
PDI a & PDI a 
Mutants  
As for PDI  22 
PDI a & PDI a 
Mutants  
EnBase expression system, following manufacturer’s 
guidelines for expression. IMAC and IEC as for PDI. 
150 
PDIp a  & PDIp a 
Mutants 
As for PDI 22 
PDIp a  & PDIp a 
Mutants 
 EnBase expression system, following manufacturer’s 
guidelines for expression. IMAC and IEC as for PDI. 
150 
 
 
3.8.2. Expression of PDIp b’xa’c  
Like PDIp, initial studies of the expression and purification of PDIp b’xa’c were 
problematic (data not shown). Using a standard protocol for expression (4 hours at 
37ºC) poor yields were obtained. Furthermore, PDIp b’xa’c did not bind to the Ni2+ 
column making it very difficult to purify by IMAC. This was particularly interesting 
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because it had been suggested that the N-terminal extension of full length PDIp was 
the cause of reduced binding. This is lacking in PDIp b’xa’c indicating that there 
must be another contributor to this problem.  
Using optimised expression protocols and a long binding step during IMAC 
improved yield significantly (see figure 3.16). Unfortunately however PDIp b’xa’c 
does not bind to the Source 30Q column in phosphate buffer (pH 7.3) or Tris-HCl 
buffer (pH 8.3). Its theoretical pI is 5.61 (ExPASy ProtParam) which is not 
significantly different to the estimated pI of the wild-type protein (5.00). Therefore 
both proteins should be negatively charged at physiological pH or above and 
consequently be able to bind to the column (anion exchanger).  
 
 
 
 
 
Finally, it was possible to purify PDIp b’xa’c by IEC using a Hepes buffer (pH 8) 
which clearly allows binding to the souce 30Q column (data not shown). The reason 
for this is unknown but it is possible that the negative charges of the PO4
-
 ions and 
Cl
- 
ions found in the phosphate and tris-HCl buffers respectively were competing 
with PDIp b’xa’c for binding to the column.  
Figure 3.16: IMAC of PDIp, PDIp a’ and PDIp b’xa’c. 12% SDS-PAGE 
gel showing total soluble protein, flow through and elution fractions for 
IMAC of PDIp (1-3), PDIp a’ (4-6) and PDIp b’xa’c (7-9) respectively. M= 
marker 
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Unfortunately having optimised the expression and purification of PDIp b’xa’c 
further study was abandoned because it was very unstable and prone to aggregation. 
2 days after purification (storage at -20ºC), a high percentage of PDIp b’xa’c is lost 
to aggregation (data not shown). Instability was not unexpected as similar issues 
arise during the purification of PDI b’xa’c. In addition to being unstable, the exposed 
hydrophobic surfaces on the b’ domain of these proteins makes them much more 
prone to dimerisation. After considerable efforts to improve stability, PDIp b’xa’c 
was removed from further study of structure and function properties in vitro. 
 
3.8.3. Expression of PDIp a’c 
Using the optimised expression protocol for PDIp sufficiently high levels of PDIp 
a’c were obtained. There were no issues in regards to binding of PDIp a’c to the Ni2+ 
column and so a long binding step and batch protocol were not required during 
IMAC (see figure 3.16). Similarly, IEC of PDIp a’ was also trouble free. During 
concentration however, PDIp a’c rapidly precipitates. As an attempt to reduce 
precipitation, fractions taken from IEC were pooled and arginine and glutamate were 
added to a total concentration of 50mM. The protein was then dialysed against 
decreasing amounts of NaCl (down to 50mM) in the presence of arginine and 
glutamate. This protocol has been shown to be able to improve protein solubility by 
up to 8 times on account of arginine and glutamate being effective in improving 
stability and reducing precipitation (Golovanov et al. 2004).  
Although this protocol showed some success in improving the solubility of PDIp a’c, 
precipitation readily occurred when lower concentrations of salt, arginine or 
glutamate were used. This therefore was unfeasible for further work which included 
NMR and in vitro assays. Consequently additional studies of PDIp a’c were 
abandoned.  
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3.9. Concluding Remarks 
 
The standard yield of PDIp that we can expect per 1ml of culture has been improved 
from only 2μg/ml to ~20μg/ml. Although expression was optimised, it is clear that 
the changes made to the purification protocol -specifically a long binding step during 
IMAC- were the most significant contributing factor. Although this is poorly 
understood, it is probable that the His-tag on the protein is mobile and therefore 
between states where it is accessible and where it is not. Based on the results of SDS-
PAGE it is likely that only 33% of the protein has an ‘accessible’ His-tag at any one 
time. Therefore a long binding step allows the His-tagged protein to be ‘trapped’ 
when in the correct conformation thus enabling a greater chance of eventual 
interaction. This also explains why a His-tag was observed by Western blot (see 
figure 3.7) even though very little binding was seen.  
We have suggested that the acidic N-terminus of PDIp is providing a ‘docking’ area 
for the His-tag therefore reducing its solvent accessibility. An N-terminal truncation 
clone shows very poor expression under conditions optimised for wild-type PDIp 
suggesting that the N-terminus may exert a more important role than originally 
anticipated. Therefore, although considerable work is required in order to obtain 
sound conclusions it is speculated that the N-terminus of PDIp could provide 
structural features required for the catalytic activity of PDIp a. 
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Chapter 4. Studies of the structure and 
enzymatic activity of human PDIp 
 
 
4.1. Introduction 
 
High resolution X-ray structures of oxidised and reduced hPDI (2.9 and 2.5 Å 
respectively) have recently been published (Wang et al. 2012). This and previous 
work show that hPDI undergoes large redox-mediated conformational changes 
centred on b’xa’ which consequently give rise to changes in total cleft volume and 
also relative exposure of the substrate binding site (Wang et al. 2011). With no 
structure currently available, it has been assumed that hPDIp, which is 45% identical 
to hPDI in sequence, exhibits a similar 3-dimensional conformation to that of hPDI: 
its most similar family member.  
The enzymatic activity of PDIp is also poorly studied. Using the insulin reduction 
assay (a classical PDI activity assay) it has been shown that PDIp has ~50% of the 
activity of PDI (Desilva et al. 1996, Fu and Zhu, 2010). Unfortunately these 
experiments are questionable as the protein being assayed contains 7 amino acids 
from the signal peptide sequence. In an oxidase assay using the mature protein, PDIp 
was again found to be less active than PDI but seemed to show an unusual pH 
dependence that was not further investigated (Alanen et al. 2006).  
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The aims of this work were to test the assumption that PDIp is similar structurally to 
PDI and also to characterise the oxido-reductase activity of PDIp relative to PDI. 
 
4.2. Redox un-controlled experiments 
 
4.2.1. Intrinsic fluorescence measurements 
Phenylalanine, tyrosine and tryptophan are intrinsically fluorescent although the 
signal emitted from phenylalanine is generally quite low. Typically therefore 
measurements of protein fluorescence reflect environments of tryptophan and 
tyrosine only. It is possible to use the intrinsic fluorescence of tryptophan and 
tyrosine to monitor protein folding because when either residue is buried within a 
protein (i.e. in the folded state) higher fluorescence intensity is observed than when 
they are solvent exposed (i.e. in the unfolded state).  
 
 
 
 
Figure 4.1: Intrinsic fluorescence of PDI and PDIp. Samples containing 10μM PDI/PDIp in 
20mM phosphate buffer (pH 7.3) were excited at 280nm and fluorescence emission measured 
between 290 and 400nm. Slit width = 2nm. 
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As all 5 PDI tryptophan residues are conserved in PDIp it is possible to compare the 
two proteins directly using intrinsic fluorescence. Shown in figure 4.1 are emission 
scans for PDI and PDIp following excitation at 280nm. The emission spectra for 
PDIp is clearly blue shifted relative to that of PDI. Recent work has indicated that 
differences between PDIred and PDIox can be determined by intrinsic protein 
fluorescence i.e. that PDIred is blue-shifted relative to PDIox (Wang et al. 2011). It is 
believed that this shift is due to PDIox being more open and less tightly folded than 
PDIred. On this basis it is possible that the difference in λmax for PDI and PDIp (see 
figure 4.1) is indicative of PDIp having a generally more folded structure than PDI. 
However this conclusion must be treated cautiously as differences in tryptophan 
environment caused by lack of sequence homology in surrounding regions could also 
be to blame.  
 
4.2.2. ANS fluorescence 
The recent X-ray crystal structure of human PDI (hPDI) has confirmed that like yeast 
PDI (yPDI), hPDI is arranged in a twisted ‘u’ structure (Wang et al. 2012). Along the 
inside of the ‘u’ are surface exposed hydrophobic amino acids giving rise to a 
hydrophobic patch associated with substrate binding. ANS is able to probe the 
hydrophobic surfaces of proteins and so is a suitable probe to investigate the inner 
surface and substrate binding cleft of PDIp 
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For both PDI and PDIp, saturation is achieved at ~100μM ANS. Although not an 
accurate probe of cleft size, figure 4.2 suggests that PDI and PDIp may have roughly 
the same total hydrophobic surface area. This is in line with the assumption that PDI 
and PDIp have similar 3-dimensional structure. 
 
4.2.3. Secondary structure analysis by far UV Circular Dichroism (CD)  
Far UV CD was used to observe the secondary structure conformations of hPDI and 
hPDIp (figure 4.3). Unexpectedly this data showed distinct differences between 190 
and 200nm: an area representative of α-helical structure. Figure 4.3 therefore 
suggests that PDIp has a greater proportion of α-helix than PDI.  
 
Figure 4.2: ANS saturation curve for PDI and PDIp. The interaction of varying 
concentrations of ANS with 1μM PDI/PDIp in 20mM phosphate buffer (pH 7.3) was recorded 
(excitation at 390nm). RFU at λmax is plotted against final ANS concentration. 
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α-helix β-sheet Turns Unordered 
PDI 31% 19% 14% 36% 
PDIp 42% 11% 13% 33% 
 
 
DichroWeb analysis of the data collected in figure 4.3 estimated that PDIp has 42% 
α-helical structure and PDI, 31% (see table 4.1). The actual α-helical content of 
reduced PDI abb’xa’ (based on crystal structure PDB: 4EKZ) is 28% (UniProt). This 
small discrepancy between calculated and measured α-helical content of PDI is a 
disadvantage of using DichroWeb which is biased by user-defined parameters. The 
quality of the PDI sample is not disputed due to the high reproducibility of the data. 
This is also true for the obvious differences between PDI and PDIp seen in terms of 
signal, particularly between 200-240nm. An explanation for this remains unclear. 
It is very unlikely that the differences between PDI and PDIp in terms of α-helical 
structure are due to the two catalytic domains (a and a’). PDI a and a’ share high 
sequence identity with the corresponding domains in PDIp (56% and 64% 
respectively) and also a  thioredoxin fold which is highly structurally conserved in 
PDI family members. It is most probable that the differences in secondary structure 
observed are due to the N-terminal extension of PDIp or the b’ domain which shares 
Figure 4.3: Far UV 
CD of PDI and PDIp 
at 20ºC. The circular 
dichroism of each 
protein (0.1mg/ml) in 
5mM phosphate was 
recorded at wavelengths 
from 190 to 260nm at 
20ºC. The mean residue 
ellipticity (MRE) was 
then calculated.  
Table 4.1: Results of 
DichroWeb analysis for PDI 
and PDIp DichroWeb analysis 
was performed using the 
CDSSTR algorithm and reference 
set SP175. Spectra were collected 
for 0.1mg/ml samples of each 
protein in 5mM phosphate at 
20ºC. 
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relatively low sequence identity with PDI b’. Discrepancies in structure between PDI 
b’ and PDIp b’ could explain why PDIp has restricted substrate specificity while PDI 
is a more general protein folding catalyst.  
 
4.2.4. Thermal denaturation using far UV CD 
Figure 4.4 shows the effect of increasing temperature on the secondary structure of 
PDI and PDIp. Method as described by Wang et al. 2010.  
 
 
 
 
 
The thermal denaturation of PDI shows a single transition step with a Tm of ~56ºC 
and is reproducible (see figure 4.4). In contrast, PDIp loses secondary structure in a 
continuous fashion between 20-60°C with no definitive Tm. This may indicate that 
PDIp has a greater degree of intrinsic flexibility than PDI and explains the issues 
Figure 4.4: Thermal denaturation of PDI and PDIp. The circular dichroism at 222nm 
was measured for each protein (0.1 mg/ml protein in 5mM phosphate) at 4°C intervals 
between 20-80°C. Samples were allowed to equilibrate for 10 minutes and then 
measurements were taken for 2 minutes. The mean CD and MRE for each temperature 
were then calculated. Method as described by Wang et al. 2010.  
  
 
Chapter 4. Studies of the structure and enzymatic activity of human PDIp 
 
104 
 
with stability that had been seen previously in chapter 3. Above 80ºC additional 
destabilisation events occur but these could not be accurately measured due to 
limitations of the equipment (data not shown). Similar to that of PDI, the thermal 
denaturation of PDIp is also reproducible.  
When looking at the extent of thermal destabilisation it is clear that of the two 
proteins, PDIp loses the smallest percentage of secondary structure. Cumulatively 
this data suggests that PDIp as an entity is not unstable but that there are regions 
within it that are sensitive to thermal denaturation. 
 
 
 
 
 
 
Refolding of PDI and PDIp can also be measured by far UV CD (see figure 4.5). As 
temperature is reduced from 80ºC to 20ºC PDI refolds with significant efficiency and 
Figure 4.5: Thermal refolding of PDI and PDIp. The circular dichroism at 222nm was measured 
for each protein (0.1 mg/ml protein in 5mM phosphate) at 4°C intervals between 80-20°C. Samples 
were allowed to equilibrate for 10 minutes and then measurements were taken for 2 minutes. The 
mean CD and MRE for each temperature were then calculated. The data points for pre-heated 
samples are circled. 
 
The circular dichroism of PDI and PDIp was measured at 222nm at 4°C intervals between 80-20ºC and the 
corresponding MRE for each calculated.  
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has a clear cut transition step. Refolding of PDIp is continuous over the temperature 
range tested. For both proteins, refolding is not 100% complete, but occurs via 
similar transition events (in reverse) to those seen in the initial unfolding experiment. 
Interestingly, early work on the purification of PDI from bovine liver included a heat 
treatment step where the crude sample was incubated at 54ºC (Lambert and 
Freedman 1983a). Figure 4.4 indicates that this is just below the Tm for PDI and 
indicates that at this temperature, PDI would be undergoing an unfolding transition. 
In their protocol the heat treatment is followed by incubation on ice (Lambert and 
Freedman 1983a). It is likely that almost full recovery of structure would be obtained 
during cooling because the unfolding transition is reversible (see figure 4.5). Clearly 
this explains why major issues with reduced protein recovery and aggregate 
formation are not seen for PDI purification using this protocol. 
 
4.2.5. Analysis of secondary structure by far UV CD after incubation at 80ºC 
Both Figure 4.6 and table 4.2 show that after incubation for 10 minutes at 80ºC, PDIp 
retains significant secondary structure relative to PDI which had seen major losses. 
This thermal stability is clearly very unusual but is supported by thermal 
denaturation studies (figures 4.4 and 4.5). This work suggests that PDIp is very 
stable at high temperatures and loses only a small amount of secondary structure. 
Again, this may imply that there are regions within PDIp that are dynamic but fewer 
than within PDI.  
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α-helix β-sheet Turns Unordered 
PDI 16% 25% 16% 42% 
PDIp 30% 17% 15% 38% 
 
 
Stability to adverse conditions may be a requirement of PDIp in vivo and therefore 
this work may provide clues to possible activities and physiological substrates of 
PDIp.  
 
4.3. Redox-controlled experiments 
 
4.3.1. Far UV CD of oxidised/reduced protein 
Recent work has shown that human PDI undergoes a redox-regulated conformational 
change centred on b’xa’ (Wang et al. 2011, Wang et al. 2012). More specifically, 
PDI appears to become more ‘open’ and expose a larger degree of its hydrophobic 
surfaces when it is in the oxidised state than when it is in the reduced state. In 
addition oxidised PDI has increased chaperone activity. This is suggested to be 
Figure 4.6: Far UV CD 
of PDI and PDIp at 
80ºC. The circular 
dichroism of each protein 
(0.1mg/ml) in 5mM 
phosphate was recorded 
at wavelengths from 190 
to 260nm at 20ºC. The 
mean residue ellipticity 
(MRE) was then 
calculated.  
Table 4.2: Results of 
DichroWeb analysis for PDI 
and PDIp incubated at 80ºC. 
DichroWeb analysis was 
performed using the CDSSTR 
algorithm and reference set 
SP175. Spectra were collected for 
0.1mg/ml samples of each protein 
in 5mM phosphate at 80ºC. 
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linked to the redox-mediated conformational changes described previously (Wang et 
al. 2011). 
Using the same method for thermal denaturation as before, the Tm of PDIred was 
found to be higher (~56°C) than that of PDIox (~52°C) i.e. PDIox is less thermally 
stable than PDIred (figure 4.7). This result correlates with published data that shows 
that in its oxidised form PDI exhibits greater surface exposure (Wang et al. 2011, 
Wang et al. 2012). There were no significant differences between the thermal 
stability of PDIpox and PDIpred. This implies that the destabilising effect of oxidation 
(probably the conformational change discussed previously) that is seen for PDI is not 
mirrored in PDIp (see figure 4.7).  
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4.3.2. Limited proteolysis experiments 
In order to investigate the effect of redox state further, limited proteolysis 
experiments were performed (see figure 4.8). Historically, limited proteolysis has 
been used to determine the domain boundaries of PDI because regions of structure 
are known to be less susceptible to proteolysis than linker regions (found between 
domains). It was expected that changes in conformation associated with the oxidation 
of PDI would give rise to increased exposure to proteases.  
Figure 4.7: Thermal denaturation of A) PDI and B) PDIp in reduced and 
oxidised states. 1mg/ml protein was prepared in 5mM phosphate buffer 
containing 5mM DTT or diamide. Desalting was then performed using a 
PD10 column. The circular dichroism at 222nm for 0.1mg/ml samples of each 
protein was then measured at 4°C intervals between 20-80°C. Samples were 
allowed to equilibrate for 10 minutes and then measurements were taken for 2 
minutes. The mean CD and MRE for each temperature were then calculated.  
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Interestingly, PDIp has fewer potential cleavage sites for trypsin and proteinase K 
than PDI. It is likely that PDIp has evolved in this way due to its location in the 
acinar cells of the exocrine pancreas i.e. the cells responsible for the secretion of 
zymogens. This may therefore be a clue to its physiological function which currently 
remains unknown. In this experiment, chymotrypsin (another pancreatic protease) 
was used. 
 
 
 
 
 
 
As expected, figure 4.8 shows that PDIox is much more susceptible to limited 
proteolysis than PDIred. PDIox is almost completely digested after 2 hours incubation 
with chymotrypsin but for PDIred a major product of ~40kDa can be seen. This 
correlates with previous data (see chapter 3) and is indicative of intrinsic flexibility at 
the x-linker region and the subsequent loss of a’. In contrast to this, both PDIpox and 
Figure 4.8: Limited proteolysis of PDI and PDIp in reduced and oxidised states. Protein 
samples (15μM) were incubated with chymotrypsin (75nM) for up to 2 hours in the presence of 
5mM DTT or diamide in 50mM Tris HCl buffer pH 7.6. 1) Untreated, 2) 0 mins, 3) 5 mins, 4) 10 
mins, 5) 20 mins, 6) 40 mins, 7) 60 mins, 8) 90 mins and 9) 120 mins.  The reaction was stopped 
with the addition of SDS-loading dye and boiling for 5 minutes. Circles indicate gel bands sent for 
peptide mass fingerprinting analysis. 
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PDIpred are similarly susceptible to chymotrypsin with major fragments in both cases 
of ~40kDa. This work suggests that like PDI, PDIp has intrinsic flexibility centred on 
b’xa’. Unlike PDI however, susceptibility of PDIp to chymotrypsin does not appear 
to be increased by oxidation. Therefore this implies that PDIp does not undergo 
redox-mediated conformational changes similar to PDI. This is also in agreement 
with thermal denaturation studies shown previously (see figure 4.7). 
To identify specific regions within PDI and PDIp that are most susceptible to 
proteolytic cleavage by chymotrypsin, peptide mass finger-printing analysis was 
performed (figure 4.9). Bands of interest were cut from the gel, subjected to further 
proteolysis (trypsin) and then any remaining peptides were detected by MALDI-TOF 
mass spectrometry. A sequence coverage map is then produced and any missing 
peptides can be identified (see figure 4.9). 
It is clear from peptide mass finger-printing data that proteolytic cleavage occurs 
preferentially at the C-terminus of both PDI and PDIp (figure 4.9). This was in 
concordance with previous data that shows that PDI is most susceptible to 
proteolysis at the x-linker and surrounding area (Wang et al. 2010). Overall low 
sequence coverage meant that it was impossible to identify the exact sites of 
cleavage. In addition the PDIox sample which on the gel has a Mw of ~25kDa (see 
figure 4.9) has peptide coverage of ~60% which is much higher than expected. This 
suggests that the sample is heterogeneous and is a disadvantage of using peptide 
mass finger printing. ESI-MS provides exact cleavage sites and therefore is able to 
identify specific regions with susceptibility to proteases. 
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Unlike the results of peptide mass finger-printing, ESI MS (figure 4.10) allowed 
identification of major cleavage sites. The benefit of using chymotrypsin rather than 
trypsin or proteinase K was that both PDI and PDIp are similarly susceptible to 
chymotrypsin based on sequence alone. This means that it is easier to determine 
potential differences in structure based on differential susceptibility to chymotrypsin. 
On the basis of possible cleavages alone (see figure 4.10), both proteins showed 
remarkable resistance especially around the N-terminus. In the reduced state there 
were 2 conserved cleavage sites for each protein giving rise to 4 peptides of ~42kDa 
(PDI D18-L372, D18-W396 and PDIp Q22-L393, Q22-L417). Based on the 
identification of these peptides it is clear that for both proteins flexibility towards the 
C-terminal end of the molecule leads to the preferential loss of the a’ domain. This is 
in agreement with PDI studies by Wang et al. (2011).  
Protein 
 
Redox 
State 
 Mw from 
ESI-MS (Da) 
Expected 
Mw (Da) 
Mass difference 
(Da) 
Peptide 
 
PDI N/A 56374 56379 -5 N/A 
PDI Reduced 55589 55596 -7 D18-Q501 
PDI Reduced 43871 43875 -4 D18-W396 
PDI Reduced 41009 41013 -4 D18-L372 
PDI Oxidised 27789 27788 +1 D18-F240 
PDI Oxidised 26727 26726 +1 D18-F249 
PDI Oxidised 25711 25710 +1 D18-L259 
PDIp N/A 56915 56919 -4 N/A 
PDIp Reduced 56271 56276 -5 Q22-M519 
PDIp Reduced 45037 45040 -3 Q22-W417 
PDIp Reduced 42191 42194 -3 Q22-L393 
PDIp Reduced 40074 40077 -3 Q22-Y375 
PDIp Oxidised 42191 42190 +1 Q22-L393 
PDIp Oxidised 40073 40073 0 Q22-Y375 
PDIp Oxidised 28895 28894 +1 Q22-F271 
PDIp Oxidised 27918 27917 +1 Q22-F262 
PDIp Oxidised 26954 26952 +2 Q22-H254 
Table 4.3: Peptides identified by ESI-MS: Proteins were digested with chymotrypsin for 
two hours and then the reaction was stopped using an excess of PMSF. Samples were then 
submitted to ESI-MS. Peptides corresponding to peaks were identified using ProtParam, 
ExPASy.  
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In the oxidised state however, cleavage of both proteins occurs much earlier on 
indicating that it is more susceptible to proteolysis than the reduced form. Table 4.4 
shows that for PDI, three peptides of ~25kDa were identified corresponding to (PDI 
D18-F240, D18-F249 and D18-L259). This indicates that the only fully intact 
domains after proteolysis are the a and b domains. Again this correlates well with the 
work of Wang et al. (2011) which suggests that PDI b’xa’ is the major redox-active 
region of the molecule and that oxidation of PDI gives rise to major conformational 
changes. Like PDI, oxidised PDIp is more susceptible to digestion by chymotrypsin 
than its reduced form. Unlike PDI however, peptide fragments of ~40kDa were 
identified by ESI-MS indicating that oxidised PDIp is far more resistant to 
proteolysis than oxidised PDI. Smaller peptides of ~25kDa were also identified for 
oxidised PDIp and these correspond perfectly to those described for PDI previously 
including having conserved cleavage sites. Clearly the two proteins are very similar 
in structure but this work may suggest that unlike PDI, PDIp only undergoes minor 
or limited redox-mediated conformational changes.  
 
4.3.3. ANS fluorescence 
ANS binding to PDI and PDIp in both redox states was used as an indicator of cleft 
size and surface exposure. As binding of ANS to a hydrophobic surface leads to an 
increase in fluorescence it can also be useful for studying the conformational changes 
that occur when PDI is oxidised.   
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The protocol used by Wang et al (2011) to measure ANS binding to PDI in the 
oxidised and reduced state describes an intial step in which PDI is incubated with 
ANS followed by a second step where either GSH or GSSG is added. Following 
addition of GSH or GSSG the sample is incubated again prior to fluorescence 
measurements being made. However, this method does not take into account the 
absorbance properties of GSH or GSSG. Figure 4.11 clearly indicates that there may 
be slight interference at 390nm, the excitation wavelength of ANS. In addition, 
fluorescence emission was found to be influenced also by presence of DTT or 
diamide as alternative reductants/oxidants (data not shown). Consequently, it is best 
practice to desalt reduced or oxidised protein prior to use in this assay. 
Using this optimised protocol, preliminary results (shown in figure 4.12) have been 
obtained.  
 
Figure 4.11: Absorbance scan for GSH and GSSG. Samples of 
1mM GSSG or 1mM GSH were made up in 20mM phosphate buffer 
pH7.3 
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Figure 4.12 shows that greater interaction occurs between ANS and PDIox than ANS 
and PDIred (ANS enhancement factor 6.83 and 2.84 respectively). This indicates that 
there is a greater hydrophobic surface available for ANS binding in the oxidised form 
and this is due to an open conformation (Wang et al. 2011). The difference between 
the interactions of ANS with PDIpox and PDIpred is much smaller (ANS enhancement 
factor 2.20 and 1.58 respectively) although like PDI there is greater fluorescence 
Figure 4.12: ANS binding experiments. The fluorescence emitted when oxidised or 
reduced protein (10μM) interacted with ANS (100uM) was measured between 400-
600nm after excitation at 390nm. The ANS enhancement factor was then calculated for 
each (ANS enhancement at λmax = (Fprotein + ANS)/FANS). 
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enhancement when PDIp is in the oxidised state. Again this implies that PDIp may 
undergo a smaller redox-mediated conformational change. Additional study of these 
interactions will provide more resolute answers. 
 
4.3.4. Dynamic Light Scattering 
In order to try to quantify the extent of conformational change being displayed 
between the two redox states the associated change in molecular diameter was 
measured by dynamic light scattering (DLS). Table 4.4 shows that oxidation of PDI 
gives rise to a 25% increase in diameter compared to the reduced protein. For PDIp 
this difference is much more subtle: an increase of 8% is observed. Similar to 
previous work, this may suggest that PDIp undergoes only a minor redox-mediated 
conformational change.  
 
 
 
 
Due to the low replicate number (4) and also the low reproducibility of 
measurements for mean diameter, the standard deviations calculated for this data are 
quite high. Furthermore the increase in diameter size for oxidised PDI relative to 
reduced PDI was found to be not significant using the student’s t-test (un-paired). As 
strict precaution was taken to monitor and reduce polydispersity, the reason behind 
inconsistencies in diameter is unknown. It could be that different biological samples 
have natural sample variance or indicate that there are various intermediate 
 
Mean Diameter +/- SD Change in Diameter (%) 
PDI(r) 5.15 +/- 1.07 N/A 
PDI(o) 6.46 +/- 1.49 +25 
PDIp(r) 5.59 +/- 1.02 N/A 
PDIp(o) 5.99 +/- 0.85 +8 
Table 4.4: Results of DLS for PDI and PDIp.  A sample containing 11uM protein and 20mM 
phosphate were prepared. The protein had been oxidised/reduced with an excess of diamide/DTT 
and were then desalted before the experiment. 
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conformations between the reduced and oxidised forms defined by the X-ray crystal 
structure of PDI (Wang et al. 2012). 
When observing the effect of redox state on PDI and PDIp by native PAGE, it is 
clear that the oxidised proteins are retarded more than the reduced proteins (see later, 
figure 5.9). As expected, the difference in mobility is more striking between redox 
states for PDI. Again this implies that both PDI and PDIp undergo a redox-mediated 
conformational change but that the change is much smaller in PDIp than PDI. 
 
4.4. Measuring the enzymatic activity of PDI and PDIp 
 
4.4.1. The Insulin oxido-reductase assay 
 
 
 
 
The insulin reduction assay has frequently been used to measure the reductase 
activity of PDI. By coupling the reduction of insulin with the oxidation of NADPH 
using glutathione reductase it is possible to measure the oxido-reductase activity of 
PDI or PDIp (see figure 4.13). Using this assay, PDIp was found to be ~50% as 
active as PDI (see figure 4.14).  
Figure 4.13: Reaction scheme for insulin oxido-reductase assay. 
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Figure 4.14: Measurements of the oxido-reductase activity of PDI and 
PDIp. Varying concentrations of protein were added to 200mM phosphate 
50mM EDTA buffer (pH 7.5) containing 8mM GSH, 1 unit of glutathione 
reductase and 120μM NADPH at 37ºC. Reaction was started by adding 
15μM insulin and the reaction was monitored by watching the rate of change 
at A340. 3 relicates were taken for 3 biological samples of each protein in an 
attempt to reduce error. A) Example trace for control sample (no protein), B) 
example traces for PDI and PDIp (1mM) and C) Graph showing rate of 
change (using gradient of line after addition of insulin) vs protein 
concentration. 
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The percentage difference in activity for PDI and PDIp (~55%) is remarkably 
reproducible. The assay however has huge day to day variance. This is largely 
uncontrollable and is due to the large number of different reactants involved and the 
high sensitivity of the spectrophotometer. In order to reduce error and standardise the 
assay the activity of PDIp was always measured relative to the activity of PDI 
measured on the same day.  
 
4.5. Concluding Remarks 
 
Our work has shown that the 3-dimensional structure of PDIp is not as similar to that 
of PDI as previously expected. Far UV CD has shown that PDIp has greater α-helical 
content than PDI and that there are differences in terms of the thermal stability of the 
two proteins. Unlike PDI, PDIp does not undergo a large redox-mediated 
conformational change and this is supported by many different lines of evidence 
including limited proteolysis, mass spectrometry and DLS.  At present we do not 
understand the implications of this but it is feasible that the chaperone activity of 
PDIp could be affected if the binding surface is not very accessible. It is possible 
therefore that PDIp undergoes conformational changes that are not redox-regulated 
but are instead substrate induced.  
PDIp has ~50% of the oxido-reductase activity of PDI. Although it is known that 
PDIp has restricted substrate specificity we expect PDIp to be able to bind insulin as 
it has a surface exposed tyrosine so it is unlikely that this difference is inability to 
bind insulin. We also believe that one of the contributors to the low oxido-reductase 
activity of PDIp is the unusual a’ active site sequence (CTHC rather than CGHC). It 
is well known for other PDI family members that the amino acid residues located 
between active site cysteines are very important for the overall reactivity of the 
active site. The implications of replacing a glycine residue with a threonine residue 
are unknown but given the size difference between between the two it is likely that 
there may be some steric effects.  
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Chapter 5. Investigation of the contribution of 
the b’xa’c region to the distinctive properties 
of PDIp 
 
 
5.1. Introduction  
 
Our studies have shown that PDI and PDIp are not just different in terms of redox 
structure but also in terms of catalytic activity. Given that the two share identical 
domain architecture and ~45% sequence identity these results were surprising. By 
comparing the structure and activity of PDI, PDIp and two chimera proteins (see 
figure 5.1) we hope that it will be possible to determine regions of PDIp that 
contribute to these differences. 
We expect that these dissimilarities are due to the b’xa’c region because we know 
that b’xa’c is the major region of redox-mediated conformational change in PDI 
(Wang et al. 2011). In addition we also expect that the unusual binding properties 
(conferred by b’) and odd a’ active site sequence of PDIp (CTHC) are contributing 
to its low oxido-reductase activity. Consequently plasmids for 2 chimera proteins, 
PDIp ½ and PDIp ¾ were kindly donated by Dr. Katrine Wallis. Both of these 
proteins share PDIp a and b domains but are different in their C-terminal half i.e. 
b’xa’c. Unfortunately up to now our studies of the C-terminus of PDIp have been 
limited because isolated PDIp b’xa’c is unstable (see chapter 3). As a result of this, 
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comparisons between wild-type PDIp, PDIp ½ and PDIp ¾ were used to study this 
region.  
 
 
.  
 
Based on our previous work and also published data, we would expect PDIp ½ to 
have similar redox conformations to PDI because it has PDI b’xa’c: the major redox-
active region defined by Wang et al. 2011. We would also expect it to have similar 
oxido-reductase activity to PDI because it has two CGHC active site motifs and also 
the PDI b’ substrate binding site. However PDIp ¾ will likely exhibit mixed 
characteristics for both structure and activity because a) it does not have the full 
redox-active cassette of PDI and b) in having the PDIp a’ domain (including a CTHC 
active site) it is probably less active as an oxido-reductase.  
 
  
Figure 5.1: Schematic showing domain architecture of PDI, PDIp and two chimera 
proteins.  
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5.2. Expression and purification of chimera Proteins  
 
5.2.1. Expression and purification of PDIp ½ 
PDIp ½ was expressed to a sufficient amount using protocols optimised for 
expression of wild-type PDIp (see chapter 3). No significant improvement in binding 
to the Ni
2+
 column was seen when using a long binding step as opposed to the 
standard IMAC protocol (data not shown). As PDIp ½ shares the same N-terminus as 
wild-type PDIp this suggests that the problems associated with binding of PDIp to 
the Ni
2+
 column are not simply caused by this region as originally postulated. This is 
supported by purification studies of PDIp b’xa’c which also saw reduced binding 
despite not having an a domain or an N-terminal extension. To fully understand the 
issues associated with column binding during IMAC further study must be 
undertaken. 
After IMAC, PDIp ½ was purified by IEC. The chromatogram for PDIp ½ is not 
dissimilar to wild-type PDI in showing a single peak with a slight shoulder (figure 
5.2A). Samples collected from IEC fractions were studied by SDS and native PAGE 
(see figure 5.2B and 5.2C). 
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Figure 5.2B shows that a large yield of PDIp ½ was expressed and purified. 
Evidently there is a small amount of degradation but this is far outweighed by the full 
length protein. When duplicate samples were analysed by native PAGE (figure 
5.2C), it was clear that PDIp ½ has a natural propensity to dimerise. Like for PDI, 
Figure 5.2: IEC of PDIp ½. A) Zoomed IEC chromatogram for PDIp ½. B) 12% SDS-
PAGE showing protein collected during IEC of PDIp ½. C) 12% Native-PAGE showing 
protein collected during IEC of PDIp ½. Fractions were taken from within region shown by 
the red line. 
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dimer is eluted from the column at a slightly higher salt concentration than the 
monomer and corresponds to the shoulder seen on the chromatogram (figure 5.2A). 
In order to separate dimer species from monomer PDIp ½ was purified further by 
SEC (see figure 5.3). 
 
 
 
Figure 5.3 indicates that it is very difficult to separate monomer and dimer forms of 
PDIp ½. Therefore only SEC fractions that contain minor dimer contamination were 
pooled and consequently a significant reduction in total yield was observed. In 
addition the longer purification time taken to perform IMAC, IEC and SEC leads to 
increased instability and degradation. Typically greater yields of PDIp ½ are 
obtained when time taken to express and purify protein is reduced (data not shown).  
 
5.2.2. Expression and purification of PDIp ¾  
Similar to PDIp ½, PDIp ¾ is optimally expressed using the conditions determined 
previously for wild-type PDIp. It can be purified easily using standard PDI protocols 
and no obvious issues with Ni
2+
 column binding have been seen. Clearly PDIp ¾ 
also dimerises easily and this is probably caused by PDI b’x (see figure 5.4C).  
 
Figure 5.3: Native PAGE 
showing SEC of PDIp ½. 
Following dialysis of PDIp ½ 
from IEC into 20mM 
phosphate buffer pH 7.3, SEC 
was performed. SEC was 
undertaken in 20mM 
phosphate, 500mM NaCl buffer 
pH 7.3. Samples were analysed 
using a 12% native PAGE gel. 
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This is in agreement with work from the RBF group that shows that constructs 
containing PDI b’x have a greater propensity to dimerise than those that do not 
(Wallis et al. 2009). Following IEC, SEC is used to remove dimer from the sample 
of PDIp ¾ (data not shown).   
Figure 5.4: IEC of PDIp ¾.  A) IEC chromatogram for PDIp ¾. B) 12% SDS-PAGE showing 
protein collected during IEC of PDIp ¾. C) 12% Native-PAGE showing protein collected during 
IEC of PDIp ¾. Fractions were taken from within region shown by the red line. 
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Like for PDIp ½, PDIp ¾ is also quite unstable and minor degradation products can 
be seen in both figure 5.4B and 5.4C. The accumulative result of losing PDIp ¾ to 
both degradation and dimer formation is that yield is significantly reduced.  By 
reducing total purification time a huge improvement in yield is observed due to 
losing less protein to dimer formation or degradation. 
 
5.3. Redox un-controlled experiments 
 
5.3.1. Far UV Circular Dichroism 
First and foremost, Figure 5.5 shows that no structural weaknesses were induced by 
the creation of the chimeras and that they are well folded. The production of chimera 
proteins with incorrect domain boundaries can give rise to difficulties during protein 
expression and often the protein is later found to be poorly structured. There is no 
evidence of this here.  
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Scans of the circular dichroism of PDIp ½ and PDIp ¾ show greater resemblance to 
PDI than PDIp in terms of secondary structure i.e. the chimera proteins also have less 
α-helical structure than PDIp (see figure 5.5). The most obvious region of difference 
is between 190-200nm where the chimera proteins clearly resemble PDI. Based on 
the spectra alone this indicates that PDIp is more α-helical than PDI, PDIp ½ and 
PDIp ¾. DichroWeb analysis confirms that both chimera protein have similar 
secondary structure content to PDI (table 5.1).  
Differences in secondary structure must be caused by b’x because it is the only 
shared region between PDI and the two hybrid proteins. Additional α-helical 
structure in this region may contribute to the differences in redox-regulated 
conformations that were seen previously. Aside from being implicated in redox-
dependent conformational change, b’ is also the substrate binding domain. Structural 
differences in b’ may therefore contribute to the limited substrate specificity of PDIp. 
 
α-helix β-sheet Turns Unordered 
PDI 31% 19% 14% 36% 
PDIp 42% 11% 13% 33% 
PDIp 1/2 29% 19% 14% 37% 
PDIp 3/4 25% 23% 13% 39% 
Figure 5.5: Far UV CD 
of PDI, PDIp and two 
chimera proteins. The 
circular dichroism of each 
protein (0.1mg/ml) in 
5mM phosphate was 
recorded at wavelengths 
190 to 260 nm and at 
20ºC. The mean residue 
ellipticity (MRE) was then 
calculated.  
Table 5.1: Results of 
DichroWeb analysis for 
chimera proteins. 
Analysis was performed 
using the CDSSTR 
algorithm and reference 
set SP175. Spectra were 
collected for 0.1mg/ml 
samples of each protein in 
5mM phosphate at 20ºC. 
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5.3.2. Thermal denaturation using far UV CD 
Although less distinct, figure 5.6 shows that like PDI, both chimera proteins undergo 
a single unfolding transition. For PDIp ½ and PDIp ¾ the Tm is ~52ºC which is lower 
than that seen for PDI indicating a reduction in thermal stability. At present it is 
uncertain whether this difference is due to PDIp content or whether it is due to 
disruption of domain interfaces during construct manufacture. It is unlikely to be the 
latter because no evidence of increased instability has been seen for either chimera 
during scans of secondary structure.  
 
 
 
 
 
 
5.3.3. Analysis of secondary structure by far UV CD after incubation at 80ºC 
After incubation at 80ºC both chimera proteins lose significant α-helical structure 
and gain β-sheet and unordered structure. Unsurprisingly therefore the CD spectra 
obtained is very similar to that of PDI (see figure 5.7). Clearly PDIp b’x is more 
Figure 5.6: Thermal denaturation of PDI, PDIp and two chimera proteins. The 
circular dichroism at 222nm was measured for each protein (0.1 mg/ml protein in 
5mM phosphate) at 4°C intervals between 20-80°C. Samples were allowed to 
equilibrate for 10 minutes and then measurements were taken for 2 minutes. The 
mean CD and MRE for each temperature were then calculated.  
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stabilising than PDI b’x. As the b’x region of PDI has been implicated as the site 
most affected during redox-mediated conformational change (Wang et al. 2011) it is 
possible that the stability of PDIp b’x prevents these movements in PDIp.   
 
 
 
α-helix β-sheet Turns Unordered 
PDI 16% 25% 16% 42% 
PDIp 30% 17% 15% 38% 
PDIp 1/2 18% 27% 15% 40% 
PDIp 3/4 7% 34% 15% 41% 
 
 
To conclude this work, PDI.PDIp chimeras show greatest resemblance to PDI in 
terms of secondary structure and thermal stability. PDI, PDIp ½ and PDIp ¾ share 
the PDI b’x region only. Therefore this data indicates that the thermal stability of 
these proteins is regulated by b’x and this is supported by previous work from Wang 
et al. 2010 which defined b’xa’ as the major flexible element of PDI.  
 
  
Figure 5.7: Far UV CD of 
PDIp ½ and PDIp ¾ at 
80ºC. The circular dichroism 
of each protein (0.1mg/ml) in 
5mM phosphate was 
recorded at wavelengths 
from 190 to 260nm at 80ºC. 
The mean residue ellipticity 
(MRE) was then calculated.  
 
Table 5.2: Results of 
DichroWeb analysis for 
chimera proteins 
incubated at 80ºC. 
Analysis was performed 
using the CDSSTR 
algorithm and reference 
set SP175. Spectra were 
collected for 0.1mg/ml 
samples of each protein in 
5mM phosphate at 80ºC. 
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5.4. Redox-controlled experiments 
 
5.4.1. Far UV CD of oxidised/reduced protein 
The redox-mediated conformational changes of PDI have been well characterised 
(Wang et al. 2011, Wang et al. 2012). Unlike PDI, PDIp only undergoes minor 
redox-controlled changes. The reason for this is currently unknown. Figure 5.8 
indicates that PDIp ½ and PDIp ¾ show no significant difference in thermal stability 
between redox states. Therefore the chimera proteins are similar to PDIp in that they 
only experience minor redox-mediated conformational changes.  
 
 
 
 
Figure 5.8: Thermal denaturation of PDIp ½ and PDIp ¾ in 
reduced and oxidised states. 0.1mg/ml protein was prepared in 5mM 
phosphate buffer also containing 5mM DTT or diamide. Desalting was 
then performed using a PD10 column. The circular dichroism at 222nm 
for each protein was measured at 4°C intervals between 20-80°C. 
Samples were allowed to equilibrate for 10 minutes and then 
measurements were taken for 2 minutes. The mean CD and MRE for 
each temperature were then calculated. A) PDIp ½ and B) PDIp ¾. 
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This data is interesting because figure 5.6 showed that PDIp ½ and PDIp ¾ have 
similar thermal stability to PDI and this characteristic was attributed to the b’x region 
which is known to have intrinsic flexibility (Wang et al. 2010). Figure 5.8 however 
provides evidence to suggest that the chimera proteins do not undergo redox-
mediated conformational changes characteristic of PDI. It is therefore suggested that 
the a and b domains of PDIp have a negative effect on the ability to exhibit alternate 
redox-state conformations. This means that despite the b’xa’ region of PDI being 
implicated as the major effector of redox-controlled conformational change (Wang et 
al. 2011, Wang et al. 2012) the presence of PDIp ab (in PDIp ½) is preventing these 
structural movements from occurring. Whether this activity is linked to the structure 
of PDIp ab or active-site chemistry is currently unknown. 
 
5.4.2. Dynamic Light Scattering 
Table 5.3 shows the percentage change in diameter associated with oxidation for 
PDI, PDIp and the two chimera proteins. It is clear that oxidised PDI has a much 
larger diameter than reduced PDI and the conformational changes associated with 
this have been characterised using X-ray crystallography (Wang et al. 2012). The 
difference in diameter between reduced and oxidised PDIp indicates that it does not 
undergo such large conformational changes. PDIp ½ and PDIp ¾ resemble PDIp in 
exhibiting only small differences in diameter upon oxidation demonstrating that they 
also undergo only minor redox mediated conformational changes. However due to 
the low replicate number for PDI ½ and PDIp ¾ (3), further accuracy will be gained 
from repeating this experiment.  
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Protein Percentage change in diameter upon oxidation (%) 
PDI +25 
PDIp +8 
PDIp 1/2 +6 
PDIp 3/4 +6 
 
 
  
 
This work seems to agree with the results shown previously (see figure 5.8) and 
provides further evidence to support the notion that PDIp exhibits minor redox-
mediated movements in a process that is regulated by it’s a and b domain. Again the 
data is not statistically significant but this may be due to intermediate conformational 
changes between the open and closed forms.  
 
5.4.3. Analysis of chimera proteins by Native PAGE 
Native PAGE analysis can be used to observe the redox-mediated conformational 
changes of PDI. When oxidised, the increased diameter of PDI causes greater 
retardation through the gel than the same protein in the reduced state. Figure 5.9 
shows that oxidised PDIp is less retarded than oxidised PDI. This is because PDIp 
undergoes less significant redox-motions and exhibits less considerable differences 
in molecular diameter upon oxidation.  
 
Table 5.3: Results of DLS for chimera proteins.  Samples containing 
11μM protein in 20mM phosphate (pH 7.3) were prepared. Protein was 
oxidised or reduced with an excess of diamide/DTT and then desalted 
before measurements were taken. The difference in diameter between 
reduced and oxidised samples is shown.  
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Unexpectedly, oxidised PDIp ½ is retarded to a greater extent than wild-type PDIp. 
This contrasts with work described previously and so interpretation requires caution. 
It may be that PDIp ½ can exist in alternate conformations but that reaching an 
‘open’ conformation is more difficult than for PDI.  
In its oxidised form, PDIp ¾ and PDIp ¾ T419G (which will be discussed later) 
seem to be present in two alternate conformations. Alongside the results of PDIp ½ 
(described previously) it could be postulated that these species are indicative of equal 
amounts of oxidant responsive and oxidant unresponsive forms of PDIp ¾ caused by 
the split nature of chimera proteins. This polymorphism appears to be absent for the 
reduced form of PDIp ¾ and PDIp ¾ T419G but actually it is likely that this result is 
due to  ~50% of the protein being retarded in the oxidised state and ~50% not.  
 
  
Figure 5.9: Redox 
state observations 
by Native PAGE 
analysis. Samples 
containing 5μg of 
protein in 20mM 
phosphate buffer 
(pH 7.3) were 
incubated in the 
presence of 10mM 
DTT or diamide for 
30 minutes prior to 
loading into a 12% 
native gel. Samples 
shown are: 1) PDI, 
2) PDIp, 3) PDIp 
½, 4) PDIp ¾ and 
5) PDIp T419G. 
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5.5. Measuring the enzymatic activity of PDIp ½ and PDIp ¾  
 
5.5.1. The Insulin oxido-reductase assay 
Figure 5.10 shows that PDIp ½ has ~75% of the oxido-reductase activity of PDI. 
This is an increase of ~20% relative to wild-type PDIp. Clearly the presence of PDI 
b’xa’c has a positive effect on the ability of PDIp to act as an oxido-reductase. This 
is probably due to the more general substrate specificity exerted by PDI b’ and the 
presence of an intact CGHC catalytic active site motif in PDI a’. In PDIp a’ there is a 
CTHC active site sequence (rather than CGHC) and this could account for the low 
oxido-reductase activity measured for wild-type PDIp. Evidently the PDIp a and b 
domains have a negative effect on the activity of the PDIp ½ construct. This is 
interesting because the same region is detrimental to redox-mediated conformational 
change also. 
PDIp ¾ has ~65% oxido-reductase activity relative to PDIp which indicates that 
PDIp b’x is only a minor contributor to the loss of activity. Although in silico studies 
had shown that insulin had a solvent exposed hydroxyl-aryl group suitable for PDIp 
binding this confirms that the interaction can occur and that reduction in activity seen 
for PDIp is not simply due to inability to bind insulin.  
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By measuring the activity of PDIp, PDIp ½ and PDIp ¾ relative to PDI measured on 
the same day the degree of error is reduced. Figure 5.10 shows that the level of error 
across 3 replicates is low. The data for PDIp ½ has the greatest amount of error at 
~10%.  
 
5.6. Activity studies of PDIp T419G and PDIp ¾ T419G 
 
5.6.1. Expression and purification of PDIp T419G and PDIp ¾ T419G 
PDIp T419G and PDIp ¾ T419G were expressed and purified as described 
previously for wild-type PDIp and PDIp ¾ respectively. Total yields for both 
proteins were ~20μg/ml of culture. Figure 5.11 shows SDS-PAGE gels of IEC 
samples taken for each protein. Like PDIp ¾, PDIp ¾ T419G can dimerise easily so 
following analysis by native-PAGE an SEC step may be required (data not shown). 
Figure 5.10: Relative oxido-reductase activities of PDIp ½ and PDIp ¾. 
Varying concentrations of protein were added to 200mM phosphate 50mM 
EDTA buffer containing 8mM GSH, 1 unit of glutathione reductase and 120μM 
NADPH at 37ºC. Reaction was started by adding 15μM insulin and the reaction 
was monitored by watching the rate of change at A340. Activity was calculated 
from plots of absorbance rate vs concentration of PDI/PDIp (see figure 4.15) as 
a percentage of the activity of PDI measured on the same day. 3 replicates were 
taken for 3 biological samples of each protein in an attempt to reduce error.  
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IEC chromatograms of PDIp T419G and PDIp ¾ T419G are similar to those 
produced for wild-type PDIp and PDIp ¾ respectively (see figures 3.13 and 5.4). 
Like for wild-type PDIp, PDIp T419G has a distinct second peak. Samples were 
collected from the major peak only and analysed by SDS-PAGE. There was no 
indication that this mutant dimerises more readily than the wild-type protein (data 
not shown).  For PDIp ¾ T419G there is only one peak but it has a distinct shoulder 
probably indicating the presence of dimer. Protein was collected from the peak 
avoiding this area. 
 
5.6.2. Insulin assay of PDIp T419G and PDIp ¾ T419G 
PDIp has ~55% of the oxido-reductase activity of PDI (see figure 5.12). This was 
assumed to be due to differences in substrate specificity conferred by the b’ domain 
and also the unusual a’ active site sequence of PDIp. Using PDIp ½ it was shown 
that the a and b domains of PDIp are also detrimental to the oxido-reductase activity. 
This was totally unexpected because the catalytic active site motif of PDIp a is the 
same as PDI a (i.e. CGHC). 
 
Figure 5.11: IEC of PDIp T419G and PDIp ¾ T419G. A) 12% 
SDS-PAGE of fractions taken from IEC of PDIp T419G B) 12% 
SDS-PAGE of fractions taken from IEC of PDIp ¾ T419G 
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As anticipated, PDIp a’ is less active than PDI a’ based on the percentage activity 
measured for PDIp ¾ and PDIp ½ (65% and 75% respectively). Therefore this work 
has shown that the activity of both active sites of PDIp is impaired relative to those 
of PDI. 
To study PDIp a’ further, active site mutants PDIp T419G and PDIp ¾ T419G were 
constructed. This mutation simulates the PDI a’ domain active site motif. It is 
necessary to use these mutants because the isolated a and a’ domains cannot be 
assayed via the insulin assay due to lacking a substrate binding site (b’). Figure 5.12 
shows that neither PDIp T419G or PDIp ¾ T419G exhibit a significant increase in 
percentage oxido-reductase activity relative to wild-type PDIp and PDIp ¾ 
respectively. This is interesting because the presence of threonine in the a’ active site 
of PDIp was expected to have a negative effect on its oxido-reductase activity and 
clearly this does not appear to be the case. This result is surprising because there is 
evidence to show that the amino acids between catalytic cysteines are important for 
0 20 40 60 80 100
PDIp 3/4 T419G
PDIp 3/4
PDIp 1/2
PDIp T419G
PDIp
PDI
Percentage Activity relative to PDI (%) 
Figure 5.12: Oxido-reductase activity of PDI, PDIp, chimera proteins and 
mutants. Varying concentrations of protein were added to 200mM phosphate 50mM 
EDTA buffer (pH 7.5) containing 8mM GSH, 1 unit of glutathione reductase and 
120μM NADPH at 37ºC. Reaction was started by adding 15μM insulin and the 
reaction was monitored by watching the rate of change at A340. Activity was 
calculated from plots of absorbance rate vs concentration of PDI/PDIp (see figure 
4.15) as a percentage of the activity of PDI measured on the same day. 3 relicates 
were taken for 3 biological samples of each protein in an attempt to reduce error.  
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conferring the activity of both thioredoxin and DsbA (Krause et al. 1991, Lundstrom 
et al. 1992 and Huber-Wunderlich and Glockshuber, 1998). 
The main reason that it is difficult to assume differences between PDIp and PDIp 
T419G is because the error bars are overlapping. Furthermore, for PDIp ¾ T419G, 
the degree of error is quite large (~20%). This could be caused by air-induced 
oxidation of NADPH over the course of the total experiment time. Suitable measures 
were taken to reduce this i.e. by making up fresh NADPH each day and storing it on 
ice during the experiment but unfortunately these things cannot be fully controlled. 
In order to improve accuracies further repeats must be undertaken.  
 
 
5.7. Concluding Remarks 
We have previously shown that PDIp is less amenable to redox-mediated 
conformational changes than PDI. This was unexpected because PDI and PDIp share 
identical domain architecture, ~45% sequence identity and were assumed to have 
similar 3-dimensional structure. Construction of PDIp ½ and PDIp ¾ has allowed us 
to study the domains that are involved in modulating redox change in PDIp. 
Far UV CD (figures 5.5 and 5.6) showed that PDIp ½ and PDIp ¾ had similar 
secondary structure composition to PDI and also a similar unfolding profile 
consisting of a solitary transition. These proteins share PDI b’x and so it is postulated 
from this work that there are significant differences in terms of stability and possible 
structure between PDI b’x and PDIp b’x. This may explain the variance in substrate 
specificity seen for PDI and PDIp. 
Figure 5.8 indicates that the PDIp chimera proteins show similar redox-state effects 
to wild-type PDIp rather than PDI. This is further confirmed by DLS (table 5.3). We 
did not expect the chimeras to resemble PDIp in these experiments because we had 
previously seen similarities conferred by PDI b’x and we know from recent work 
that the major redox-active cassette of PDI is b’xa’ (Wang et al. 2011). The chimera 
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proteins share PDIp ab with PDIp so therefore this region must be more active in 
redox change than originally suggested. Finally, native PAGE analysis reveals 
possible polymorphisms for PDIp ½ and PDIp ¾ (see figure 5.9). These were not 
seen by Far UV CD or DLS because these techniques give average readings for the 
sample provided. This work requires further study. 
PDIp has ~55% of the oxido-reductase activity of PDI. PDIp ½ has ~75% activity 
(see figure 5.10). This indicates that the a and b domains of PDIp have a negative 
effect on activity. PDIp ¾ has ~65% activity and this suggests that the a’c region of 
PDIp also has a negative effect (but to a lesser extent). Given that the catalytic sites 
of PDIp are a and a’ this work demonstrates that these domains of PDIp are less 
catalytically active than those of PDI. For PDIp a this was unexpected because the 
active site motif is identical to that seen in PDI a. 
 Interestingly studies of PDIp T419G and PDIp ¾ T419G indicate that the presence 
of a threonine instead of a glycine residue at the position immediately next to the N-
terminal cysteine of the a’ active site, doesn’t have a significant effect on the oxido-
reductase activity. This indicates that unexpectedly, the reduced activity of the a 
domain of PDIp is the major contributor to low oxido-reductase activity. The exact 
mechanism for which is undeciphered. 
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Chapter 6. Involvement of the active site of the 
a domain in the distinctive properties of PDIp 
 
 
6.1. Introduction 
 
We have been unable to identify distinct regions of PDIp responsible for its unusual 
redox conformations or oxido-reductase activity. Our work has shown that PDIp is 
more thermally stable than PDI in the b’x region and we have suggested that this 
may explain restricted substrate specificity. In addition the a and b domains of PDIp 
seem to be involved in modulating redox-mediated conformational change which is 
in contrast to work on PDI which implicated b’xa’ only (Wang et al. 2011).  
Studies of the oxido-reductase activity of PDIp seem to show that PDIp a has a 
detrimental effect on activity. This was unexpected because unlike PDIp a’, PDIp a  
has a normal CGHC motif. Furthermore, the T419G mutant has no significant 
difference in activity from the wild-type protein implying that the low oxido-
reductase activity of PDIp is not caused by the unusual a’ active site sequence. 
Therefore our data indicates that the reactivity of PDIp a is unexpectedly low. 
The reactivity of the active site cysteines can be measured by calculating their pKa. 
The pKa is the pH at which the residue (in this case cysteine) is 50% protonated. The 
pKa’s of the catalytic cysteines of PDI a domain have been determined in a  variety 
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of different ways but have been studied more recently by measuring the pH 
dependence of the reaction between PDI a and DTNB (Karala et al. 2010). In this 
work the N-terminal cysteine of PDI a was found to have a pKa of ~4.8 and the C-
terminal cysteine ~8.6. This means that at physiological pH the N-terminal cysteine 
favours the thiolate state and therefore is more reactive. The reactivity of the C-
terminal cysteine is more complex and needs to change according to position in the 
reactive cycle. In order to enable this, the pKa of the C-terminal cysteines is 
modulated by nearby residues (i.e. R120 in PDI a). In this way the catalytic cycle is 
completed (see figure 6.1). 
 
 
 
 
 
 
 
 
Figure 6.1: Schematic showing reaction schemes of PDI (adapted from 
Karala et al. 2010). Only one active site of PDI is shown for clarity.   
Nucleophilic attack of the PDI disulphide bond by a substrate protein leads to 
formation of a mixed disulphide. As the pKa of the C-terminal cysteine of PDI 
is high (~8.6), typically this is resolved by the substrate thiol leading to its 
oxidation. The net result of these reactions is that PDI is in the reduced state. 
To return to the oxidised state, the N-terminal cysteine of PDI nucleophilically 
attacks GSSG leading to the formation of a mixed disulphide. To resolve this 
mixed disulphide, the C-terminal cysteine must have a low pKa making it 
reactive enough to nucleophilically attack the N-terminal cysteine and give rise 
to disulphide bond formation. The pKa of the C-terminal cysteine therefore is 
remarkably changeable and this is modulated by a nearby residue, R120 
(Karala et al. 2010).  
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6.2. Studies of PDIp a 
 
6.2.1. Expression and purification of PDI a and PDIp a 
Using standard expression protocols for full length PDIp, yields of both PDI a and 
PDIp a were found to be very high. Figure 6.2 shows that negligible amounts of PDI 
a / PDIp a were found in the flow through indicating that there were no issues with 
binding during IMAC. Consequently a long binding step was not required for 
purification of PDI a or PDIp a.  
Figure 6.2 shows that PDI a exists as a double band on a 12% SDS-PAGE gel. This 
does not appear to be the case for PDIp a but again this is difficult to interpret. The 
reason for this double banded nature is unexplained but is expected to be due two 
alternate conformations of PDI a. No further information was found from running 
native gels or analysing this further (data not shown).  
 
 
 
 
 
IEC of both PDI a and PDIp a is also unusual in that neither protein binds strongly to 
the source 30Q column because they have pI’s of ~6.49 and 5.9 respectively 
(ProtParam). Consequently PDI a and PDIp a can be purified from contaminating 
Figure 6.2: 12 % SDS-PAGE showing IMAC fractions and purified protein 
for PDI a and PDIp a. In order as seen on gel: marker, PDI a soluble proteins, 
PDI a flow through, PDI a elute, purified PDI a (after IEC), PDIp a soluble 
proteins, PDIp a flow through, PDIp a elute and purified PDIp a (after IEC). 
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protein by their inability to bind to the source 30Q column and typically elution 
occurs before a salt gradient is started (see figure 6.3). The purity of the resulting 
protein is high and can be seen in figure 6.2. In addition both proteins are uniformly 
monomeric which is in agreement with work suggesting that the presence of b’ 
increases dimerisation (Wallis et al. 2009). 
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Figure 6.3: IEC of PDI a and PDIp a. A) IEC chromatograph for PDI a. B) IEC 
chromatograph for PDIp a. 
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6.2.2. Far UV CD of PDI a and PDIp a 
Together figure 6.4 and table 6.1 show that PDI a has slightly greater α-helical 
content than PDIp a. More generally they confirm that both proteins are well folded 
and indicate that the domain boundaries used for their construct are correct.  
  
 
 
 
α-helix β-sheet Turns Unordered 
PDI a 34% 20% 20% 28% 
PDIp a  31% 20% 21% 30% 
 
 
 
6.2.3. Molecular modelling of PDIp a 
Using the amino acid sequence of PDIp a and the X-ray crystal structure of PDI a 
from the recent full length structure of human PDI (PDB: 4EKZ), a structural model 
of PDIp a was made (Yasara). Figure 6.5 shows the structural alignment of PDIp a 
and PDI a (taken from the X-ray structure of full length PDI). As expected there is 
significant structural homology between PDI a and PDIp a. The major region of 
discrepancy is the N-terminus which in PDIp includes a long acidic extension.  
Figure 6.4: Far UV 
CD of PDI a and 
PDIp a. The circular 
dichroism of each 
protein (0.1mg/ml) in 
5mM phosphate was 
recorded at 
wavelengths 190 to 
260 nm and at 20ºC. 
The mean residue 
ellipticity (MRE) was 
then calculated.  
 Table 6.1: DichroWeb 
analysis for PDI a and 
PDIp a. Analysis was 
performed using the 
CDSSTR algorithm and 
reference set SP175. Spectra 
were collected for 0.1mg/ml 
samples of each protein in 
5mM phosphate at 20ºC. 
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An additional minor difference between the structures of PDI a and PDIp a is that the 
3 core β-strands appear to be longer in PDI a than PDIp a although this may be an 
artefact of using a model of PDIp a rather than actual structural information. Within 
the area surrounding the active site (shown in figure 6.5 by an arrow) there appears 
to be none/negligible differences in structure. 
 
6.2.4. 
15
N HSQC: oxidised and reduced PDIp a 
PDI a and PDIp a were expressed in minimal media containing 
15
N-labelled 
ammonium sulphate. Aside from media, the protocols used for expression and 
purification were the same as those described previously and gave roughly equivalent 
yields. Collaborators at the University of Kent performed 
15
N HSQC on 
Figure 6.5: PyMOL alignment of PDIp a model and PDI a. Having 
obtained a model for PDIp a using Yasara it was aligned with PDI a (from 
4EKZ) using PyMOL. PDI a is shown in green and PDIp a in red. Arrow 
indicates active site region.  
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reduced/oxidised PDI a and PDIp a in order to observe possible differences in 
structure caused by change in redox state (see figure 6.6). At this time, observing 
peak shifts is the extent of analysis. Time has not been taken to try to assign peaks of 
PDIp a.  
Figure 6.6A shows HSQC spectra for oxidised and reduced PDI a. Clearly oxidation 
does not give rise to significant peak shifts indicating minor structural differences 
between redox states. For HSQC spectra of oxidised and reduced PDIp a (figure 
6.6B) there are more significant differences and clear peak shifts. This indicates that 
the structural changes associated with the oxidation of PDIp are considerable. This 
also may explain the differences in redox-mediated conformational change seen for 
PDIp and chimeras containing PDIp a. It is very interesting because published data 
for PDI suggests that the major redox active cassette for PDI is b’x’a’. It is now clear 
that for PDIp this is not the case.  
This experiment will be repeated because pH was not strictly controlled. In order to 
rule out the possibility that pH is affecting the structure of PDIp a rather than redox 
state this experiment is essential. However, previous work has not implicated pH in 
structural changes.  
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Figure 6.6: 
15
N HSQC for PDI a and PDIp a in the reduced/oxidised state. 
1mM protein in 20mM phosphate buffer (pH 7.3) was reduced or oxidised using 
50mM GSH or GSSG. Data was recorded at 25ºC. 
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6.3. Studying the activity of PDIp a using PDIp a W146F 
 
6.3.1. Molecular biology to make PDIp a W146F mutant  
The plasmid encoding PDIp a W146F (pKLW14) was made using the protocol 
described by QuikChange, Agilent. The polymerase used was PFU turbo. Primers 
were designed to be 33 base pairs in length and were bought from IDT (for primer 
sequence see methods). PDI a W128F (pAKL2), which was used for comparison, 
was kindly donated by Lloyd Ruddock.  
 
6.3.2. Expression and purification of PDI a W128F and PDIp a W146F 
PDI a W128F and PDIp a W146F were expressed using EnBase. This system makes 
use of an enzyme which slowly breaks down a synthetic substrate into glucose and in 
doing so prevents rapid growth and toxicity of the E. coli cells. Using this system and 
the protocol described by manufacturers, a yield of ~150μg/ml of culture was 
obtained. This is approximately 10x more than typical yields of protein expressed in 
LB.  
As for PDI a and PDIp a, standard IMAC followed by IEC was sufficient for 
purification of PDI a W128F and PDIp a W146F. Far UV CD proved that both 
proteins were similarly folded to the wild-type and showed that the mutation of 
W128 and W146 (for PDI and PDIp respectively) had no deteriorating effect on 
structure (data not shown). 
 
6.3.3. Re-oxidation activity of PDIp a W146F 
The activity of PDI a and PDIp a cannot be studied by the insulin assay as for full 
length PDI and PDIp because it requires binding at the b’ substrate binding site. For 
both proteins, mutating out the second tryptophan (W128 and W146 for PDI and 
PDIp respectively) leaves only the tryptophan adjacent to the N-terminal cysteines 
(WCGHC). By measuring the intrinsic fluorescence of both proteins it is possible to 
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determine redox state because in the oxidised state, the presence of a disulphide bond 
gives rise to fluorescence quenching.  
 
 
 
 
Figure 6.8B shows that reduced PDIp a W146F is ~4x less easily oxidised than PDI 
W128F. The re-oxidation activity of both PDI a and PDIp a is dependent on the 
nucleophilicity of the N-terminal catalytic cysteine. This means that it is likely that 
the nucleophilicity of the N-terminal cysteine of PDIp a is impaired in some way. 
This data may also indicate that PDIp a was not fully reduced prior to the experiment 
because relative fluorescence was low compared to PDI a even at low concentrations 
of GSSG (figure 6.8A). 
 
 
 
 
 
 
 
 
 
 
Figure 6.7: Reaction scheme for the reaction of reduced PDI a with GSSG. 
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Figure 6.8: Re-oxidation of reduced PDI a W128F and PDIp a W146F.  100μM of 
PDI a W128F and PDIp a W146F was reduced using 5mM DTT for 30 minutes at 
room temperature. Protein was desalted and stored in aliquots at -80ºC prior to use. 
The reaction of 10μM protein in 0.1M phosphate, 0.1M boric acid buffer pH 7 with 
varying concentrations of GSSG was measured using a KinTek SF-2004 stopped-flow 
fluorimeter (excitation: 280nm, bandpass emission  >320nm and temperature: 25ºC). 
A) Raw data for experiment with 20mM GSSG. B) Plot of rate vs [GSSG]. 
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This experiment has only been repeated twice but figure 6.8 shows that relative error 
is small. In addition, due to the clear differences between PDI and PDIp in re-
oxidation activity it is questionable as to whether accuracy could be improved 
significantly by repeating the experiment further.  
 
6.3.4. Re-reduction activity of PDIp a W146F 
Similar to the studies of re-oxidation, re-reduction activity can also be determined by 
measuring the fluorescence of the tryptophan adjacent to the active site. Figure 6.9 
shows that PDIp a W146F is ~10x less active than PDI a W128F in this assay. 
Clearly the reactivity of the active site cysteines of PDIp a is far reduced relative to 
PDI a. 
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Figure 6.9 shows data collected from two repeats for PDI a and PDIp a. It is clear 
that the reproducibility of the assay is very high because data points overlay one 
Figure 6.9: Re-reduction of oxidised PDI a W128F and PDIp a W146F.  100μM of 
PDI a W128F and PDIp a W146F was reduced using 5mM GSH for 30 minutes at room 
temperature. Protein was desalted and stored in aliquots at -80ºC prior to use. The 
reaction of 10μM protein in 0.1M phosphate, 0.1M boric acid buffer pH 7 with varying 
concentrations of GSH was measured using a KinTek SF-2004 stopped-flow fluorimeter 
(excitation: 280nm, bandpass emission >320nm and temperature: 25ºC). A) Raw data for 
experiment with 20mM GSH. B) Plot of rate vs [GSH]. 
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another. Again the difference in re-reduction in activity between PDI a and PDIp a is 
clearly distinguishable and so it is not necessary to repeat the experiment further in 
order to improve accuracy.  
For PDI however, figure 6.9 shows that reduction by GSH is negligible until ~5mM 
GSH. This indicates that spontaneous oxidation of GSH may be occurring. Samples 
were newly prepared and stored on ice so all precautions to prevent this were taken.  
 
6.4. Determination of pKa’s for the active site cysteines of PDIp a  
 
6.4.1. Molecular biology to make PDIp a C71S and PDIp a C74A 
In order to measure the pKa of the active site cysteines of PDIp a, single cysteine 
mutants needed to be made. As the a and a’ domains of PDIp are like PDI in having 
high sequence homology being very GC rich they are difficult to mutate in the full 
length protein. By using the isolated PDIp a domain a lot of these difficulties are 
minimised. 
 
 
 
 
Figure 6.10: DNA gel showing PCR products for PDIp a C71S and 
PDIp a C74A mutant. Mutagenesis was performed as described by the 
QuikChange protocol using primers described in methods and PFU ultra 
(Agilent). DNA was cut from gel and transformed into DH5α super 
competent cells (NEB). Arrow indicates DNA band cut from gel. A 
fermentas 1Kb DNA ladder is shown on the left.  
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Figure 6.10 shows PCR products for QuikChange mutagenesis of plasmid encoding 
PDIp a (pLR1368). Clearly the C71S mutatagenesis reaction was more successful 
than the C74A mutation as it gives rise to a higher yield of PCR product. These 
bands were cut from the gel and transformed into super competent cells (for protocol 
see methods). DNA extraction from these cells confirmed that both mutants had been 
made.  
Previous work has shown that PDIp a’ and PDIp b’xa’c are very unstable (see 
chapter 3). In order to measure the pKa of the active site cysteines of PDIp a’ 
quadruple cysteine mutants would also need to be made. Work to make these 
mutants (full length PDIp C71S C74A C364S C418S and PDIp C71S C74A C364S 
C421A) has already begun. To make these mutants it is necessary to use the BamHI 
site in the middle of the PDIp DNA sequence because this prevents primers from 
annealing to the wrong domain as a result of high sequence identity (see methods). 
By making 4 full length mutants with a single active site cysteine mutated out and 2 
full length proteins with the double active site mutation it should be possible to make 
a full length triple active site cysteine mutant using a restriction digest and ligation 
based protocol (see figure 6.11). Finally, mutating out C364 gives rise to the 
quadruple mutant. This work still needs to be completed but 4/6 of the required 
constructs have already been made.  
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6.4.2. Expression and purification of PDIp a C71S and PDIp a C74A 
Similar to other PDIp a mutants, PDIp a C71S and PDIp a C74A could be expressed 
and purified in large amounts using the EnBase system, IMAC and IEC. Far UV CD 
also confirmed that the active site mutations introduced had no effect on the overall 
secondary structure of PDIp a (data not shown). 
 
6.4.3. Stopped flow pKa measurements of PDIp a C71S 
The pKa of the C-terminal cysteine was determined by measuring the pH dependence 
of the rate of reaction between PDIp a C71S and DTNB by stopped flow. At pH 
values above the pKa of the cysteine it should be in the thiolate (S
-
) state. Free 
thiolates react with DNTB producing the NTB
2-
 ion the concentration of which can 
be measured spectroscopically at 412nm.  
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Analysis of the data over the pH range 7.5 to 9.5 indicated that the data fitted to a 
single pKa dependent event with a measured pKa for PDIp C74 of 9.18 +/- 0.04 (see 
figure 6.12). This value is slightly higher than for the corresponding cysteine in PDI 
(C56) which has a pKa of 8.60 +/- 0.02 (Karala et al. 2010). Data taken at > pH 9.5 
Figure 6.12: pKa determination of the C-terminal cysteine of PDIp a (C74). The reaction 
of 25μM PDIp a C71S and 0.073 mg/ml DTNB was measured using KinTek SF-2004 stopped 
flow equipment at 25ºC. The buffer used was 0.1M Na2HPO4 and 0.1M boric acid for all pH’s 
(pH 7.5-10). Curve fitting by IGOR Pro software. A) Raw data for pH 8, B) plot of rate vs pH. 
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were excluded from curve-fitting analysis because clear destabilising events had 
occurred.  
 
6.4.4. Stopped flow pKa measurements of PDIp a C74A 
Similar to the data for C71S, the C74A mutant also showed a clear-cut titration.  
 
 
 
 
Figure 6.13: pKa determination of the N-terminal cysteine of PDIp a (C71). The reaction of 
25μM PDIp a C74A and 0.073 mg/ml DTNB was measured using KinTek SF-2004 stopped 
flow equipment at 25ºC. The buffer used was 0.1M Na2HPO4 and 0.1M boric acid for all pH’s 
(pH 6.5-10). Curve fitting by IGOR Pro software. A) Raw data for pH 8, B) plot of rate vs pH. 
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Figure 6.13 suggests that the pKa of C71 is in the region of 8.3-8.5. However, curve-
fitting of the data (using IGOR Pro) indicated that there were 2 pKa dependent events 
with pKa’s of 8.09 +/- 0.04 and 8.55 +/- 0.04. These are considerably higher than the 
typical pKa’s calculated for the N-terminal cysteines of PDI family members. Again 
data taken at >pH 9.5 were excluded from curve fitting analysis. 
The high pKa of the N-terminal cysteine of PDIp a explains the poor reactivity that 
has been seen for PDIp. A high pKa value means that at physiological pH the N-
terminal cysteine is in the unreactive thiol state, while that of PDI which has a pKa of 
4.8 is fully ionised.   
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6.5. Exploring the potential role of Q75 in modulating the pKa of 
C71 
 
6.5.1. Sequence alignment of PDI a and PDIp a domains 
Studies of C71 identified two pKa dependent events (see figure 6.12) suggesting that 
the reactivity of the N-terminal cysteine of PDIp a was being modulated by nearby 
residues. In this way the N-terminal cysteine may be slightly less reactive than would 
be expected for a reduced cysteine. To identify amino acids in PDIp a that could 
potentially contribute to this result, a sequence alignment was performed for PDIp a 
and PDI a (see figure 6.14). 
 
 
 
 
 
It is clear from figure 6.14 that there are 21 differences in charge for PDI a and PDIp 
a. In total there are 13 charged residues in PDI that are not conserved in PDIp and 8 
charged residues in PDIp that are not conserved in PDI. However R120, the residue 
implicated in modulation of PDI a, is conserved in PDIp a (Karala et al. 2010). It 
remains uncertain which residues are involved in maintaining/modulating the high 
pKa of the N-terminal cysteine of  PDIp a but PDIp Q75 seems like a particularly 
probable candidate because it is immediately adjacent to the active site in PDIp a 
Figure 6.14: Sequence alignment of PDI a and PDIp a (CLUSTAL). Charged 
residues in PDI that are not conserved in PDIp are shown in green and charged 
residues in PDIp that are not conserved in PDI are shown in red. 
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(WCGHCQ). Furthermore figure 6.15 shows that in PDI, ERp57 and ERp72, a lysine 
residue is conserved at this position (WCGHCK). 
 
 
 
 
 In PDI the positive net charge of K57 interacts with the thiolate ion at the N-
terminal cysteine stabilising it by electrostatics but for PDIp this is not the case 
because glutamine is uncharged.  However it is possible that the the side group of 
glutamine could be acting as a hydrogen bond acceptor (see figure 6.16). If a 
hydrogen bond between Q75 and the unreactive thiol group this may explain why 
PDIp a exhibits some reactivity despite the N-terminal cysteine being in the 
predominantly unreactive thiol state. Overall this may explain the low oxido-
reductase activity seen for wild-type full length PDIp.  
  
Figure 6.15: Sequence alignment of PDI, PDIp, ERp57 and ERp72. PDIp Q75 is 
highlighted in red, typically a lysine residue is conserved at this position (highlighted in green). 
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6.6. Concluding Remarks 
 
Previously we showed that PDIp has ~50% of the oxido-reductase activity of PDI. 
This was expected to be caused by differences in substrate specificity conferred by 
the b’ domain and also the unusual a’ domain active site sequence (CTHC). We have 
since shown that while the b’ and a’ do have a slight negative effect on the activity 
of PDIp , the effect of PDIp a is far more significant.  
Stopped flow studies of PDIp a that measured the reactivity of the active site with 
either GSH or GSSG confirmed that it was much less reactive than originally 
postulated. As PDIp a has a normal active site sequence (CGHC) this was 
unexpected. Additional stopped flow studies to measure the pKa of the active site 
cysteines of PDIp a showed that the N-terminal cysteine had an exceptionally high 
pKa. This means that at physiological pH the N-terminal cysteine is in the unreactive 
Figure 6.16: PyMOL images of the active site regions of PDI a and PDIp a. The structure of 
PDI Leu44-Tyr63 was observed using PyMOL and PDB: 4EKZ because this region is conserved 
in PDI and PDIp (with the exception of Q75 adjacent to active site. For PDIp K57 is mutated to 
Q using PyMOL mutagenesis function. N-terminal cysteine is shown in red, histidine in blue and 
either lysine or glutamine in orange (PDI and PDIp respectively). A) Interaction between positive 
charge of lysine and the negative charge of the thiolate ion on N-terminal cysteine (shown by 
white line). B) Hydrogen bond between SH group and oxygen on the side chain of glutamine 
leading to slight negative charge on the donating sulphur atom (shown by white line).  
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thiol state and explains the lack of activity seen for PDIp a and also the reduced 
activity of full length PDIp. 
Further study identified Q75, an amino acid found immediately adjacent to the PDIp 
a domain active site that is not conserved in other PDI family members (which 
typically have a lysine residue at this position). Additional work is required to 
confirm our hypothesis, but we believe that the presence of a glutamine residue at 
position 75 in PDIp a instead of a lysine residue (seen for other PDI family 
members), leads to overall stabilisation of the thiol state at the N-terminal cysteine. 
Consequently the N-terminal cysteine of PDIp a is not as reactive as that of PDI a 
which is stabilised in the thiolate form by electrostatic interactions with lysine. A 
PDIp a Q75K mutation should therefore stabilise the thiolate state of the N-terminal 
cysteine and therefore increase the overall reactivity of the active site. 
In regards to structure, an unreactive N-terminal cysteine could explain why only 
minor redox-mediated conformational changes were observed. For example if the N-
terminal cysteine is highly unreactive this would mean that it would be very difficult 
to oxidise PDIp a. This means that in our studies of redox structure oxidised PDIp 
could have a reduced a active site and an oxidised a’ active site and explains the 
polymorphisms seen by native-PAGE (chapter 5). This does however indicate a role 
for the a domain in the redox conformations of PDIp. This is not the case for PDI for 
which b’xa’ is the minimal requirement for redox conformational change. Therefore 
PDI and PDIp must be different in terms of redox structure. Further work is required 
to confirm this.  
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Chapter 7. Discussion 
 
7.1. Expression & purification of PDIp and PDIp constructs 
 
7.1.1. Determining protocols for optimal expression and purification of PDIp 
Initial studies of the expression and purification of recombinant PDIp led to 
attainment of very low yields (~2μg/ml of culture). We attributed this to: a) poor 
expression , b) limited binding during IMAC and c) reduced stability. While we were 
able to improve expression yield significantly by increasing induction time, it was 
clear that the major contributing factor to poor yield was the inefficiency of IMAC.  
Typically during IMAC, the hexa-Histidine tag that is artificially added to the protein 
binds to the immobilised Ni
2+
 of the column material thereby separating it from the 
crude cell lysate. Protein can then be eluted from the column using a strong chelating 
agent such as EDTA. In our studies of PDIp binding, we found that this process was 
inefficient. Furthermore any PDIp that did bind was very easily eluted even in the 
absence of imidazole or EDTA.  
Having aligned the N-terminus of PDIp with that of PDI, we noted that for PDIp, this 
region was much longer and more negatively charged. Subsequently we suggested 
that the His-tag might be folding back onto the N-terminus of PDIp via electrostatic 
interaction, and therefore may not be solvent accessible. This theory has since been 
supported by the fact that increasing exposure time of the Ni
2+ 
column with the hexa-
His tagged PDIp led to an increase in total binding. This work therefore suggests that 
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the His-tag is dynamic and therefore may exist in N-terminus bound and unbound 
forms.  
Although we improved purification yield significantly by increasing column 
exposure time, we also considered using molecular biology to improve binding 
efficiency. Plasmid pKLW1 was designed to have a truncated N–terminus that would 
hopefully prevent the His-tag from binding to it. Unfortunately this clone did not 
express well and so we were unable to determine whether binding efficiency had 
improved as a result of the truncation. We now believe that poor expression was 
caused by the N-terminal a domain boundary being compromised by the truncation. 
This work therefore shows a possible consequence of making mutations close to 
domain boundaries. It would be useful to re-design this clone to avoid disrupting the 
a domain boundary and so that we could identify differences in column binding 
associated with a truncated N-terminus.  
An additional mutant which could have been made to aid purification is a GST-
tagged PDIp construct. Having made this, PDIp could be purified using another form 
of affinity chromatography which relies on the ability of glutathione-s-transferase to 
bind to column-bound GSH. Again study of this construct would help us to 
understand the interaction between the His-tag and the N-terminus of PDIp. 
Currently, the physiological role of the negatively charged N-terminus of PDIp is 
unknown. Furthermore, PDIp also has an acidic C-terminal tail which too has an 
unknown function. It will be useful to study these regions with the aim to identify 
their role. An acidic C-terminal tail is fairly typical for PDI family members and for 
PDI it has been shown to be very flexible, preventing crystallisation (Wang et al. 
2012). In addition, although the C-terminal tail of PDI was found to be unimportant 
for isomerase activity, it has been shown to stabilise chaperone activity and may also 
act as a calcium binding site (Klappa et al. 1998a, Tian et al. 2004, Macer and Koch, 
1988).  
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7.1.2. Studies to improve the stability of PDIp 
We found recombinant PDIp to be very unstable and after just 3 days storage at -
20ºC there was significant loss of the full length protein. This is due to the presence 
of E.coli proteases and is easily resolved by adding PMSF, leupeptin and pepstatin 
during cell harvest and cell lysis. Clearly, recombinant expression of PDIp is toxic to 
the cell and leads to induction of a stress response. Whether this is simply due to 
over-expression or whether PDIp is genuinely toxic remains unclear (for review see 
Gasser et al. 2008). Furthermore such cellular toxicity is not seen during the 
recombinant expression of PDI but this may be on account of a shorter expression 
period. 
This work highlights the importance of balancing recombinant expression with the 
stress response and we noted for example, that expression times of over 20 hours 
gave rise to a reduction in yield relative to at 16 hours. This may also explain why 
we saw negligible yields of PDIp using the EnBase system which uses a 24 hour 
expression time. The advantage of this media system is that it utilises ‘slow glucose 
feeding’ with the aim of increasing cell number without inducing cellular stress.  
Unfortunately for the expression of PDIp this seems to be futile. It is clear therefore 
that during expression of recombinant PDIp, the up-regulation of cellular proteases is 
detrimental to stability and final yield. 
Interestingly, unstable PDIp gives to rise to one major product. This protein fragment 
has a Mw of ~40kDa which corresponds to the approximate Mw of hexa-His tagged 
PDIp abb’x and indicates the loss of the a’ domain. This shows that similar to PDI, 
PDIp exhibits intrinsic flexibility and susceptibility to proteases at the x-linker region 
(Wang et al. 2010). After the loss of the a’ domain, PDIp abb’x was very stable and 
did not seem to deteriorate any further in the time tested (data not shown). Again this 
is indicative of an almost hinge-like region at the C-terminus of PDIp that may give 
rise to redox-mediated conformational changes similar to those described for PDI 
(Wang et al. 2011, Wang et al. 2012). 
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7.1.3. Studies of the structure and activity of PDIp using PDI.PDIp chimera proteins 
Plasmids encoding PDIp ½, PDIp ¾ and PDIp ¾ T419G (pAKW5, pAKW11 and 
pAKW12 respectively) were kindly donated by Dr. Katrine Wallis.  The domain 
boundaries of these proteins were constructed as described by Alanen et al. (2003) 
and Pirneskoski et al. (2004). The disadvantage of using chimera proteins as we have 
done is that if the domain boundaries are incorrect and/or domain interface 
interactions are disturbed, then the protein can be unstable or incorrectly folded as 
we have seen previously for our full length N-terminal truncate. If this were the case, 
the chimera proteins would not be suitable for further study. 
In our work, we were careful to control for the possibility that the chimera proteins 
were not correctly folded. In PDIp ½ there is one non-native domain boundary (b-b’) 
and in PDIp ¾ and PDIp ¾ T419G there are two (b-b’ and x-a’). The first indicator 
that these boundaries had been constructed correctly was that we were able to 
generate significant yields of soluble protein for all 3 chimeras (Alanen et. al 2003). 
In addition, far UV CD of this protein showed that PDIp ½, PDIp ¾ and PDIp ¾ 
T419G were all well folded with similar overall secondary structure to wild-type PDI 
and denaturation studies showed that they were no less stable than wild-type PDIp. It 
is clear from this work that our chimera proteins are well structured. We can 
therefore conclude that the artificial domain boundaries that have been introduced 
into these chimeras are at least not detrimental to the overall structure of the protein. 
Obviously despite having performed these controls, it is not ideal to use chimera 
proteins because they are not true representations of either parent protein. 
Furthermore we cannot assume that 2 domains that have a particular characteristic in 
one protein will act identically in another. Therefore we must be cautious in the 
conclusions that are taken from studies of chimera proteins. For our work however, 
these studies have been essential in our understanding of the structure and activity of 
PDIp. 
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7.1.4 Studies of the structure and activity of PDIp using mutant 
Similar to our studies of chimera proteins, we must be vigilant when using mutants to 
ensure that the introduced mutation is not detrimental to the integrity of the protein. 
Again we used far UV CD to study the effect of any mutations on the secondary 
structure of the protein. Although for most mutants no significant change in 
secondary structure was observed, for PDIp H278A and PDI H256A there was a 
huge loss of α-helical structure relative to the wild-type proteins (data not shown). 
These mutants were designed to probe the role of H278 and H256 (PDIp and PDI 
respectively) in substrate binding. In published work on PDIp H278A, the change in 
secondary structure described here is not commented upon (Fu et al. 2011). Authors 
focus instead on the loss of oestradiol binding activity which may in fact be caused 
by structural changes in the substrate binding site. On account of these structural 
observations we ceased further study on PDI H256A and PDIp H278A. 
 
7.2. Redox-mediated conformational changes of PDIp 
 
7.2.1. The 3-dimensional structure of PDIp 
Currently there is very limited structural information for PDIp but we have assumed 
that its 3-dimensional structure is similar to the recently published X-ray crystal 
structure of hPDI (Wang et al. 2012). Unfortunately however, initial structural work 
indicated that this may be an over-simplification and far UV CD data clearly shows 
that PDIp has more α-helical structure than PDI. Furthermore, additional study using 
chimera proteins, PDIp ½ and PDIp ¾ (PDIp ab PDI b’xa’c and PDIp ab PDI b’x 
PDIp a’c respectively), attributed this difference to the b’x region. This is 
particularly interesting because we know that PDI b’ harbours the substrate binding 
site (Klappa et al. 1998a). Consequently it is possible that physical differences 
between PDI and PDIp in this area may contribute to their contrasting substrate 
binding properties. Further study of the structure of PDIp b’x will be essential for 
clarification. 
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The b’x region of PDI is also important for redox-mediated conformational change 
and is part of the larger redox-active cassette, b’xa’c (Wang et al. 2011, Wang et al. 
2012). If PDIp b’x has a larger percentage of α-helical content than PDI b’x this may 
mean that it is also more stable. Although this hasn’t been studied directly, we have 
shown by far UV CD that PDIp has remarkable thermal stability and retains 
significant secondary structure after incubation at 80ºC. The implications of 
increased stability for PDIp could be that unlike PDI, PDIp does not undergo large 
redox-mediated conformational changes. Furthermore this characteristic could help 
protect PDIp from the harsh environment of the exocrine pancreas. 
 
7.2.2. Studies of the redox-mediated conformational changes of PDIp 
The recent X-ray crystal structures of reduced and oxidised hPDI show the structural 
changes associated with the two redox states (Wang et al. 2012). For example in 
reduced PDI, the a’ domain is tightly packed against b’ via numerous inter-domain 
interactions but in the non-reduced structure these are broken and the b’ and a’ 
domains are distinct. The net effect of this is that upon oxidation, PDI exhibits a 
more open conformation which increases exposure of hydrophobic surfaces and 
promotes substrate binding (Wang et al. 2012). In this way the redox-mediated 
conformational changes of PDI have a significant effect on modulating its activities 
and recent work has shown that for its chaperone activity, PDI is most efficient in its 
oxidised form (Wang et al. 2011).  
Our studies show that unlike PDI, PDIp undergoes only minor redox-mediated 
conformational changes. For example we showed that the thermal stability of PDIp is 
unaffected by redox state, whereas for PDI a reduction in Tm of ~4ºC was seen for 
the oxidised protein. Surprisingly, the thermal stability of PDIp ½ and PDIp ¾ which 
are similar to PDIp in having PDIp a and b domains, also appears to be unaffected by 
redox state. Therefore contradicting our original hypothesis, differences between PDI 
and PDIp in response to redox state do not seem to be caused by PDIp b’x but 
instead may be due to PDIp ab.  
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In agreement with this work, dynamic light scattering (DLS) experiments show that 
the chimera proteins are more similar to PDIp than PDI in terms of redox-mediated 
conformational change. More specifically, the diameters of PDIp, PDIp ½ and PDIp 
¾ are increased by ~8% in the oxidised form rather than ~25% which is the 
percentage change in diameter seen for oxidised PDI. Unfortunately however, the 
difference in diameter for reduced and oxidised PDI (25%) was found to be not 
significant using the student’s t-test. This was not unexpected because standard 
deviation was high and replicate number was low. Therefore increasing the number 
of measurements should reduce variance and as a consequence also improve 
significance.  
 The role of PDIp ab in influencing redox-mediated conformational change was 
completely unexpected because recent studies have shown that for PDI, b’xa’c is the 
minimum redox-active cassette (Wang et al. 2011, Wang et al. 2012). In contrast, 
our work shows that that for PDIp ½, the presence of PDI b’xa’c is not sufficient for 
redox-mediated conformational change and therefore indicates that PDIp ab may be 
preventing this from occurring. Further study is required to understand how PDIp ab 
exerts this effect and it would be useful to observe the thermal stability of PDI ½ and 
PDI ¾ (PDI ab PDIp b’xa’c and PDI ab PDIp b’x PDI a’c respectively) in order to 
see how their redox-conformations differ compared to wild-type PDI. In this way we 
could identify whether this moderating activity is unique to PDIp ab or whether it 
has simply been overlooked in PDI ab. 
An additional concern is that the process of making chimera proteins has artificially 
implicated ab as a modulator of redox-conformational change. This is a possibility 
because we have disrupted the domain boundaries between b and b’. Having studied 
the secondary structure and intrinsic flexibility of both PDIp ½ and PDIp ¾ by far 
UV CD and limited proteolysis respectively (for the latter, data is not shown), we 
believe that this is not the case. Both chimera proteins are well folded and do not 
show increased susceptibility to proteolysis compared to the wild-type. We conclude 
that the implied role of ab in redox-mediated change is real and not an artefact 
caused by using chimera proteins. 
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7.2.3. Limited proteolysis experiments to examine intrinsic flexibility 
In light of the significant contribution made by PDIp ab in moderating redox-
regulated conformational change, we decided to use limited proteolysis to examine 
regions of flexibility that may or may not be linked to redox state. These experiments 
have traditionally been very useful for domain boundaries determination and have 
more recently been used to identify b’x as the site of greatest plasticity in PDI 
(Darby et al. 1996, Wang et al. 2010). Limited proteolysis of yPDI however shows 
that the linker between a and bb’ is the most flexible region and thus exhibits the 
greatest degree of conformational change (Tian et al. 2008). It was important to 
study PDIp by limited proteolysis in order to rule out the slight possibility that it may 
have an alternative mechanism of conformational change that may or may not be 
similar to yPDI. 
As anticipated, limited proteolysis experiments show that like hPDI, PDIp is most 
susceptible to chymotrypsin at its C-terminus and preferentially loses the a’ domain 
(Wang et al. 2010). In addition, PDIp shows remarkable resistance to proteolysis at 
its N-terminus indicating that it does not exhibit conformational changes similar to 
yPDI (Tian et al.2008). In regards to redox-linked conformational changes, these 
limited proteolysis experiments show that although PDIp has increased susceptibility 
to chymotrypsin in its oxidised state (relative to the reduced form), this is less 
significant than for hPDI. Furthermore, 2 distinct populations of peptides could be 
seen following the digestion period: those with Mw <30kDa (similar to oxidised 
hPDI) and those with Mw >30kDa. This could be indicative of 2 different start 
species (i.e. diamide sensitive/insensitive) or may indicate that due to accessibility 
limitations, the full cleavage reaction requires a longer incubation time than 2 hours. 
Reduced sensitivity to chymotrypsin, an enzyme produced by the acinar cells of the 
pancreas for example, may provide protection for a protein catalyst exclusively 
expressed there. 
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7.2.4. Molecular mechanisms for conformational change in PDIp 
We have shown that PDIp undergoes less significant redox-mediated conformational 
change than PDI but have not yet determined an exact mechanism to explain this. 
Our studies have however shown that: a) PDIp is more thermally stable than PDI and 
that this property is probably due to b’x, b) the limited redox change seen for PDIp is 
mediated by its a and b domains and c) that PDI and PDIp exhibit almost identical 
regions of susceptibility to chymotrypsin indicating that they probably have quite 
similar tertiary structure. However we have not yet discussed the possible role of 
inter-domain interactions. 
In their paper, Wang et al. (2011) describe several inter-domain reactions that occur 
between PDI b’ and PDI a’ in the reduced protein and that are broken when in its 
oxidised state. Consequently they can be described as ‘tethering’ interactions. One 
such interaction seen in reduced PDI, is a cation-π interaction between R300 in b’ 
and W396 in a’. Research shows that when the a’ active site is oxidised, due to the 
proximity of W396 (WCGHC), steric hindrance leads to the breakage of the R300: 
W396 interaction. When this bond is broken, the PDI a’ domain rotates ~45º around 
the x-linker and toward the hydrophobic surface of b’ (Wang et al. 2011, Wang et al. 
2012). In support of the importance of R300: W396 in tethering the reduced 
conformation, mutating either residue led to increased susceptibility to proteolysis 
and therefore suggested presence of the open conformation (Wang et al. 2011, Wang 
et al. 2012). 
Interestingly, R300 is not conserved in PDIp and instead there is a His residue at this 
position. We postulated that the H321:W417 interaction could be stronger than that 
of R300:W396 because His and Trp could interact via a parallel stacking interaction 
(Samanta, 1999). Consequently the H321:W417 interaction would be a major 
contributing factor in the limited redox-mediated conformational changes of PDIp. In 
order to test this hypothesis we made PDIp H321R mutants but no significant 
difference in redox-linked conformation was seen relative to wild-type PDIp (data 
not shown). Furthermore for PDIp ¾, which has PDI b’x (and so PDI R300) and 
PDIp a’ (W396) there was also no sign of redox-mediated change. This preliminary 
work may therefore give rise to several conclusions: a) that the H321: W417 is not 
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stronger than R300:W396 and/or b) the tethering interactions of PDIp are not the sole 
cause of limited redox-mediated conformational change. Further data is needed to 
fully understand the role of this interaction in the redox-linked conformational 
changes of PDI and PDIp. 
 
7.2.5. Implications of a limited redox-mediated conformational change 
In the X-ray crystal structure of reduced PDI, the cleft diameter is ~15 Å and 
therefore is significantly limited in its potential interaction targets being only able to 
accommodate small peptides. The active site of the a’ domain is also largely shielded 
suggesting that the catalytic activity may also be limited. In the oxidised crystal 
structure however, the cleft diameter is ~ 30 Å and both the hydrophobic surfaces 
and the a’ active site are exposed (Wang et al. 2012). Therefore having been 
oxidised, PDI has greater ability to interact with much larger protein substrates i.e. 
non-native protein structures. In support of this, oxidised PDI exhibits greater 
chaperone activity than the reduced form (Wang et al. 2011). 
Due to sharing identical domain architecture and ~45% sequence identity we have 
assumed that PDI and PDIp share similar 3-dimensional structure. If this is the case, 
reduced PDIp will have a similarly small cleft size. The implication here however is, 
that if PDIp does not undergo large redox-mediated conformational change as we 
have shown to be the case, then how does it accommodate substrate?  
We know that PDIp is able to interact with large protein substrates as we have been 
able to study its activity in the insulin oxido-reductase assay (discussed in more 
detail later). In addition, we also know that the b and b’ domains are capable of 
chaperone activity (Fu et al. 2010). Therefore on account of this, PDIp must undergo 
conformational changes that lead to exposure of its inner hydrophobic surfaces.  
One possible mechanism for non redox-mediated conformational change is substrate 
binding induced conformational change. This would mean that PDIp is less likely to 
exhibit an open conformation in an environment where potential substrates are 
limited. This could be a protective mechanism because if PDIp exhibited redox-
mediated conformational change like PDI, its chaperone activity could be affected by 
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non-specific substrate competition. It would also prevent PDIp from exposing its 
most susceptible areas to the harsh environment of the exocrine pancreas if there was 
a limited substrate pool.  
 
7.2.6. The redox conformation debate 
There is an on-going debate about the use of organic oxidant/reductants for studies of 
structural conformation such as those described here (for review see Hatahet and 
Ruddock, 2009). As noted previously, recent work has shown that oxidation of PDI 
by GSSG leads to conformational change associated with increasing cleft size (Wang 
et al. 2011). However, the disadvantage of using GSSG in these studies is that it is 
able to bind to PDI and has been shown to inhibit the association of PDI with the α-
subunit of prolyl-4-hydroxylase (Lumb and Bulleid, 2002). Unfortunately this is not 
limited to GSSG, and the X-ray crystal structure of PDI bb’xa’ shows a molecule of 
oxidised DTT trapped at the b’ domain (Wang et al. 2011). It has therefore been 
suggested that the conformational changes that have been presented for PDI, are not 
oxidation induced, but instead are caused by ligand binding. 
If conformational change is found to be associated with substrate binding rather than 
oxidation state, this will be in agreement with our studies of PDIp. It is easy to 
suggest that the reason PDIp exhibits limited redox-mediated conformational change 
is because unlike PDI, it has more restricted substrate specificity and therefore is 
unable to bind GSSG or DTT. Certainly it is known that GSSG can inhibit binding of 
PDI to the α-subunit of prolyl-4-hydroxylase (Lumb and Bulleid, 2002). In our 
studies of redox-conformation we have used diamide and DTT as our 
oxidant/reductant of choice. At this time it is unknown whether these molecules are 
also able to bind PDI/PDIp. Consequently we are still unable to determine whether 
these structural changes are associated with redox-state or ligand binding.  
The suggestion that ligand binding may be inducing conformational change is in 
direct contrast with the recent X-ray crystal structure of untreated PDI (Wang et al. 
2012). Compared to DTT-treated PDI, this structure has a significantly larger cleft 
diameter indicating that even in the absence of oxidant, PDI has an open 
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conformation. This therefore implies that redox-state does dictate conformation. 
Although not reduced, this structure is not a true representation of the oxidised form 
as the a domain is only ~70% oxidised (Wang et al. 2012). Consequently the true 
extent of conformational change may still be unknown. 
In order to determine whether conformational change is associated with ligand 
binding or redox-state, we could replace GSSG and DTT with non-organic 
oxidant/reductants such as H2O2 and Tris-2-carboxyethyl phosphine (TCEP). 
Performing several of the experiments described earlier e.g. thermal denaturation, 
limited proteolysis etc, in the presence of H2O2 or TCEP will establish their effect on 
redox structure and finally identify the true reason for conformational change. 
 
7.3. The oxido-reductase activity of PDIp 
 
7.3.1. Historical measurements of activity for PDIp 
Prior to this work the catalytic activities of PDIp were poorly characterised. 
Published studies on the oxido-reductase activity of PDIp are tainted by their use of a 
PDIp construct termed Pa-1 PDIA2 which has an incorrect N-terminus (Desilva et al. 
1996). Unfortunately this construct has been routinely used in studies of recombinant 
PDIp and there is now a significant amount of published data that is irrelevant to the 
wild-type protein. An example of this is seen in work published by Fu and Zhu 
(2009a) which identifies an inter-subunit disulphide bond centred on an aberrant 
cysteine residue in the Pa-1 PDIA2 construct. This issue has now been formally 
resolved with publication of the correct construct (Walker et al. 2012). Furthermore 
authors suggest that Pa-1 PDIA2 is the product of an unusual recombination event 
that ultimately led to insertion of an incorrect start codon.  
7.3.2. Measurements of the oxido-reductase activity of full length wild-type PDIp 
We have shown that PDIp has ~55% of the oxido-reductase activity of PDI (see 
figure 4.14) and this is not dissimilar to the measured activity of Pa-1 PDIA2 
(Desilva et. al 1996). This result was expected because the catalytic active sites are 
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not affected by the discrepancy at the N-terminus. It was important to confirm this 
because we know that the Pa-1 PDIA2 construct dimerises readily and this may have 
affected the reported activity (Fu and Zhu, 2009a). 
Initially we proposed that differences between the oxido-reductase activity of PDI 
and PDIp were caused by a) differences in substrate specificity and b) the unusual a’ 
domain active site motif for PDIp (CTHC instead of CGHC).  
 
7.3.3. The role of the b’ domain in the oxido-reductase activity of PDI and PDIp 
We know that in our assay, substrate binding at the b’ domain is essential for oxido-
reductase activity because negligible activity is seen for the isolated PDI/PDIp a and 
a’ domains (data not shown). This is consistent with work by Darby et al. (1998) 
which showed significantly increased oxidase/reductase activity for constructs 
containing the PDI b’ domain compared to those that did not. Like PDI, PDIp clearly 
requires large substrates/ligands to be bound at b’ before the catalytic domains are 
able to act upon them.  
Despite having restricted substrate specificity, our studies show that PDIp is able to 
bind insulin although it is unclear whether this process is the same or less efficient 
than for PDI. In silico studies show that insulin (porcine) has at least one exposed 
hydroxy-aryl group (PDB ID: 4INS) and this satisfies the minimal requirement for 
PDIp binding. Insulin is highly conserved in vertebrates: human and porcine insulin 
differ by one amino acid and human and bovine insulin differ by 3 amino acids.  
In order to study the role of insulin binding in our oxido-reductase assay a PDI/PDIp 
chimera was made. PDIp ¾ has PDIp ab, PDI b’x and PDIp a’c. Figure 5.10 shows 
that the effect of replacing PDIp b’x with PDI b’x is positive and gives rise to an 
increase in activity of ~12% i.e. that PDIp ¾ has ~67% of the activity of PDI. This 
therefore indicates that in our assay, the measured activity of wild-type PDIp is 
limited to a small extent by its inefficiency in binding insulin. It also implies that 
there are additional requirements for ligand binding that are not linked to the 
presence/absence of a hydroxy-aryl group. Further studies of the ligand binding 
properties of PDIp will be essential in order to resolve this. 
Chapter 7. Discussion 
 
179 
 
One such study would include measuring the activity of a PDI ¾ chimera (PDI ab, 
PDIp b’x and PDI a’c). This would determine definitively the effect of PDIp b’x (i.e. 
the role of substrate binding) on the oxido-reductase activity of PDI. It would also be 
interesting to identify conserved residues between PDI and PDIp that are implicated 
in the binding site of PDI (Byrne et. al 2010). Mutating out these residues one at a 
time should allow us to recognise those that are directly involved in binding insulin 
to PDI or PDIp.  
Similar to this, Fu et al. (2011) have shown that for the interaction of 17-β-oestradiol 
with PDIp, His278 (found in the b’ domain) is essential. This residue supposedly 
forms a hydrogen bond with estradiol-3-hydroxyl group and when mutated out leads 
to negligible/no binding. We are cautious of this work for two main reasons: a) the 
incorrect Pa-1 PDIA2 clone was used and b) our studies of PDIp H278A and PDI 
H256A indicate that the secondary structure of these mutants is compromised 
relative to the wild-type proteins (data not shown). Although further work is required 
to fully interpret this result it is possible that these structural changes are the real 
cause of reduced binding. No evidence of these structure controls are shown in the 
paper of Fu et al. (2011). 
 
7.3.4. The effect of the a’ domain on the oxido-reductase activity of PDIp 
Unlike PDI and ERp57, its closest family members, PDIp has a CTHC active site 
motif instead of CGHC. The implications of this are currently unknown but it is 
likely that this contributes to the reduced oxido-reductase activity of PDIp. In PDI it 
is thought that the positive charge of the imidazole ring of the histidine residue at 
position 3 in the CXXC motif plays a role in stabilising the low pKa of the N-
terminal cysteine (Ferrari and Söling, 1999). If this is true it is likely that the 
presence of a much larger amino acid side chain at position 2 in the a’ domain of 
PDIp (threonine instead of glycine) will sterically block the interaction between the 
histidine side chain and the N-terminal cysteine. The consequence of this may be that 
the N-terminal cysteine is unstable as a thiolate ion and a less potent nucleophile.  
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In order to study this further a PDIp T419G mutation was made. This protein has an 
a’ domain active site that mimics that of PDI. Our studies of the oxido-reductase 
activity of PDIp T419G show that it is ~65% as active as PDI (see figure 5.12). This 
means that this construct has roughly equivalent activity to the PDIp ¾ mutant and is 
~10% more active than the wild-type protein. Clearly PDIp a’ has a much lesser 
effect on the low oxido-reductase activity than initially postulated.  
Additional studies showed that PDIp ¾ T419G was ~63% as active as an oxido-
reductase as PDI (see figure 5.12). Based on previous results we had expected a 
cumulative effect of the two mutations but this indicates that the PDIp ¾ T419G 
mutant was similarly active to both PDIp ¾ and PDIp T419G mutants. Unfortunately 
the high standard deviation (11.06) means that it is difficult to interpret the actual 
activity of the PDIp ¾ T419G mutant. In order to resolve this additional repeats 
should be performed to reduce variance.  
This work indicates that the unusual PDIp a’ domain catalytic motif has a much less 
significant effect on the oxido-reductase activity of PDIp than originally postulated. 
We have not studied the oxido-reductase activity of PDI G398T or PDI ½ (PDI 
abb’x, PDIp a’c) but these mutants would provide greater insight into the molecular 
mechanisms determining the activity of PDI and PDIp. Measuring the activity of PDI 
G398T for example would allow us to directly observe the negative effect of this 
mutation within a PDI background. In PDIp there are so many unknown variables 
governing activity that it would be useful to see the effect of this mutation in PDI 
which has been better characterised. This work could be supplemented by molecular 
modelling studies which are able to predict the orientation of the threonine residue 
within the active site and the possible consequences for activity.  
The benefit of studying the PDI ½ chimera is that it would be possible to observe the 
effect of the complete PDIp a’ domain on the oxido-reductase activity of PDI. We 
have assumed that the major cause of the low activity observed for PDIp is due to the 
a’ active site rather than the whole domain because PDIp a’ shares ~65% sequence 
identity with PDI a’. However this may not be the case and other regions within 
PDIp a’ may be exerting a negative effect.  
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7.3.5. Studies of PDIp b’xa’c  
We have shown that both the reduced substrate binding capacity of PDIp and the 
unusual PDIp a’ domain catalytic motif have a negative effect on the oxido-reductase 
activity of PDIp relative to PDI. Unexpectedly however the cumulative effect of both 
of these does not equal the sum of the loss of activity. Furthermore the PDIp ¾ 
T419G mutant only exhibits ~65% of the oxido-reductase activity of PDI despite 
sharing b’x with PDI and having a CGHC a’ domain catalytic active site. Clearly 
there are still factors involved in the oxido-reductase activity of PDIp that have not 
yet been identified. 
Unfortunately our studies of PDIp b’xa’c were thwarted by instability issues and 
consequently a reproducible value for its oxido-reductase activity was not recorded. 
Using the PDIp ½ chimera (PDIp ab PDI b’xa’c) it was possible to infer the effect 
that PDIp b’xa’c has on the activity of PDIp. We showed that this chimera has ~78% 
of the oxido-reductase activity of PDI. This is an improvement in activity of ~23% 
but indicates that PDIp ½ is still 22% less active than wild-type PDI. The 
implications of this work are that a) PDIp b’xa’c accounts for approximately half of 
the difference in oxido-reductase activity between wild-type PDI and PDIp and b) 
PDIp ab must also have impeded activity relative to the same region in PDI. 
Additional study of PDIp ab is therefore required to elucidate this.  
The activity of PDIp ½ also shows the importance of repeating activity studies for 
PDIp ¾ T419G. Clearly the discrepancy between these proteins could be due to 
differences in the a’ domain but it could also be linked to the high standard deviation 
seen for activity measurements of PDIp ¾ T419G. Repeating the experiment will 
clarify this, as it is possible that PDIp ¾ T419G has a higher percentage oxido-
reductase activity than previously measured.  
7.3.6. Studies of the activity of PDIp a 
PDIp a shares ~55% sequence identity with PDI a and unlike PDIp a’ has an intact 
CGHC active site motif. Furthermore residues adjacent to and surrounding the 
catalytic active site of PDIp a are almost fully conserved in PDI. For these reasons it 
was not anticipated that PDIp a would exhibit significantly different oxido-reductase 
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activity to PDI a. As a result of increasing evidence from chimera studies that 
implicated PDIp a as a contributor to the low oxido-reductase activity of PDIp we 
decided to study the catalytic activity of isolated PDIp a relative to PDI a. 
Unfortunately it is impossible to measure the oxido-reductase activity of the 
individual catalytic domains of PDI and PDIp using the insulin assay described 
previously. This is because for ligands as large as insulin the b’ substrate binding 
domain is also required. Consequently a fluorescence based assay was used. Our 
studies of the re-oxidation of reduced PDI a W128F and PDIp a W146F show that 
PDI a is ~4x more active than PDIp a (see figure 6.8). In addition, re-reduction of 
oxidised PDI a W128F and PDIp a W146F indicates that PDI a is ~10x more active 
than PDIp a (see figure 6.9). Clearly the PDIp a domain catalytic active site has 
impaired oxido-reductase activity relative to PDI a. 
The low reduction activity of oxidised PDIp a implies that the N-terminal cysteine is 
incapable of accepting electrons. Typically we would expect GSH to nucleophilically 
attack the N-terminal cysteine of oxidised PDIp a  breaking the disulphide bond and 
leading to formation of a mixed disulphide. Clearly this is not the case. This work 
therefore suggests that for the most part the N-terminal cysteine of PDIp a is in an 
un-reactive thiol state despite being treated with GSSG. Clearly this state is stable at 
the pH of this experiment ~pH 7.3 indicating that the pKa of the N-terminal cysteine 
is much higher than anticipated. 
 
7.3.7. Determination of pKa values for PDIp C71 and C74 
For PDI and many other PDI family members, catalytic activity relies on the 
unusually low pKa of the N-terminal cysteine. For PDI a this is ~4.8 (Karala et al. 
2010) and leads to stabilisation of the thiolate state at physiological pH. 
Consequently PDI a is a potent catalyst of oxidation. The C-terminal cysteine of PDI 
a has multiple roles in the catalytic cycle and therefore requires that its pKa is 
modulated by surrounding residues according to the activity in hand. The measured 
pKa of the C-terminal cysteine of PDI a is ~8.6 and is significantly increased in 
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R120Q and R120D mutants indicating a role for R120 in modulating the catalytic 
activity of PDI a (Karala et al. 2010).  
Our studies show that the N-terminal cysteine of PDIp a has an unusually high pKa 
(~8.09). This is typical for free cysteines in aqueous solution but is completely 
atypical for the N-terminal cysteine of PDI family members. Such a high pKa 
explains the low reactivity of PDIp a in our previous studies of oxidation and 
reduction activities as it suggests that for the most part the N-terminal cysteine of 
PDIp a is in an unreactive thiol state.  
We have postulated that Q75, which is immediately adjacent to the C-terminal 
cysteine of PDIp a and is not conserved in PDI family members, is modulating the 
pKa of the N-terminal cysteine. By acting as a hydrogen bond donor to the side chain 
of Q75, the unreactive thiol group of the N-terminal cysteine is made slightly more 
reactive. The consequence of this is that PDIp a maintains some/low level activity 
and this correlates with our studies described previously. Obviously further study 
including mutagenesis of Q75 is very important to justify these assumptions. We 
have already made a series of mutants and hope to continue study of this residue 
using NMR and a stopped flow kinetics assay.  
It is also possible that other amino acids close to the substrate thiol have a role in 
modulating the pKa of PDIp a. This correlates well with our understanding that PDIp 
has very limited substrate specificity. Therefore PDIp may confer specificity in its 
catalytic domains (a domain at least) and also the b’ domain as described previously. 
If this is the case we would speculate that the N-terminal cysteine of PDIp would be 
most active towards thiols with a nearby positive charge (i.e. an adjacent arginine, 
histidine or lysine residue) which may help to stabilise the thiolate state. Similar 
modulation by a positively charged residue is seen for PDI C53 and R120 (Karala et 
al. 2010).  
7.3.8. DsbD: comparisons to PDIp 
DsbD is a prokaryotic transmembrane protein with 3 domains. Its most C-terminal 
domain has a typical thioredoxin fold and a catalytic CXXC active site motif. The 
main function of DsbD is to transfer electrons from thioredoxin in the cytoplasm via 
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a disulphide cascade involving cysteine residues in each of its 3 domains. 
Interestingly the N-terminal cysteine of the catalytic motif of cDsbD (C-terminal 
domain of DsbD) has an unusually high pKa ~10.5 (Mavridou et al. 2007). This 
means that like PDIp, cDsbD is relatively unreactive towards substrate thiols.  
In cDsbD the high pKa of C461 is maintained by two nearby adjacent negatively 
charged acids: D455 and E468. In addition when cDsbD forms a complex with the 
N-terminal domain (nDsbD) the nucleophilicity of its N-terminal cysteine is 
markedly improved (Mavridou et al. 2008). In this way the activity of cDsbD has 
evolved to be environment sensitive and therefore it protects itself from non-specific 
re-oxidation.  
Currently we do not know how PDIp interacts with its binding partners. We have 
postulated that the high pKa of the N-terminal cysteine is modulated by a nearby 
glutamine residue (Q75) and also that the binding interaction is specific to ensure 
improved nucleophilicity. Therefore PDIp may be very similar to cDsbD in its 
reaction mechanisms and clearly is not alone in being an oxido-reductase with a 
seemingly inactive active site.  
 
7.3.9. Alternative methods to determine pKa 
Studying pKa by monitoring the rate of alkylation as a function of pH (as used in this 
work) has been very successful for members of the Trx superfamily. For the most 
part this success is down to the fact that the cysteine of interest is chemically reactive 
and solvent exposed. Unfortunately however, when cysteine side chains are protected 
by the protein structure the rate of alkylation can be quite significantly affected. 
There are many alternate experimental approaches that could have been used for 
these calculations but due to lack of structural information unfortunately 
computational methods such as PROPKA were unsuitable. 
One such alternative, more traditional method for pKa determination makes use of 
UV absorption spectroscopy. The basis of this assay is that the thiolate exhibits 
greater absorption of UV light at 240nm than the thiol, so that it is possible to 
monitor the change in absorbance as pH is varied. Perhaps the biggest disadvantage 
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of this method is that the side chains of Phe, Tyr and Trp also absorb at 240nm. 
Consequently if their molecular environment changes during the titration process, 
this can affect their absorption properties. This interference can significantly reduce 
the accuracy of these pKa measurements but can be counteracted by comparing 
spectra to an identical control protein only differing in lacking a thiol group.  
The protocol described above was used for early measurements of the pKa of PDI a 
catalytic cysteines (Kortemme et al. 1996). Similar to more recent work which shows 
that the N-terminal cysteine of PDI a has a pKa of ~4.8  (Karala et al. 2010), this 
group showed that the pKa of the N-terminal cysteine of PDI a was ~4.5. Clearly 
despite obvious technical issues this protocol remains an accurate and useful tool to 
study pKa.  
 
7.4. Implications of our studies of PDIp 
 
7.4.1. Implications of the low catalytic activity of PDIp a 
PDIp is a pancreas-specific homolog of PDI with unusual substrate specificity. Its 
physiological role is unknown but it is highly expressed alongside PDI in the acinar 
cells of the pancreas. We believe that it is highly unlikely that a protein folding 
catalyst with such limited activity as an oxido-reductase would be conserved when a 
significantly more active general folding catalyst such as PDI is co-expressed in the 
same location. Consequently PDIp must have been conserved in order to act on a 
unique substrate set. 
Although this seems a reasonable explanation, work by Rutkevich et al. (2010) has 
shown that PDI family members are capable of compensating for one another to a 
much greater extent than originally expected. For example depletion of PDI in 
HepG2 cells had only a modest impact on the capability of the ER secretory pathway 
(Rutkevich et al. 2010). If the PDI family members are able to compensate for one 
another why has PDIp been conserved with exclusivity to the pancreatic acinar cells? 
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Particular emphasis has been put on the ability of PDIp to bind 17-β-oestradiol. This 
interaction is highly specific (17-α-oestradiol cannot bind, Klappa et al. 2001) and 
has a Kd of ~170nM (Fu and Zhu, 2009b). It is unlikely to be an essential 
physiological interaction however because a) physiological concentrations of 
oestradiol in a fertile female are <1.5nM (Akerlund et al. 1981) and b) PDIp has been 
shown to be expressed similarly in both male and female rats (Fu et al. 2009). 
Whether this interaction is important for modulation of substrate binding and/or 
catalytic activity is currently unknown. Furthermore it has been suggested that the 
role of PDIp may be to catalyse folding of pancreatic zymogens. Modulation of this 
activity by 17-β-oestradiol may be a contributor to digestive malfunctions such as 
hyperemesis (Baron et al. 1993). 
 
7.4.2. The structural and catalytic significance of PDIp ab 
We have shown that PDIp ab is able to act as a modulator of redox-mediated 
conformational change. This is in contrast to recent work which shows that PDI 
b’xa’c is the minimal requirement for redox-linked activity (Wang et al. 2011). This 
is clearly an oversimplification as our studies of PDIp ½ show that the presence of 
PDIp ab can prevent conformational change from occurring in the seemingly redox-
active, PDI b’xa’c. Therefore for both PDI and PDIp, the a and b domains are more 
influential in redox-mediated conformational change than originally anticipated.  
For PDIp a, we have shown that the pKa of both active site cysteines is high and for 
the N-terminal cysteine, this was entirely unexpected. The implication of this is that 
at physiological pH, the PDIp a domain will have a predominantly reduced active 
site. Furthermore the PDIp a active site thiols will be hard to oxidise. Consequently, 
the limited redox-mediated conformational change exerted by diamide treated PDIp 
may be due to the fact that PDIp a remains in a mostly reduced state indicating that 
in contrast to published data, the a domain is important for redox-mediated 
conformational change.  
Unfortunately until pKa measurements were taken for PDIp a its inability to be 
oxidised went unnoticed.  This was because we assumed that the pKa of the PDIp a 
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domain cysteines would be similar to those of PDI a, and that using an excess of 
oxidant or reductant would sufficiently control redox state. This was not an irrational 
assumption because PDI a and PDIp a share significant sequence identity and have 
identical CGHC active site motifs. Furthermore given the unusual active site motif in 
PDIp a’, we anticipated that the low oxido-reductase activity measured for PDIp 
would be caused by the a’ domain and not the catalytic activity of a. 
The effect exerted by the redox state of PDI a on redox-mediated conformational 
change, has not been studied although clearly it has been assumed that there is no 
effect (Wang et al. 2011). In recent work, Wang et al. (2011) attempted to study the 
effect of PDI a and a’ on the redox-mediated conformational changes of PDI. To do 
this they made two, double active site mutants which they described as PDIaSSa’CC 
and PDIaCCa’SS. Interestingly, they found that only the PDIaCCa’SS mutant 
showed increased susceptibility to proteolysis leading to the conclusion that 
oxidation of the a’ domain only, was sufficient for redox-mediated conformational 
change. However as the redox state of the remaining cysteines was not controlled, we 
can assume that they were ~50% reduced and ~50% oxidised. Therefore this work 
does not indicate the implications on redox mediated conformational change that 
occurs if PDI a is trapped in a reduced state (as is seen in PDIp). We have shown 
previously that for PDIp ½, which almost certainly has a reduced PDIp a active site, 
redox-mediated conformational change does not occur despite having an oxidised 
PDI a’ active site. 
In this work and in published work by Wang et al. (2011, 2012) the redox state of 
both PDI active sites is manipulated by using an excess of oxidant or reductant. 
Clearly this is not physiological and in vivo there will be times when the two active 
sites of PDI are in different redox states i.e. PDI a will be reduced and PDI a’ 
oxidised. The implication of this on redox-linked conformation is unknown (Wang et 
al. 2011, 2012) but our work suggests that if the active site of PDI a is in the reduced 
state, then major redox-mediated conformational changes may not occur. 
 In the recent X-ray crystal structure of oxidised PDI however, the active site of the 
a’ domain is shown to be oxidised (as expected) but the a domain is shown as a 
mixture of oxidised (70%) and reduced (30%) forms (Wang et al. 2012). Despite 
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this, the structure of ‘oxidised’ PDI exhibits a significantly more open conformation 
than reduced PDI. We can speculate therefore, based on our understanding of the role 
of PDI a in redox-mediated conformational change, that in this structure the 
molecule is not fully open i.e. that complete oxidation will give rise to an even more 
open conformation. In addition it is also possible that unlike PDIp a, the redox state 
of PDI a has no effect on the redox conformations of PDI. Further study to 
identify/nullify the function of PDI a in the redox-mediated changes of PDI are 
required. 
 
7.4.3. Does PDIp display asymmetrical oxidase activity similar to PDI? 
Our data shows that PDIp has an unusually unreactive a domain active site. This was 
unexpected because unlike the a’ domain, PDIp a contains an active site motif 
identical to that seen for PDI (CGHC). Although the b’ and a’ domains of PDIp 
clearly make some contribution to its low oxido-reductase activity (~50% relative to 
PDI), we now know that the major factor is the high pKa of the a domain N-terminal 
cysteine. The benefits for PDIp in having an inactive thioredoxin domain at its N-
terminus are currently unknown. 
Interestingly, in Ero1-Lα mediated oxidative folding, the a’ domain of PDI is much 
more active than the a domain (Wang et al. 2009). This means that the a’ domain is 
preferentially oxidised by Ero1-Lα over the a domain. This is also true for yPDI and 
the Ero1-Lα yeast homolog, Ero1p (Kulp et al. 2006). In both cases, the ability to 
bind Ero1 has been shown to be position dependent rather than a or a’ dependent and 
consequently PDI bb’xa has been found to be more active than PDI a’bb’x. 
Furthermore it has been suggested that binding of Ero1-Lα to hPDI at the b’ domain, 
inhibits the oxido-reductase activity of PDI a. Authors therefore suggest that the PDI 
a’ domain may be responsible for oxido-reductase activity and PDI a domain, 
isomerase activity. In this way PDI is able to synchronise isomerase activity with 
oxido-reductase activity potentially making it more efficient as a protein folding 
catalyst (Wang et al. 2009). 
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This work provides a possible explanation for the asymmetric oxido-reductase 
activity of PDIp. Alongside PDI, PDIp is the only other PDI family member that has 
been shown to bind Ero1β and has a rate of oxidation of ~50% of that seen for PDI 
(Wang et al. 2011). This in itself is unexpected because it implies that the activity of 
PDIp a’ is still far lower than that of PDI a’ and is not in agreement with our work 
described here. It would be useful to measure the oxido-reductase activity of PDIp 
C71S C74A and PDIp C417S C420A to explore this further. Additionally, pKa data 
for the active site cysteines of PDIp a’ would also help to elucidate this problem. 
Therefore like PDI, the a’ domain of PDIp may exhibit functional activity as an 
oxido-reductase while the a domain operates as an isomerase. Certainly we have 
shown that PDIp a is inefficient as an oxido-reductase. Although it is unlikely that 
the low activity of PDIp a is position dependent, this may explain why PDIp a’, 
which is at the C-terminus of PDIp next to x, has retained oxido-reductase activity. 
In this way PDIp a may direct oxido-reductase activity to the a’ active site while 
simultaneously performing complex isomerisation reactions.  
 
7.4.4. The role of glycosylation in the activities of PDIp in vivo 
In contrast to all other PDI family members, in vivo PDIp has 3 glycosylation sites: 
one in each of the a and b’ domains and one in c (Desilva et al. 1996, Walker et al. 
2012). Our work describes the in vitro activity of recombinant PDIp (E. coli) and so 
fails to consider the potential effect of glycosylation on activity. Currently this has 
been very poorly studied, but it has recently been shown that all 3 sites are 
glycosylated. Furthermore, the glycan on the b’ domain (N284) prevents 
dimerisation and so it would be expected that it would also interfere with substrate 
binding (Walker et al. 2012). This is probably not the case however, because we 
know from early cross-linking studies, that PDIp derived from sheep pancreas 
microsomes could effectively bind many of the different ligands tested (Klappa et al. 
1998b). 
As PDIp is unique (as a PDI family member) in being glycosylated, it is likely that 
glycosylation is important for either its structure or function within the cell. 
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Therefore it is essential that it is studied further. Obviously the difficulty with this at 
the moment is that no pancreatic, PDIp-expressing cell line has currently been 
identified and therefore as a consequence, we are limited to in vitro studies. 
Hopefully this is something that will be rectified in the future. 
7.5. Further work 
 
7.5.1. NMR studies of PDIp a 
There are no published structures of PDIp. Based on the work presented here it is 
deemed important to obtain a structure for PDIp a so that residues that may interact 
with and enable the reactivity of the active site can be determined. Due to the 
equipment and expertise available to us, we will use solution state NMR. The 
advantage of this is that unlike in X-ray crystallography, the molecule is not fixed in 
its structure. Nevertheless, following full assignment of PDIp a a molecular model 
can be made and we can start to make predictions about possible interactions that 
may help to improve/reduce the activity of the active site. Furthermore, NMR can 
also be used to study the effect of single point mutations (e.g. Q75K) on the overall 
structure of PDIp a (by measuring changes in peak width). 
Recent work has shown that redox potentials can be measured using NMR (Taylor et 
al. 2013). Therefore the redox potential of PDIp a could also be measured. Having 
already created a full length PDIp C71S C74A mutant with an intact a’ domain,  it 
would be useful to determine its redox potential because it is difficult to stabilise the 
PDIp a’ domain in its isolated form. This information would supplement the pKa 
studies (described previously). 
 
7.5.2. Studies of the effect of Q75 on the reactivity of PDIp a 
In order to study the effect of Q75 on the reactivity of PDIp a a number of mutants 
need to be made: 
1. PDIp a Q75K (made) 
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2. PDIp a Q75A 
3. PDIp a Q75K W146F (made) 
4. PDIp a Q75A W146F 
5. PDIp a C71S Q75K (made) 
6. PDIp a C71S Q75A 
7. PDIp a C74A Q75K (made) 
8. PDIp a C74A Q75A  
9. PDIp Q75K 
10. PDIp Q75A 
11. PDI a K57Q 
12. PDI a K57A 
13. PDI a K57Q W128F  
14. PDI a K57A W128F 
15. PDI K57Q 
16. PDI K57A 
 
By studying the reactivity of these mutants via stopped flow experiments  and the 
insulin assay (full length proteins only) it should be possible to determine the role of 
Q75 and K57 in modulating the reactivity of the N-terminal cysteine of PDI a and 
PDIp a respectively. It is expected that the Q75K PDIp mutation will have a positive 
effect on the activity of PDIp a and also the molecule as a whole. Similarly the K57Q 
mutation should be detrimental to the activity of PDI a and the overall activity of 
PDI.  
 
7.5.3. Studies of the catalytic cysteines of PDIp a’ 
Up to now the catalytic activity of PDIp a’  has not been studied. For the most part 
this is because PDIp b’xa’c and PDIp a’ are unstable and therefore very difficult to 
work with. It would be useful to determine the activity of PDIp a’ and this could be 
done using the insulin assay and the PDIp C71S C74A mutant that has already been 
made.  
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In order to measure the pKa for both PDIp a’ domain catalytic cysteines, quadruple 
mutants need to be made : PDIp C71S C74A C364A C418S and PDIp C71S C74A 
C364A C421A. Although we expect that the N-terminal cysteine of PDIp a’ will be 
characteristic of normal PDI family members in having a very low pKa this needs to 
be confirmed. Mutating the active site threonine to glycine in these mutants will also 
indicate the effect of this residue (if any) on the pKa of the catalytic cysteines.  
 
7.6. Concluding Remarks 
This work represents the first study to characterise the in vitro oxido-reductase 
activity of PDIp. Despite having an unusual a’ active site sequence (CTHC), we 
found that the abnormally high pKa of the a domain N-terminal cysteine was the 
major contributor to the low oxido-reductase activity of PDIp.  
In regards to structure, we found that unlike PDI, PDIp undergoes only minor redox-
mediated change. Using chimera proteins we concluded that this may be due to 
modulation by the a and b domains, probably as a result of the low reactivity of the a 
domain catalytic site. Furthermore we also saw that the minimum redox-active 
cassette of PDI, b’xa’c, could also be modulated by PDIp ab and so led to the loss of 
redox-mediated conformational change. Therefore this work is in contrast to recent 
work by Wang et al. (2011) which suggests that the a and b domains are unimportant 
for redox-mediated structure.  
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